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ELISA Enzyme-linked immunosorbent assay 
ER Endoplasmic reticulum 
ERCP Endoscopic retrograde cholangiopancreatography 
FACS Fluorescence-activated cell sorting 
FasL Fas ligand 
FCS Foetal calf serum 
FITC Flourescein isothiocyanate  
FOXP3 Forkhead winged helix transcription factor P3 
FSC Forward scatter 
G Guanine 
GAL Galectin 
GALT Gut-associated lymphoid tissue 
GATA-3 GATA binding protein-3 
GGT Gamma glutamyl transpeptidase 
GITR Glucocorticoid-induced tumour necrosis factor receptor family- 
 related protein 
HAVCR Hepatitis A virus cellular receptor 
HBV Hepatitis B virus 
HCV Hepatitis C virus 
HEp2 Human epithelial type 2 
HIV Human immunodeficiency virus 
HLA Human leukocyte antigen 
HS Healthy subject 
HSC Haemopoietic stem cell 
HSC Hepatic stellate cells 
HSV Herpes Simplex Virus 
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IAIHG International Autoimmune Hepatitis Group 
IB Immunoblot 
IBD Inflammatory bowel disease 
ICCS Intracellular cytokine staining 
IDO Indoleamine 2,3-deoxigenase 
IFN- Interferon-gamma 
Ig Immunoglobulin 
IIF Indirect immunofluorescence 
IL Interleukin 
INR International normalised ratio 
IPEX Immunodysregulation, polyendocrinopathy and enteropathy, X- 
 linked syndrome 
Irf-4 Interferon regulatory factor-4 
ITAM Immunoreceptor tyrosine-based activation motif 
iTregs Peripherally-induced adaptive Tregs 
KIM-1 Kidney injury molecule-1 
LAG-3 Lymphocyte activation gene 3 
LAP Latency associated peptide 
LC-1 Liver cytosol type 
LD Linkage desiquilibrium 
LKM-1 Liver kidney microsomal type 1 
LP Liver pancreas 
LSECS Liver sinusoidal endothelial cells 
LSP Liver specific protein 
LT Liver transplantation 
MAb Monoclonal antibody 
MBP Myelin basic protein 
MF Microfilament 
MHC Major histocompatibility complex 
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MMF Mycophenolate mofetil 
MOG Myelin oligodendrocyte glycoprotein 
MS Multiple sclerosis 
mTECs Medullary thymic epithelial cells 
N/A Not applicable 
NAFLD Non-alcoholic fatty liver disease 
neg Negative 
NFAT Nuclear factor of activated T cells 
NF-κB Nuclear factor-κB 
NK Natural killer 
NKT Natural killer T 
NOD Non-obese diabetic 
Nrp-1 Neuropilin 
NS Non significant 
nTregs Natural T-regs 
nv Normal value 
OVA Ovalbumin 
pANCA Perinuclear anti-neutrophil cytoplasmic antibody 
pANNA Peripheral anti-nuclear neutrophil antibody 
PBC Primary biliary cirrhosis 
PBMCs Peripheral blood mononuclear cells 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PD-1 Programmed death 1 
PDH Pyruvate dehydrogenase 
PE Phycoerythrin   
PerCP Peridinin-chlorophyll-protein complex 
PI3K Phosphotidylinositol 3-kinase 
PMA Phorbol 12-mystrate 13-acetate 
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Pos Positive 
PSC Primary sclerosing cholangitis 
PtdSer Phosphatidylserine 
RA Rheumatoid arthritis 
RIA Radio-immune-precipitation assay 
RISC RNA-induced silencing complex 
RNAi RNA interference 
ROR Retinoic acid-related orphan receptor alpha 
RORt Retinoic acid-related orphan receptor gamma t 
RPMI Roswell Park Memorial Institute 
Runx1 Runt-related transcription factor 1 
SEM Standard error of the mean 
SEM Standard error of the mean 
siRNA Small-interfering RNA 
SLA Soluble liver antigen 
SLE Systemic lupus erythematosus 
SMA Smooth muscle antibody 
sn-RNPs Small nuclear ribonucleoproteins 
SP Single positive 
SSC Side scatter 
STAT Signal transducer and activator of transcription 
T Tubules 
T1D Type 1 diabetes 
TAPR T cell and airway phenotype regulator 
Tbet T box expressed in T cells 
TCR T cell receptor 
Teff Effector T cell 
TGF-β Transforming growth factor beta 
Th T helper 
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TIM T-cell Ig and mucin domain 
TLR-4 Toll-like receptor 4 
TNBS 2,4,6-trinitrobenzene sulfonic acid 
TNF Tumour necrosis factor 
TNFR Tumour necrosis factor receptor 
TPMT Thiopurine methyltranferase 
TRAIL Tumour-necrosis-factor-related apoptosis-inducing ligand 
Tregs Regulatory T cells 
Tris-EDTA Trishydroxymethylaminomethane/ethylene diamine tetraacetic acid 
tRNP
(ser)sec
 tRNA suppressor-associated antigenic protein 
TSDR Treg-cell specific demethylated region 
UC Ulcerative colitis 
UDCA Ursodeoxycholic acid 
UGT Uridine glucuronosyltransferase 
V Vessels 
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ABSTRACT 
Autoimmune hepatitis (AIH), an immune-mediated liver disorder with a strong 
female preponderance, is characterised by hypergammaglobulinaemia, seropositivity for 
autoantibodies and interface hepatitis on histology. The aetiology of AIH is unknown, 
though both genetic and environmental factors are involved. CD4 effector lymphocytes 
are the main orchestrators of liver damage, their proliferation and pro-inflammatory 
cytokine secretion being correlated with the activity and severity of liver disease. A 
wealth of data indicates that in AIH the extent of self-reactive CD4 T cell effector 
immune responses is associated with defective CD4
pos
CD25
pos
 regulatory T cells 
(Tregs), a lymphocyte subset central to immune-tolerance maintenance. Whether 
impaired immune-regulation in AIH is due to a reduced number of Tregs, intrinsic 
defects in their function; or effector cell resistance to their suppression or even a 
combination of all them is unknown. Recent studies have shown that functional Tregs 
express very low levels of CD127, whereas activated T cells were characterised by the 
expression of this marker, indicating CD127 as a good phenotypic marker for the 
quantification of these cell population. On the other hand, murine studies have shown 
that galectin-9 (GAL-9), a member of the galectin family expressed by Tregs, inhibits 
Th1 effector immune responses after binding to the T-cell-imunoglobulin-and-mucin-
domain-3 (TIM-3), its receptor on CD4 effector cell. The aims of this Thesis were thus 
to investigate possible causes of functional Treg impairment by exploiting the role of 
CD127 and that of TIM-3/GAL-9 pathway in patients with autoimmune liver disease. 
Seventy-seven patients with anti-nuclear (ANA) and/or smooth-muscle antibody 
(SMA) positive AIH, including thirty nine patients diagnosed with AIH/sclerosing 
cholangitis (AISC) overlap syndrome, were studied. When considered together they are 
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referred to as autoimmune liver disease (AILD). Circulating CD127
neg
 and GAL-
9
pos
CD4
pos
CD25
pos 
and TIM-3
pos
CD4
pos
CD25
neg
 T cell phenotype was assessed by flow 
cytometry. CD127
neg 
Treg ability to suppress was evaluated in a proliferation assay 
following co-culture with CD25
neg
 responder cells. To determine whether GAL-9 
expression is essential to Treg function, Tregs were treated with small-interfering-RNA 
to repress GAL-9 translation; Treg suppressor function was assessed by a reduction in 
target cell proliferation. To evaluate whether TIM-3 expression renders CD4
pos
CD25
neg
 
T cells amenable to Treg control, purified CD4
pos
CD25
neg
TIM-3
pos
 (TIM-3
pos
) and 
CD4
pos
CD25
neg
TIM-3
neg
 (TIM-3
neg
) cells were co-cultured with Tregs. 
The frequency of CD4
pos
CD25
pos
CD127
neg
 cells was reduced in AILD patients 
compared to HS. Compared to conventional CD4
pos
CD25
pos
 (cTregs), CD127
neg 
Tregs 
from both AILD and HS had a) higher numbers of FOXP3
pos
, CTLA-4
pos
 and IL-10
pos
 
cells; b) lower numbers of T-bet
pos
, RORC
pos
, IFNpos and IL-17pos cells; and c) similar 
numbers of TGF-pos cells. CD127neg Tregs inhibited CD25neg cell proliferation more 
effectively than cTregs, though less markedly in AILD than in HS. In AILD, treatment 
with anti-IFN and anti-IL-17 neutralising antibodies ameliorated the suppressive 
ability of cT-regs, while leaving unchanged that of CD127
neg 
Tregs; exposure to anti-IL-
10 neutralising antibodies reduced Treg suppression in HS, but not in AILD.   
In AILD the frequency of GAL-9 expressing Tregs was reduced, and inversely 
correlated with IgG levels and autoantibodies titres. Within GAL-9
pos
 cells the 
frequency of: a) FOXP3
pos
 cells was lower in AILD than in HS; b) Tbet
pos
, GATA-3
pos
 
and RORC
pos
 cells was similar in AILD and HS; c) IL-10-producing cells was lower in 
AILD than in HS but higher than in the GAL-9
neg 
Treg fraction for both; d) TGF--
producing cells was lower in AILD than in HS; e) IFN-- and IL-17-producing cells was 
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higher in AILD than in HS. siRNA treatment of GAL-9
pos
 Tregs reduced drastically 
Treg ability to suppress responder cell proliferation.  Treatment with anti-IL-10 
neutralising antibodies reduced Treg ability to suppress CD25
neg
TIM-3
pos
 cell 
proliferation, while did not affect TIM-3
neg
 cell proliferation. 
 In AILD TIM-3
pos
 cells within CD4
pos
CD25
neg
 cells and their Tbet
pos
 and 
RORC
pos
 subsets were fewer and contained higher numbers of IFN-pos and IL-17pos 
cells than in HS. In patients and HS TIM-3
pos
 cells proliferated less vigorously and were 
more susceptible to Treg control than TIM-3
neg
 cells. The frequency of TIM-3
pos
 cells 
inversely correlated with the levels of AST. 
In conclusion reduced numbers of CD127
neg
 Tregs, as well as of reduced 
expression of GAL-9 on Tregs and of TIM-3 on CD4
pos
CD25
neg
 effector cells contribute 
to impaired immune-regulation in AILD by rendering Tregs less capable of suppressing, 
and effector cells less prone to Treg control 
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RESUMO 
A hepatite autoimune (HAI) é um processo inflamatório hepatocelular auto 
perpetuado de etiologia desconhecida e que se caracteriza por hipergamaglobulinémia, 
positividade para auto-anticorpos e hepatite de interface na histologia. A sua etiologia é 
desconhecida, embora fatores genéticos e ambientais estejam envolvidos. Os linfócitos 
T CD4 efetores são os principais orquestradores da lesão hepática, sendo que a sua 
proliferação e secreção de citocinas pró-inflamatórias se correlacionam com a atividade 
e gravidade da doença. Vários estudos mostraram que na HAI a magnitude da resposta 
imune dos linfócitos CD4 auto-reativos está associada a um defeito das células T 
CD4
pos
CD25
pos
, designados por linfócitos T reguladores (Tregs), uma população celular 
essencial para a manutenção da tolerância imune. Desconhece-se, no entanto, se este 
distúrbio imunorregulatório na HAI é devido a uma redução do número de Tregs, a um 
defeito intrínseco da sua função, ou a resistência das células efetoras à inibição exercida 
pelas Tregs, ou ainda a uma combinação de todos estes mecanismos. Estudos recentes 
mostraram que as Tregs funcionais se caracterizam pela expressão muito baixa ou 
mesmo ausente de CD127, enquanto as células T ativadas se distinguem pela expressão 
desta molécula, indicando que o CD127 poderá ser um bom marcador fenotípico para a 
distinção destas duas populações celulares. Por outro lado, estudos em ratinhos 
demonstraram que a galectina-9 (GAL-9), um dos membros da família da galectinas e 
que é expressa pelas Tregs, inibe as respostas Th1 após se ligar ao T cell 
immunoglobulin and mucin domain 3 (TIM-3), o seu recetor nas células efetoras. Posto 
isto, esta Tese teve como objetivo investigar possíveis causas responsáveis pelo 
comprometimento funcional das Tregs, explorando o papel desempenhando pelo 
CD127 e pela via TIM-3/GAL-9 na doença hepática auto-imune. 
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Foram estudados setenta e sete doentes, incluindo 39 doentes com o diagnóstico 
de síndrome de sobreposição HAI-colangite esclerosante. Quando considerados em 
conjunto, HAI e síndrome de sobreposição serão referidos como doença hepática 
autoimune (DHAI). A frequência e fenótipo das células CD4
pos
CD25
pos
CD127
neg
 e 
GAL-9
pos
 bem como das células CD4
pos
CD25
neg
TIM-3
pos
 foram avaliados por citometria 
de fluxo. A função supressora das Treg foi avaliada, após cultura com células CD25
neg
. 
Para determinar se a expressão da GAL-9 é essencial para a sua função, as Tregs foram 
tratadas com small-interfering-RNA para reprimir a tradução da GAL-9. Para avaliar se 
a expressão de TIM-3 confere susceptibilidade às células CD4
pos
CD25
neg
 T efetoras à 
ação supressora das Tregs, foram purificadas células CD4
pos
CD25
neg
TIM-3
pos
 (TIM-
3
pos
) e CD4
pos
CD25
neg
TIM-3
neg
 (TIM-3
neg
). 
A frequência das células reguladoras CD4
pos
CD25
pos
CD127
neg
 está reduzida nos 
doentes com DHAI. No entanto, esta população quando comparada com as Tregs 
convencionais (ie, aquelas CD4
pos
CD25
pos
, cTregs) caracteriza-se por uma expressão 
mais elevada de FOXP-3, CTLA-4, IL-10
, 
e uma expressão reduzida de Tbet, RORC, 
IFN- e IL-17, e expressão semelhante de TGF-As Tregs CD127neg inibiram a 
proliferação das células T CD25
neg
 com maior eficácia que as cTregs. Nos doentes com 
DHAI, o tratamento com anticorpos monoclonais anti-IFN- e anti-IL-17 melhorou a 
capacidade supressora das cTregs, mantendo inalterada aquela das Tregs CD127
neg
. O 
tratamento com anti-IL-10 resultou numa redução da função supressora das Tregs em 
indivíduos saudáveis, mas não nos doentes com DHAI. 
Na DHAI, a frequência das Tregs que expressam GAL-9 está reduzida e 
correlaciona-se com os níveis de IgG e com os títulos de auto-anticorpos. No seio das 
células GAL-9
pos
, a(s) frequência(s) de: a) células FOXP3
pos
 é inferior na DHAI quando 
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comparado com os controlos saudáveis; b) células Tbet
pos
, GATA-3
pos
 e RORC
pos
 são 
semelhantes nos dois grupos de indivíduos; c) células produtoras de IL-10 é menor na 
DHAI do que nos controlos, e mais elevada na fração GAL-9
neg
 em ambos os grupos; d) 
células produtoras de TGF- é menor na DHAI do que nos controlos; e) células 
produtoras de IFN- bem como de IL-17 são mais elevadas na DHAI do que os 
controlos saudáveis. O tratamento das Tregs GAL-9
pos
 com siRNA reduziu 
drasticamente a sua capacidade de suprimir a proliferação das células-alvo.  
Na DHAI, a frequência das células TIM-3
pos
 no seio das células CD4
pos
CD25
neg
 
e das suas populações Tbet
pos
 e RORC
pos
 foi inferior que nos controlos saudáveis. As 
células TIM-3
pos
 proliferaram menos vigorosamente e demonstraram ser mais 
suscetíveis ao controlo exercido pelas Tregs do que as células TIM-3
neg
. 
Em conclusão, redução do número das Tregs CD127
neg
, bem como diminuição 
da expressão de GAL-9 pelas Tregs e de TIM-3 pelas células efetoras contribuem para o 
defeito na imunorregulação na DHAI, tornando as Tregs menos capazes de suprimir, e 
as células efetoras menos suscetíveis a serem reguladas. 
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1. Definition of autoimmune hepatitis 
Autoimmune hepatitis (AIH) is a severe hepatopathy of unknown cause 
progressing to cirrhosis and liver failure if not treated. AIH was first described in 1950 
by Jan Waldenström, who reported a series of young women affected by a severe form 
of fluctuating persistent hepatitis associated with acneiform rashes, spider angiomas, 
anovulatory amenorrhea and marked elevations of serum immunoglobulins 
(Waldenström 1950). Subsequent observations reporting the presence of lupus 
erythematosus cells and antinuclear antibodies (ANA) in a proportion of patients, led to 
postulate that a loss of immunological tolerance was the basis of this condition, that 
Mackay termed “lupoid hepatitis” in 1956 (Mackay et al. 1956, Joske and King 1955). 
Studies performed in the early 1960s reported a good response to steroid treatment 
(Mackay and Wood 1963); three clinical controlled trials carried out in the following 
decade established the life-saving value of corticosteroids in the treatment of patients 
with “HBsAg-negative hepatitis” (Cook et al. 1971, Soloway et al. 1972, Murray-Lyon 
et al. 1973, Kirk et al. 1980). In the following years AIH was recognised as a separate 
clinical entity which was named “chronic active autoimmune hepatitis” (Gurian et al. 
1985, Mackay 1994, McFarlane 1996). That term continued to be used until the end of 
the 1980s; after two international working meetings held in 1992 (Brighton, UK) and 
1994 (Los Angeles, USA), it was substituted by the term of “autoimmune hepatitis” on 
the basis that the disease appears to have a genetic predisposition and is therefore a 
priori chronic and is often characterised by a fluctuating course with periods of 
treatment-induced or spontaneous remission and consequently is not always active 
(Mackay 1993, Ludwig 1995). The panels of the two working meetings composed the 
International Autoimmune Hepatitis Group (IAIHG). The IAIHG was responsible for 
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the introduction of an established (Johnson and McFarlane 1993) and meanwhile 
revised (Alvarez et al. 1999) scoring system for the diagnosis of AIH. More recently, a 
simplified score intended to be used in the clinical practice has been proposed by the 
group (Hennes et al. 2008). 
Based on the type of serum autoantibodies, two types of AIH are recognised: 
type 1 (AIH-1), positive for ANA and/or anti-smooth muscle antibody (SMA), and type 
2 (AIH-2), defined by the positivity for anti-liver kidney microsomal type 1 antibody 
(anti-LKM-1) or for anti-liver cytosol type 1 antibody (anti-LC-1). 
 
2. Epidemiology 
The actual prevalence of AIH is unknown. Few descriptive epidemiological 
studies are available and the majority of them do not rely on standard criteria for 
patients´ inclusion, since they were performed prior to the introduction of the IAIHG 
scoring system. Moreover, early studies did not exclude patients with chronic hepatitis 
C. In a study conducted in a Norwegian population, Boberg et al. found a mean annual 
incidence of 1.9 cases per 100,000 people per year with a prevalence of 16.9 cases per 
100,000 people (Boberg et al. 1998). Another study, conducted in a Spanish population, 
reported an annual incidence of 0.83 cases per 100,000 inhabitants in the population 
aged > 14 years with a prevalence of 11.6 cases per 100,000 (Primo et al. 2004); it 
should be pointed out, however, that this was a hospital-based study, consequently 
limited by tertiary referral bias, which can result in an underestimation of incidence and 
prevalence and in an overestimation of disease severity. A study that examined the 
prevalence of AIH in Alaskan natives reported a prevalence of definite AIH of 34.5 
cases per 100,000 (Hurlburt et al. 2002); this was the first study to use the IAIHG 
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scoring system and the rate observed was over twice as high as that of the other 
previous population based study, the Norwegian one referred to earlier. A study from 
the United Kingdom, conducted in a secondary care referral centre, showed that the 
annual incidence of AIH is 3.5 per 100,000 inhabitants (Whalley et al. 2007). More 
recently, an epidemiological study, carried out in New Zealand and in which 
standardised inclusion criteria were deployed, reported an annual incidence of 2.0 cases 
of AIH per 100,000 and a point prevalence of 24.5 cases per 100,000 (Ngu et al. 2010). 
In Asia, most reports come from Japan, where AIH is considerably less frequent than in 
Western countries with an incidence estimated between 0.08 and 0.15 cases per 100,000 
people per year (Toda et al. 1997, Nishioka 1998). Similarly, AIH was long thought to 
be uncommon in China (Lam et al. 1980); however, with a more refined diagnostic 
work-up of patients, AIH has increasingly been reported in that country (Qiu et al. 
2011). 
The prevalence of AIH-2, which affects mainly children and young adults, is 
unknown, also owing to the fact that the diagnosis is often overlooked. At King´s 
College Hospital tertiary paediatric hepatology referral centre there has been a seven-
fold increase in the incidence of both types of AIH over the last decade (Vergani 2007). 
AIH represents approximately 10% of some 400 new paediatric referrals per year, two 
thirds of the cases being AIH-1 and one-third AIH-2 (Vergani 2007).  
AIH, though characterised by a strong female preponderance (ratio female/male 
= 3.6/1; Manns et al. 2010a), occurs in children and adults of both sexes. Although AIH 
was believed to be a disease of the young and middle aged population, it is now clear 
that it affects adults of all ages, including individuals older than 60 (Al-Chalabi et al. 
2006, Czaja and Carpenter 2006a). 
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3. Clinical Presentation 
AIH is characterised by highly variable modes of presentation and clinical 
manifestations (Krawitt 2008). In 30 to 40% of patients the onset of AIH is ill defined, 
mimicking that of acute hepatitis due to other causes (Crapper et al. 1986). Rarely, AIH 
presents as fulminant hepatic failure (Kessler et al. 2004). The majority of adult 
patients, however, have an insidious onset with a clinical course characterised by 
progressing  fatigue, relapsing jaundice, weight loss and sometimes arthralgia (Vergani 
and Mieli-Vergani 2011a). A presentation with complications of portal hypertension, 
such as gastrointestinal bleeding or hypersplenism, can occasionally occur (Gregorio et 
al. 1997). Finally, some patients are completely asymptomatic and are diagnosed after 
incidental discovery of abnormal liver function tests. At least a third of patients, 
regardless of the mode of presentation, have histological evidence of cirrhosis at the 
time of diagnosis, indicating that they probably have had subclinical disease for a long 
time (Krawitt 2006). Even in the group of patients presenting with acute disease, liver 
biopsy often shows signs of advanced fibrosis or cirrhosis (Lohse and Mieli-Vergani 
2011).  
AIH may occasionally develop during pregnancy or post-partum in a previously 
asymptomatic patient (Schramm et al. 2006, Samuel et al. 2004). Furthermore, post-
partum exacerbations may occur in patients whose condition improved during 
pregnancy (Heneghan et al. 2001), possibly due to the natural pregnancy-associated 
immunosuppressive state (Aluvihare et al. 2004).  
A family history of autoimmune diseases is present in 40% of patients. Also, at 
least 20% of AIH patients have concomitant autoimmune diseases or will develop them 
during follow-up (Gregorio et al. 1997; Table 1.1.). 
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Disease Frequency Reference
Common
Thyroiditis 10 – 23% Werner et al., 2008, Al-Chalabit et al., 2008, Muratori et al. 2009
Diabetes 7 – 9% Werner et al., 2008
Inflammatory bowel disease 2 – 8% Perdigoto et al., 1992, Anagnostopoulos et al., 2006,
Rheumatoid arthritis 2 – 5% Nobili et al., 2005, Muratori et al., 2009
Psoriasis 3% Werner et al., 2008
Sjögren s syndrome 1 – 4% Matsumoto et al., 2005, Werner et al., 2008, Muratori et al., 2009
Mixed connective tissue disease 2.5% Muratori et al., 2009
Systemic lupus erythematosus 1 – 2% Irving et al., 2007, Werner et al., 2008, Muratori et al. ,2009
Coeliac disease 1 – 2% Kaukinen et al., 2002, Villalta et al., 2005, Caprai et al., 2008
Glomerulonephritis 1% Werner et al., 2008, 
Multiple sclerosis 1% Nunez et al., 2004, Muratori et al., 2009
Case reports
Anti-phospholipid syndrome Uthman and Khamashta, 2007
Autoimmune pancreatitis Quinet de Andrade et al., 2000
Felty syndrome Inaba et al., 1995, Sema et al., 2005
Fibrosing alveolitis Paul et al., 1991
Haemolytic anemia Gurundu et al., 2001
Idiopatic thrombocytopenia purpura Yamaike et al., 2002
Mononeuritis multiplex Luth et al., 2006
Myastenia gravis Han et al., 2000
Panniculitis Banerjee et al., 1989, Fujiwara et al., 2000, 
Polyglandular autoimmune syndrome type 1 Michele et al., 1994
Polymiositis Ko et al., 1995
Uveitis Romanelli et al., 2006, Romanelli and Almerigogna, 2009
Vitiligo Sacher et al.,  1990
Table 1.1. Extra-hepatic diseases associated with autoimmune hepatitis.  
 
Complications in AIH are those seen in any other progressive liver disease: in 
some patients, despite immunosuppressive treatment, chronic hepatitis progresses to 
cirrhosis and ultimately to hepatocellular carcinoma (HCC; Krawitt 2006). HCC, 
however, occurs rarely in AIH, where it is less frequent than in patients with chronic 
viral hepatitis (Yeoman et al. 2008). 
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Feature Definite AIH Probable AIH
Serum biochemistry Any abnormality in serum aminotransferases, 
especially if the serum alkaline phosphatase is not
elevated.
Normal levels of 1-anti-trypsin and
caeruloplasmin
Same as for definite AIH but patients with
abnormal serum concentrations of copper or
caeruloplasmin may be included contigent on the
exclusion of Wilson s disease by appropriate
investigations
Serum immunoglobulins Total serum globulins or gamma-globulin or IgG 
concentrations > 1.5 times upper limit of normal
Any elevation of serum globulin, gamma-
globulin or IgG over the upper limit of normal
Serum autoantibodies ANA, SMA or anti-LKM-1 titres ≥ 1:80.
Lower titres (particularly anti-LKM-1) may be
significant in children.
Negative AMA
Same as for definite but at titres ≥ 1:40 or
presence of other specified autoantibodies
Liver histology Interface hepatitis of moderate or severe activity 
with or without lobular hepatitis or bridging 
necrosis.
No biliary lesions, granulomas or other 
preeminent changes suggestive of a different 
etiology
Same as for definite AIH
Viral markers Negativity for markers of current infection with 
hepatitis A, B and C viruses
Same as for definite AIH
Other etiological markers Average alcohol consumption    < 25 g/day.
No recent use of hepatotoxic drugs 
Average alcohol consumption    < 50 g/day and 
no recent use of hepatotoxic drugs.
Patients who have consumed large amounts of 
alcohol or who have recently taken potentially 
hepatotoxic drugs may be included, if there is 
clear evidence of continuing liver damage after 
abstinence from alcohol or withdrawl of the drug
4. Diagnosis 
4.1. Scoring systems   
The diagnosis of AIH is based on the presence of elevated transaminase and 
immunoglobulin (Ig) G levels, positivity for circulating autoantibodies, and a picture of 
interface hepatitis on histology (Table 1.2.). 
 
Table 1.2. Descriptive criteria for the diagnosis of autoimmune hepatitis. 
 
AIH, autoimmune hepatitis; AMA, anti-mitochondrial antibodies; ANA, anti-nuclear antibodies; 
SMA, anti-smooth muscle antibodies; anti-LKM-1, anti-liver kidney microsomal type 1 
antibodies 
Adapted from Alvarez F, Berg PA et al. J Hepatol 1999; 31: 929-9 
 
The criteria for the diagnosis of AIH have been established and revised by the 
IAIHG (Johnson and McFarlane 1993, Alvarez et al. 1999). This diagnostic system, 
which includes positive and negative scores, grades clinical, laboratory and histological 
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features of AIH, including response to treatment. The system was originally designed 
for research purposes with the intent of standardising the diagnosis of AIH throughout 
the literature, but it later proved to be also clinically useful in assessing patients with 
few or atypical features of the disease (Czaja and Carpenter 1996, Czaja and Manns 
2010).  
In the IAIHG scoring system, differences between a definite and probable 
diagnosis of AIH relate mainly to the degree of serum gamma-globulin or IgG 
elevation, levels of ANA, SMA or anti-LKM-1 and exposure to alcohol, medications or 
infections that can cause liver injury. Cholestatic laboratory and histological changes 
carry a negative score. In rare cases, the presence of autoantibodies to 
asialoglycoprotein receptor (anti-ASGPR), LC-1, soluble liver antigen/liver pancreas 
(anti-SLA/LP) and atypical perinuclear anti-neutrophil cytoplasmic antibodies 
(pANCA) supports a probable diagnosis of AIH in the absence of conventional 
autoantibodies. Response to steroids strengthens the diagnosis of AIH and has been 
incorporated into the scoring system. A definite diagnosis before steroid treatment 
requires a score higher than 15, while a definite diagnosis after steroid treatment 
requires a score higher than 17 (Table 1.3.).  
The diagnositic criteria for children are slightly different from those of adults. In 
view of the fact that healthy children are very rarely positive for autoantibodies, titres as 
low as 1:20 for ANA and SMA and 1:10 for anti-LKM-1 are compatible with the 
diagnoses of type 1 and type 2 AIH respectively (Mieli-Vergani et al. 2009). 
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Parameter Feature Score
Sex Female +2
ALP:AST (or ALT) ratio > 3 –2
1.5 – 3 0
< 1.5 +2
Serum globulins or IgG (times above normal) > 2.0 +3
1.5 – 2.0 +2
1.0 – 1.5 +1
< 1.0 0
ANA, SMA or anti-LKM-1 titres > 1:80 +3
1:80 +2
1:40 +1
< 1:40 0
AMA Positive –4
Viral markers of active infection Positive –3
Negative +3
Hepatotoxic drug history Yes –4
No +1
Average alcohol < 25 g/day +2
> 60 g/day –2
Histological features Interface hepatitis +3
Plasma cells +1
Rosettes +1
None of the above –5
Biliary changes a –3
Atypical changes b –3
Immune diseases Thyroiditis, colitis, other +2
HLA DR3 or DR4 +1
Seropositivity for other autoantibodies Anti-SLA/LP, actin, ASGPR, p-ANNA +2
Response to therapy Remission +2
Relapse +3
Table 1.3. International autoimmune hepatitis group revised diagnostic scoring system. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pre-treatment score >15: definite AIH; 10-15: probable AIH; Post-treatment score >17: definite 
AIH; 12-17: probable AIH 
ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; 
IgG, immunoglobulin G; ANA, anti-nuclear antibody; SMA, anti-smooth muscle antibody; anti-
LKM-1, anti-liver kidney microsomal type 1 antibodies; AMA, anti-mitochondrial antibodies; 
SLA/LP, soluble liver antigen/liver pancreas; ASGPR, asialoglycoprotein receptor; p-ANNA, 
peripheral anti-nuclear neutrophil antibody; HLA, human leukocyte antigen 
a
 Including granulomatous cholangitis, concentric periductal fibrosis, ductopenia, marginal bile 
duct proliferation and cholangiolitis 
b
 Any other prominent feature suggesting a different aetiology 
Adapted from Alvarez F, Berg PA et al. J Hepatol 1999; 31: 929:938 
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Variable Cut-off Points
ANA or SMA ≥ 1:40 1
ANA or SMA ≥ 1:80 2 a
or anti-LKM-1 ≥ 1:40
or SLA Positive
IgG > upper limite of normal 1
> 1.10 times upper limit of normal 2
Liver histology Compatible with AIH 1
Typical of AIH 2
Absence of viral hepatitis Yes 2
Recently, a simplified scoring system has been proposed by the IAIHG (Hennes 
et al. 2008). This system, intended to be used in the clinical practice, assesses only four 
criteria: autoantibodies, IgG, histology and exclusion of viral hepatitis (Table 1.4.). 
 
Table 1.4. Simplified criteria for the diagnosis of autoimmune hepatitis.  
 
 
 
 
 
 
 
 
 
 
 
Score ≥ 6: probable AIH; ≥7: definite AIH 
ANA, anti-nuclear antibody; SMA, anti-smooth muscle antibody; anti-LKM-1, anti-liver kidney 
microsomal antibody type 1; SLA, soluble liver antigen; IgG, immunoglobulin G; AIH, 
autoimmune hepatitis 
a
 Addition of points achieved for all autoantibodies cannot exceed a maximum of 2 points 
Adapted from Hennes EM, Zeniya M et al. Hepatology 2008; 48: 169-176 
 
4.2. Laboratory abnormalities 
AIH is characterised by elevated levels of transaminases. In general the increase 
in aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels is much 
more striking than that observed for the levels of bilirubin and alkaline phosphatase 
(AP). Nonetheless, in some patients cholestasis is present; in these cases, extra-hepatic 
obstruction and cholestatic forms of viral hepatitis, drug-induced disease, primary 
biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and overlap syndromes 
(see section 5.) must be taken into consideration (Krawitt 2008).  
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Another laboratory feature typical of AIH, albeit not always present, is a 
generalised elevation of serum globulins and particularly gamma globulins mainly due 
to an increase in the IgG fraction (McFarlane 2002). The serum autoantibodies typically 
present in AIH include: ANA, SMA, anti-LKM-1, and anti-LC-1 (see section 4.3.). 
Anti-mitochondrial antibodies (AMA), typically present in PBC, are occasionally 
present in patients with AIH (Bhat et al. 2009) . Since autoantibodies may also be found 
in other liver diseases their presence as such is not diagnostic of AIH. 
 
4.3. Diagnostic autoantibodies 
A key diagnostic criteria shared by all the scoring systems referred above is the 
presence of autoantibodies to nuclear components, smooth muscle and liver kidney 
microsome type 1 (Table 1.5.). Testing for these autoantibodies should be performed in 
all cases of cryptogenic liver disease (Vergani et al. 2004). Autoantibody detection not 
only assists in the diagnosis but also allows the differentiation of AIH into type 1 and 
type 2. Positivity for ANA and/or SMA – characterising AIH-1 –, and for anti-LKM-1 – 
which defines AIH-2 –, tend to be mutually exclusive (Vergani et al. 2004); in those 
rare cases in which they are present simultaneously, the clinical course is similar to that 
of AIH-2. Antibodies to LC-1, SLA/LP, and to neutrophil cytoplasmic antigens  may be 
helpful to assist in the diagnosis of those patients negative for the defining AIH 
autoantibodies; for this reason, they were also included in the original and revised 
IAIHG diagnostic scoring systems (Johnson and McFarlane 1993, Alvarez et al. 1999).  
Figure 1.1. provides an algorithm for the use of autoantibodies in the diagnosis 
of AIH. 
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Autoantibody Target antigen (s) Liver disease Value in AIH Conventional 
method
of detection
Molecular 
based assays
ANA Multiple targets 
including:
chromatin 
ribonuclueoproteins
ribonucleoprotein 
complexes
AIH
PBC
PSC
Drug-induced
Chronic hepatitis C
Chronic hepatitis B
NAFLD
Diagnostic of AIH-1 IIF N/A
SMA Microfilaments 
(filamentous actin)
Intermediate filaments 
(vimentin, desmin)
Same as ANA Diagnostic of AIH-1 IIF N/A
Anti-LKM-1 Cytochrome P450 2D6 AIH-2
Chronic hepatitis C
Diagnostic AIH-2 IIF ELISA, IB, RIA
Anti-LC-1 Forminino-transferase 
cyclodeaminase
AIH-2
Chronic hepatitis C
Diagnostic of AIH-2
Prognostic of severe 
disease
IIF, DID, CIE ELISA, RIA
SLA/LP tRNP(Ser)Sec AIH
Chronic hepatitis C
Diagnostic of AIH
Prognostic of severe 
disease, relapse and
treatment dependence
Inhibition 
ELISA
ELISA, IB, RIA
Atypical 
p-ANCA
(p-ANNA)
Nuclear lamina 
proteins
AIH
PSC/AISC
Point towards
diagnosis of AIH
IIF N/A
AMA E2 subunits of 2-oxo-
acid dehydrogenase 
complexes, particularly 
PDC-E2
PBC Against diagnosis of 
AIH
IIF ELISA, IB, RIA
Table 1.5. Autoantibodies and their targets in autoimmune liver diseases. 
ANA, anti-nuclear antibodies; SMA, anti-smooth muscle antibodies; anti-LKM-1, anti-liver 
kidney microsomal antibody type 1; anti-LC-1, anti-liver cytosol antibody type 1; SLA/LP, 
soluble liver antigen/liver pancreas; pANCA, perinuclear anti-neutrophil cytoplasmic antibodies; 
pANNA, peripheral anti-nuclear neutrophil antibodies; AMA, anti-mitochondrial antibodies; 
AIH, autoimmune hepatitis; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; 
NAFLD, non-alcoholic fatty liver disease; IIF, indirect immunofluorescence; DID, double-
dimension immune-diffusion; CIE, counter-immune-electrophoresis; ELISA, enzyme-linked 
immunosorbent assay; IB, immunoblot; RIA, radio-immune-precipitation assay; N/A, not 
applicable 
 
Recognition and interpretation of immunofluorescence patterns is not always 
straightforward; such an operator-dependent technique allied to the relative rarity of 
AIH leads, not infrequently, to reporting errors. In addition, clinical interpretation errors 
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Liver disease of unknown cause 
Conventional serological 
testing
Secondary serological 
testing
ANA
SMA
LKM-1
AMA
F-actin
SLA/LP
LC-1
PDH-E2
pANNA
Cryptogenic 
chronic hepatitis
PSC
PBC
AIH
may occur due to the relative lack of standardisation of the tests and to a degree of 
unfamiliarity of some clinicians with the AIH disease spectrum. In this regard, the 
IAIHG has established a serology committee in order to define guidelines and develop 
procedures and reference standards for more reliable testing (Vergani et al. 2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Serological tests in the evaluation of acute or chronic hepatitis of unknown 
cause. The initial serological assessments for antinuclear (ANA), anti-smooth muscle (SMA), 
anti-liver kidney microsome type 1 (LKM-1), and anti-mitochondrial (AMA) antibodies. The 
results of these conventional tests direct the diagnostic effort. If one or more tests are positive, 
the diagnosis of autoimmune hepatitis (AIH) or primary biliary cirrhosis (PBC) should be 
pursued. If these tests are negative, other serological assessments are appropriate, including tests 
for antibodies to actin (F-actin), soluble liver antigen/liver pancreas (SLA/LP), liver cytosol type 
1 (LC-1), the E2 subunits of the pyruvate dehydrogenase complex (PDH-E2), peripheral anti-
nuclear  neutrophil antibodies (pANNA). These results may suggest other diagnoses, including 
primary sclerosing cholangitis (PSC), overlap syndromes or cryptogenic chronic hepatitis. 
Adapted from Manns MP, Czaja AJ et al. Hepatology 2010; 51: 2193-2213. 
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4.3.1. Anti-nuclear antibodies 
ANA, the first AIH-associated autoantibody (Mackay et al. 1956), is readily 
detectable and gives a nuclear staining in rodent kidney, stomach and liver sections 
(Figure 1.2.). In most cases, its pattern, especially in the liver, is homogeneous, with a 
coarsely or finely speckled pattern observed less frequently (Czaja et al. 1997). 
Figure 1.2. Antinuclear antibodies in autoimmune hepatitis. Immunofluorescence pattern of 
antinuclear autoantibodies on rodent liver section. 
 
Human epithelial type 2 (HEp2) cells, characterised by prominent nuclei, should 
be used for a clearer definition of the nuclear pattern (Figure 1.3.); however, they should 
not be used for screening purposes due to a high positivity rate in adult and paediatric 
healthy populations (Tan et al. 1997, Hilario et al. 2004). In AIH, ANA target antigens 
are heterogeneous and not completely defined. ANA have been found to be reactive 
with single- and double-stranded deoxyribonucleic acid (DNA), small nuclear 
ribonucleoproteins (sn-RNPs), centromeres, histones, chromatin and cyclin A 
(Burlingame et al. 1993, Czaja et al. 1994, Strassburg et al. 1996a).  The mechanism 
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leading to ANA production in AIH is not clear, although it has been related to the 
release of nuclear components following hepatocyte injury and/or a loss of B cell 
tolerance to several nuclear components (Nishioka 1998). In AIH, ANA titre is 
clinically relevant if higher than 1/40 in adults and than 1/20 in children (Vergani et al. 
2004), in whom it correlates with disease activity (Gregorio et al. 2002). 
 
Figure 1.3. Anti-nuclear antibody immunofluorescence pattern on human epithelial type 2 
cells. The homogeneous pattern (left) is the most common in autoimmune hepatitis (AIH). The 
speckled pattern (right) is less common in AIH, but more frequent in other conditions (e.g. 
chronic hepatitis C infection). 
 
ANA have also been identified in up to 52% of patients with PBC (Strassburg 
and Manns 2002), a disease condition associated with the presence of AMA. However, 
while no AIH-specific ANA has been reported so far, PBC-specific ANA have been 
demonstrated and are recognisable by immunofluorescence giving a multiple nuclear 
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dot or a rim-like membranous pattern on HEp-2 or HeLa cells used as substrate 
(Szostecki et al. 1987, Bandin et al. 1996, Wesierska-Gadek et al. 1996). ANA are 
present not only in other autoimmune disorders such as systemic lupus erythematosus 
(SLE), Sjögren syndrome and scleroderma (Tan 1989) but also in patients with viral 
hepatitis, drug-induced hepatitis, and alcoholic and non-alcoholic fatty liver disease 
(Strassburg and Manns 2002, Adams et al. 2004); thus, though considered useful as 
diagnostic markers, ANA are not specific for AIH 
 
4.3.2. Anti-smooth muscle antibodies 
SMA antibodies are detected on rodent kidney, stomach and liver sections, 
where they stain the walls of the arteries. In the stomach they also stain the muscularis 
mucosa and the lamina propria. On the renal substrate, it is possible to visualise the V 
(vessels), G (glomeruli) and T (tubules) patterns (Bottazzo et al. 1976; Figure 1.4.). The 
VG and VGT patterns are more specific for AIH than the V pattern. The VGT pattern 
corresponds to the “F-actin” or microfilament (MF) pattern observed when cultured 
fibroblasts are used as substrate (Muratori et al. 2002). Neither the VGT nor the anti-
MF patterns are, however, entirely specific for AIH. SMA are directed against 
components of the cytoskeleton such as actin and non-actin components including 
tubulin, vimentin, desmin, and skeletin (Strassburg and Manns 2002). 
 In AIH, they usually occur at titres higher than 1/80, though in very young 
patients with AIH-1 the titres may be as low as 1/20 (Gregorio et al. 1997). Like ANA, 
SMA are not specific for AIH, since their presence – particularly its V pattern – has also 
been reported in advanced liver disease of other aetiologies, infectious diseases and 
rheumatic disorders (Manns and Vogel 2006). 
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Figure 1.4. Anti-smooth-muscle antibodies in autoimmune hepatitis. Immunofluorescent 
pattern of anti-smooth-muscle antibodies (SMA) on rodent renal section. SMA stains the 
glomeruli (G) and arterial vessels (V). 
 
It has been reported that antibodies to actin are found in a subset of patients that 
also produce SMA and are characterised by reactivity to F-actin in laboratory tests 
(Lidman et al. 1976, Toh 1979). Depending on the assay, antibodies to actin can be 
more specific than SMA for the diagnosis of AIH and for prognostic purposes (Fusconi 
et al. 1990). Indeed, patients that test positive for anti-actin antibodies in at least two 
different assays present at an earlier age and are less responsive to corticosteroids than 
patients without these antibodies (Czaja et al. 1996).  
 
4.3.3. Anti-liver kidney microsomal type 1 antibodies 
Anti-LKM-1 antibodies, the AIH-2 serological marker, stain the hepatocellular 
cytoplasm and the P3 portion of the renal tubules on rodent substrates. Since both anti-
LKM-1 and AMA stain liver and kidney, they can be misdiagnosed (Bogdanos et al. 
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2008). Compared to anti-LKM-1, AMA stains the liver more faintly and the renal 
tubules more diffusely with an accentuation of the distal ones (Figure 1.5.). Moreover, 
while AMA stains gastric parietal cells, anti-LKM-1 does not (Rizzetto et al. 1973).  
Figure 1.5. Immunofluorescence pattern of anti-liver kidney microsomal type 1 and anti-
mitochondrial antibodies. Anti-liver kidney microsomal type 1 (anti-LKM-1) antibodies 
(A&B) stain stronger the proximal tubules (A), while anti-mitochondrial (AMA) antibodies 
(C&D) stain the smaller, distal tubules (C) of rodent kidney. Since these specificities are 
sometimes confused, the use of rodent liver (B) and stomach (D) sections is recommended to 
discriminate between the two reactivities; AMA typically stain the gastric parietal cells while 
anti-LKM-1 stain the liver but not the stomach. 
 
The identification of the molecular targets of anti-LKM-1 – cytochrome 
P4502D6 (CYP2D6) –, and AMA – enzymes of the 2-oxo-acid dehydrogenase 
complexes –, have led to the establishment of immune-assays based on the use of 
recombinant or purified antigens. Commercially available enzyme-linked 
immunosorbent assays (ELISAs) are accurate for detecting anti-LKM-1, at least in the 
context of AIH-2, and reasonable for the detection of AMA. Thus, if 
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immunofluorescence remains doubtful, the use of molecularly based immune-assays 
may be of help (Vergani et al. 2004, Mieli-Vergani et al. 2009).  
Anti-LKM-1 titre is clinically relevant if equal or higher than 1/40 in adult 
patients and 1/10 in subjects up to the age of 18 years (Vergani et al. 2004). 
Intriguingly, anti-LKM-1 are also present in up to 10% of patients with chronic hepatitis 
C virus (HCV) infection, and their titre has been found to be associated with disease 
activity (Lenzi et al. 1990). 
A second type of anti-LKM antibodies (anti-LKM-2), nowadays of historical 
interest, was associated with hepatitis induced by ticrynafen, an uricosuric diuretic, 
withdrawn from clinical use in the United States in 1980 because of its severe 
hepatotoxicity.  Anti-LKM-2 antibodies were found to react most intensely with the 
cells in the initial third of the proximal tubule and their target antigen was defined as 
cytochrome P4502C9 (CYP2C9; Lecoeur et al. 1996). Anti-LKM-3, which target 
members of the uridine glucuronosyltransferases (UGTs) family 1, give an 
immunofluorescent pattern similar to anti-LKM-1, though they occur mainly in hepatitis 
delta (D) patients; their presence, however, has also been reported in up to 19% of 
patients with AIH-2 (Philipp et al. 1994, Strassburg et al. 1996b, Csepregi et al. 2001). 
 
4.3.4. Anti-liver cytosol type 1 antibodies 
Anti-LC-1 antibodies stain the cytoplasm of liver cells with relative sparing of 
centrilobular area (Martini et al. 1988), but is usually obscured by concurrent presence 
of anti-LKM-1 (Figure 1.6.). In the presence of anti-LKM-1, anti-LC-1 can be detected 
by the use of liver cytosol in double-dimension immunodiffusion, or counter-
immunoelectrophoresis, and a positive reference serum (Muratori et al. 1995). 
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Figure 1.6. Anti-liver cytosol type 1 antibodies. Immunofluorescence pattern of anti-liver 
cytosol type 1 (anti-LC-1) antibodies on a rodent liver section: they stain the cytoplasm of 
hepatocytes with a weakening of the stain around the central vein. 
 
Anti-LC-1 antibodies have been found either alone or in association with anti-
LKM-1 in patients with AIH-2 (Abuaf et al. 1992). Their presence scores positively 
towards the diagnosis of AIH-2, allowing prompt initiation of treatment. Anti-LC-1 
antibodies have also been reported in patients with HCV (Lenzi et al. 1995) and in AIH-
1 (Han et al. 1995). The molecular target has been identified as the formimino-
transferase cyclodeaminase, an enzyme involved in folate metabolism and most highly 
expressed in the liver (Lapierre et al. 1999). The presence and titre of anti-LC-1 
antibodies has been found to correlate with disease activity and represents a potentially 
useful marker of residual hepatocellular inflammation in AIH (Muratori et al. 1998). 
 
4.3.5. Anti-soluble liver antigen/liver-pancreas antigen antibodies 
Anti-SLA and anti-LP, originally described as individual antibodies, share the 
same antigenic target and have subsequently been identified as the same autoantibody 
General introduction 
 
 
[74] 
 
(Wies et al. 2000). Anti-SLA/LP are detected by radioimmunoassay and ELISA but 
cannot be detected by immunofluorescence (Vergani et al. 2009).  
The presence of anti-SLA/LP in the absence of conventional antibodies, has led 
to the proposed definition of a third group of AIH (AIH-3; Manns et al. 1987). 
However, early reports used a cut-off point for conventional autoantibody levels higher 
than those currently used for the diagnosis of AIH; therefore, this entity has not been 
accepted by the IAIHG. Nevertheless, anti-SLA/LP appears to be highly specific for the 
diagnosis of AIH, and its detection at the time of diagnosis identifies patients with a 
more severe disease and a worse outcome (Ma et al. 2002a).  
Screening of cDNA expression libraries using high titre anti-SLA serum has 
allowed to identify UGA tRNA suppressor-associated antigenic protein (tRNP
(ser)sec
) as 
the anti-SLA target (Costa et al. 2000). More recently, this target antigen has been 
renamed as Sep (O-phosphoserine) tRNA:Sec (selenocysteine) tRNA synthase (Palioura 
et al. 2009). Molecularly based diagnostic assays have become available, but their full 
evaluation is still underway (Vergani et al. 2009). 
 
4.3.6. Anti-neutrophil cytoplasmic antibodies 
ANCAs react to cytoplasmic components of neutrophils and give a perinuclear 
(pANCA) or a cytoplasmic (cANCA) pattern. In AIH-1, akin to PSC and inflammatory 
bowel disease (IBD), pANCAs are frequently detected, but they are atypical, since they 
react with peripheral nuclear membrane components (hence the name of peripheral anti-
nuclear neutrophil antibody [pANNA]; Bogdanos et al. 2009). In contrast to AIH-1, 
pANNA is absent in AIH-2. Detection of pANNA aids the diagnosis of AIH, 
particularly in the absence of other autoantibodies (Vergani et al. 2004).    
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4.3.7. Anti-asialoglycoprotein receptor antibodies 
Attempts to identify putative auto-antigens specifically expressed on the 
hepatocyte surface in AIH have led to the description of a crude liver extract preparation 
known as the liver specific protein (LSP) and its major component, the 
asialoglycoprotein receptor (ASGPR; McFarlane et al. 1984). ASGPR, also designated 
hepatic lectin, is a type II transmembrane glycoprotein. It is the only known liver-
specific auto-antigen, and is constitutively expressed on the hepatocellular membrane. 
Antibodies to ASGPR are observed in 88% of all patients with AIH and can co-exist 
with ANA, SMA and anti-LKM-1 (Strassburg and Manns 2002). However, they are not 
disease specific, as they can also be found in viral hepatitis, drug-induced hepatitis and 
PBC (Treichel et al. 1993). In AIH the levels of anti-ASGPR correlate with 
inflammatory disease activity and may be used as an additional marker to monitor 
treatment efficacy (Treichel et al. 1994). 
 
4.4. Histology 
Since transaminases and IgG levels do not reflect the extent of histological 
inflammatory activity, or the presence or absence of cirrhosis, liver biopsy is mandatory 
not only to confirm the diagnosis but also to evaluate the severity of liver damage. 
Hepatitis at the portal-parenchymal interface, known as interface hepatitis, is 
typical, though not exclusively observed in AIH (Czaja and Carpenter 1997). This 
picture is characterised by a lymphoplasmacytic infiltrate that crosses the limiting plate 
and invading the liver parenchyma (Figure 1.7.). Lymphocytes, plasma cells and 
histiocytes surround individual dying hepatocytes at the portal-parenchymal interface 
and in the lobule. Though plasma cells are usually abundant at the interface and 
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throughout the lobule, their presence in low number does not exclude the diagnosis of 
AIH (Vergani et al. 2009).  
Other lesions that may be present include hepatocyte swelling and pycnotic 
necrosis. Fibrosis is present in all but the mildest forms of the disease. In contrast to 
patients with an insidious course, those presenting with acute liver failure show 
histologic features that predominate in the centrilobular area (Stravitz et al. 2011). 
Many patients presenting with fulminant hepatic failure tend to have massive necrosis 
and multilobular collapse; importantly, they have less fibrosis than those presenting 
with a more insidious course (Krawitt 2006). 
 
Figure 1.7. Histology of autoimmune hepatitis. The portal and periportal inflammatory 
infiltrate characteristic of autoimmune hepatitis is composed of lymphocytes, 
monocytes/macrophages and plasma cells (arrows showing plasma cell infiltratation), and is 
known as interface hepatitis. Haematoxilin & eosin staining (Picture kindly provided by Dr 
Alberto Quaglia, Institute of Liver Studies, King´s College Hospital). 
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Despite the fact that sampling variation may occur in needle biopsy specimens, 
especially in the presence of cirrhosis, the severity of the histological appearance is 
usually of prognostic value. However, even patients with cirrhosis at presentation 
respond well to immunosuppressive treatment (Mieli-Vergani and Vergani 2002). 
Although the characteristic portal-parenchymal lesion usually spares the biliary 
tree, a small proportion of patients may show inflammatory changes surrounding the 
bile ducts, suggesting the presence of an overlap with sclerosing cholangitis, which 
occurs more frequently in the pediatric setting (Gregorio et al. 2001). 
 
5. Overlap syndromes 
The term “overlap syndrome” has been introduced  to the field of hepatology to 
describe variant forms of AIH presenting with concomitant features of AIH and PBC or 
PSC (Czaja 1996). Standardisation of diagnostic criteria for overlap syndromes has not 
been achieved so far. There is still controversy as to whether these overlap syndromes 
represent distinct entities or are variants of the major autoimmune liver diseases (Beuers 
2005). In this regard, a recent position statement published by the IAIHG advocates that 
patients with overlapping features should not be categorised as separate diagnostic 
entities, but instead considered to be part of the ‘‘classical’’ diseases  (Boberg et al. 
2011).  
The common forms that have been described are: 1) PBC with features of AIH 
and 2) AIH with biliary features suggestive of PSC. Although they usually occur at the 
same time (termed as “true” overlap syndromes), they can also occur sequentially, i.e. 
patients present with features of one disease and subsequently develop characteristics of 
the other (Abdo et al. 2002). 
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5.1. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome 
AIH and PBC are the most prevalent autoimmune liver diseases. Liver function 
tests typically show a hepatitic pattern in AIH, and a predominantly cholestatic pattern 
in PBC; moreover, while an elevation in IgG level is typical of AIH, an increase in IgM 
is present in the majority of PBC patients (Vierling 2004). Patients presenting with 
features of both diseases have been described since the 1970s (Kloppel et al. 1977, 
Okuno et al. 1987). In 1996, Czaja reported that PBC-AIH overlap was present in 8% of 
patients with AIH or PBC (Czaja 1996). This information was then confirmed by 
Chazouillères et al. who found that PBC-AIH overlap accounted for 9% of PBC patients 
(Chazouilleres et al. 1998). Subsequently, the same authors reported that AIH can 
develop in patients with long standing PBC (Poupon et al. 2006). Accordingly, it is 
speculated that in PBC, the overlap syndrome represents one end of a spectrum of 
immune-mediated injury in which damage to hepatocytes is more prominent and may 
assume the form of interface hepatitis (Lohse et al. 1999). 
 
5.2. Autoimmune hepatitis-primary sclerosing cholangitis overlap syndrome 
 AIH-PSC overlap syndrome has been described in various reports over the last 
few decades, and  is now assumed to be present in a considerable proportion of patients 
with autoimmune liver disease (el-Shabrawi et al. 1987, Rabinovitz et al. 1992, Gohlke 
et al. 1996, McNair et al. 1998). AIH-PSC overlap is characterised by ANA and/or 
SMA seropositivity, hypergammaglobulinaemia and interface hepatitis – all features 
typical of “classical” AIH – in conjunction with cholestatic biochemical alterations, 
frequent concurrence of IBD, and histological features of fibrous obliterative 
cholangitis, ductopenia, portal tract oedema and/or bile stasis (Floreani et al. 2005). The 
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diagnosis is supported by cholangiographic changes of intra-hepatic and/or extra-
hepatic PSC (Kaya et al. 2000). In children, overlapping features of AIH and PSC are 
much more common than in adults and the term autoimmune sclerosing cholangitis has 
been coined (Gregorio et al. 2001; see section 7.2.). 
 
6. Treatment 
The goal of AIH treatment is to obtain early complete remission, to prevent 
disease progression, and to maintain this in the long term on the lowest possible dose of 
medication (Vergani and Mieli-Vergani 2011b). With the exception of a fulminant 
presentation with encephalopathy, AIH responds satisfactorily to immunosuppressive 
treatment whatever the degree of liver impairment, with a reported remission rate 
around 80% (Krawitt 2006). 
 
6.1. Standard treatment 
In the early 70s, three randomised clinical trials in adults with AIH provided the 
basis for the current immunosuppressive regimens, collectively suggesting that 
treatment with prednisolone improves liver function tests, ameliorates symptoms and 
prolongs survival (Cook et al. 1971, Soloway et al. 1972, Murray-Lyon et al. 1973). 
Although azathioprine was not able to induce remission when used on its own, it did 
allow the maintenance of remission in association with a significantly reduced dose of 
steroids (Johnson et al. 1995). Initial treatment with prednisone (or prednisolone) with 
or without azathioprine should be instituted as soon as the diagnosis is made, and not 
delayed for 6 months as suggested in the early studies (Lohse and Mieli-Vergani 2011). 
Standard treatment regimens are summarised in Table 1.6. 
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Population Initial regimen Maintenance
Adults Prednis(ol)one 60 mg/day
OR
Prednis(ol)one 30-60mg/day in combination with 
azathioprine 1-2 mg/kg/day
Prednis(ol)one 10 mg/week reduction until 20 
mg/day, followed by of 5 mg/week reduction 
until 10 mg/day and by 2.5 mg/week reduction to 
reach maintenance (5 mg/day)
Azathioprine 1-2 mg/kg/day if in combination 
with prednis(ol)one or 2 mg/kg/day if alone
Children Prednis(ol)one 1-2 mg/kg/daily (up to 60 
mg/daily) for two weeks either alone or in
combination with azathioprine  1-2 mg/kg/day
Prednis(ol)one taper over 6-8 weeks to 0.1-0.2 
mg/kg/day or 5mg/day
Azathioprine 1-2 mg/kg/day if added initially
The initial approach to therapy partly depends upon histologic findings (Krawitt 
2006). Standard treatment is indicated in any patient with evidence of interface 
hepatitis, with or without fibrosis or cirrhosis (Manns et al. 2010a). Transaminase and 
IgG levels do not correlate with histological damage and consequently provide limited 
help with respect to treatment initiation. In patients with portal inflammation only, 
institution of therapy is determined by AST and IgG levels, and/or by the presence of 
symptoms (Krawitt 2008). The therapeutic approach in patients with a milder form of 
the disease – who may be asymptomatic or pauci-symptomatic, and are detected 
incidentally after discovery of abnormal liver function tests – is less clear (Vergani and 
Mieli-Vergani 2011b). The benefit of therapy is undefined and may be so low that the 
risk of corticosteroid side effects might outweigh its possible benefits; this is 
particularly relevant when starting therapy in post-menopausal women and elderly 
patients (Al-Chalabi et al. 2006). 
 
Table 1.6. Immunosuppressive treatment regimens for adults and children with 
autoimmune hepatitis.  
Adapted from Manns MP, Czaja AJ et al. Hepatology 2010; 51: 2193-2213. 
 
Although some patients may remain in remission after drug treatment is 
withdrawn, most require long-term maintenance therapy. Despite the absence of firm 
guidelines, it is cautious not to attempt withdrawal of immunosuppression within 2 
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years of diagnosis (Manns et al. 2010a). During withdrawal attempts, it is essential to 
closely monitor the liver function tests, as relapse may be severe and even fatal. Patients 
who have successfully stopped immunosuppression should undergo long-term follow-
up, as relapse can occur even 10 years later (Vergani and Mieli-Vergani 2011b). 
 
6.1.1. Adverse side-effects 
Corticosteroid-related side-effects must be considered and may influence the 
decision of treatment and the choice of medications (Table 1.7.). The most common 
side effect of steroid treatment is cushingoid changes, which affect the majority of 
patients after prolonged treatment (Summerskill et al. 1975). Less common, but severe, 
side-effects include osteoporosis, vertebral collapse, diabetes, cataract, hypertension and 
psychosis. These conditions are not necessarily contra-indications for the use of 
corticosteroids, but their presence may require special precautions and monitoring. In 
13% of patients the development of such complications leads to dose reduction or even 
premature drug withdrawal; the most common reasons for treatment withdrawal are 
cosmetic changes or obesity, osteopenia with vertebral collapse, and brittle diabetes 
(Manns et al. 2010a).  
Complications of azathioprine in AIH affect 10-20% of patients and include 
cholestatic hepatitis, veno-occlusive disease, pancreatitis, nausea and vomiting, rash and 
bone marrow suppression; these complications usually subside upon drug withdrawal 
(Manns et al. 2010a; Table 1.7.).  The major side-effect of azathioprine is cytopenia; the 
risk to develop it relates to low erythrocyte concentration of thiopurine methyltranferase 
(TPMT) activity (Lennard et al. 1989, Ben Ari et al. 1995). The genes encoding TPMT 
are highly polymorphic, and deficiency of TPMP is present in 0.3-0.5% of the 
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Prednisolone-related Azathioprine-related
Common
Facial rounding Nausea
Dorsal hump striae Emesis
Weight gain Rash
Acne Fever
Facial hirsutism Cytopenia
Alopecia
Uncommon
Osteopenia Pancreatitis
Vertebral compression Opportunistic infections
Cataracts Arthralgia
Diabetes (brittle) Cholestatic liver injury
Emotional instability
Hypertension (labile)
Rare
Pancreatitis Malabsorption
Opportunistic infections Malignancy
Bone marrow failure
Teratogenicity
population (Gisbert et al. 2007), though not all patients with deficiency experience bone 
marrow failure (Kaskas et al. 2003). While azathioprine is contra-indicated in 
homozygotes for TMTP deficiency, heterozygotes tolerate azathioprine at low doses 
and the level of enzyme activity may actually increase with continued administration of 
the drug (Cuffari et al. 2004; Czaja and Carpenter 2006b). Determination of enzyme 
activity is for this reason warranted only in the presence of pretreatment cytopenia, 
cytopenia developing during therapy or administration of higher-than-conventional 
doses of azathioprine (Czaja 2008). 
 
Table 1.7. Side effects associated with standard treatment of autoimmune hepatitis. 
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A well described complication of continuous immunosuppressive therapy is the 
development of malignancies (Wang et al. 1989, Werner et al. 2009). The incidence of 
extra-hepatic neoplasms in treated AIH patients is 1 in 194 patients-year, and the 
probability of tumor occurrence is 3% after 10 years (Wang et al. 1989, Manns et al. 
2010a). Tumours do not have a predominant cell type, and they are not related to age, 
sex, treatment regimen or cumulative duration of treatment (Wang et al. 1989, Johnson 
et al. 1995). Nevertheless, since the risk of malignancy associated with chronic low 
dose azathioprine therapy has been reported to be 1.4-fold higher than that of age- and 
sex-matched normal populations, the beneficial effect of this drug as a corticosteroid-
sparing agent must be must be counterbalanced with its risks (Wang et al. 1989). 
 
6.2. Alternative treatments 
In the group of patients that show failure to standard therapy, intolerance or low 
compliance to standard immunosuppression, alternative immunosuppressive treatments 
have been proposed (Yeoman et al. 2010). Decisions regarding the use of such regimens 
have to be based, however, on the scarce data available, mainly on the basis of studies 
conducted on small numbers of patients or case reports.  
These alternative treatments include mycophenolate mofetil (MMF; Richardson 
et al. 2000), tacrolimus (Van Thiel et al. 1995), cyclosporine (Fernandes et al. 1999), 
methotrexate (Burak et al. 1998, Venkataramani et al. 2001), cyclophosphamide 
(Kanzler et al. 1997), ursodeoxycholic acid (UDCA; Czaja et al. 1999a), and rituximab 
(Barth and Clawson 2010; Table 1.8.). Although some encouraging results have been 
described, the progress with these non-standard treatments has evolved slowly and none 
has yet been incorporated into a standard management algorithm.  
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Drug Advantages Disadvantages
Mycophenolate mofetil Favourable toxicity profile
Experience as a transplant immunosuppressant
Contradictory reports regarding its efficacy
Cyclosporine Potent immunosuppressant
Experience in the transplant setting
Renal toxicity
Tacrolimus Potent immunosuppressant
Experience in the transplant setting
Renal toxicity
Budesonide High first pass metabolism in the liver
Immunosuppressive action
Ineffective in the cirrhotic liver
Cyclophosphamide Efficacy Dependency on continuous therapy
Hematological side effects
Methotrexate Favourable toxicity profile Efficacy yet to be shwon
Ursodeoxycholic acid Putative immunomodulatory capacities Efficacy yet to be shown
Rituximab Relatively favourable toxicity profile Efficacy yet to be shown
MMF is a purine antagonist that selectively inhibits proliferation of activated 
lymphocytes but is not dependent on TPMP activity (Heneghan and McFarlane 2002). It 
improves various symptoms of AIH, but many patients may also experience drug 
intolerance – headache, diarrhoea, nausea, dizziness, hair loss, and neutropenia (Vergani 
and Mieli-Vergani 2011b). In patients for whom standard immunosuppression fails to 
induce stable remission, or who are intolerant to azathioprine, MMF, together with 
prednisolone, is currently the treatment of choice (Manns et al. 2010a). 
Calcineurin inhibitors, cyclosporine and tacrolimus, have been used as a rescue 
treatment for difficult-to-treat cases of AIH. As large studies in this subgroup of patients 
are lacking, they should be used with caution (Vergani and Mieli-Vergani 2011b). 
 
Table 1.8. Alternative treatments for autoimmune hepatitis. 
 
Budesonide, a corticosteroid with the highest affinity for the glucorticoid 
receptor and with a high first pass metabolism, is presently receiving considerable 
attention as an alternative to prednisone or prednisolone in AIH treatment. First reports 
were somewhat contradictory, but in a recently published large European study a 
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combination of budesonide and azathioprine was reported to induce remission in a 
higher proportion of noncirrhotic patients with fewer adverse effects than medium-dose 
standard steroids and azathioprine. In this study, remission was achieved in 60% of the 
budesonide group but in only 39% of the prednisone group. (Manns et al. 2010b). It 
should be noted, however, that the latter remission rate is much worse than that reported 
in both adults and children (~80%) when a higher starting dose of prednisone is used. 
Moreover, budesonide cannot be used  in cirrhotic patients, who represent at least a 
third of the AIH population (Hempfling et al. 2003). 
Figure 1.8. provides an algorithm of the treatment strategy for adult patients 
with AIH as suggested by the British Society for Gastroenterology (BSG) and the 
American Association for the Study of the Liver (AASLD) published guidelines. 
 
6.3. Liver transplantation 
Liver transplantation (LT) is the ultimate treatment for AIH patients presenting 
with fulminant liver failure, or who develop end-stage chronic liver disease and for 
those with hepatocellular carcinoma that meet the transplant criteria (Reich et al. 2000, 
Mottershead and Neuberger 2008).  
A combination of prednisolone and a calcineurin inhibitor is the most common 
immunosuppressive regimen used after LT, leading to a very successful outcome with 
reported 5-year and 10-year patient survival of 80-90% and 75% respectively (Manns et 
al. 2010a). 
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Figure 1.8. Treatment approach for adult patients with autoimmune hepatitis.  
ALT, alanine aminotransferase; AST, aspartate aminotransferase; MMF, mycophenolate mofetil 
Adapted from Gleeson D, Heneghan MA. Gut 2011; 60: 1611-1629  
Prednisolone 30-60mg/day
Add azathioprine 1mg/kg/day
•Switch to MMF and continue prednisolone
OR
•Double prednisolone dose
Monitor ALT, AST
Reduce Prednisolone gradually to maintain fall
•Keep on prednisolone 5-10 mg/day + 
Azathioprine 1mg/kg/day
•Consider re-biopsy after a further 
12-24 months (total 24-30 months)
•Assess compliance
•Continue prednisolone 5-10 mg/day + 
Azathioprine 2mg/kg/day 
OR
•Use other agent
Consider further biopsy after 1-2 years
Consider non-compliance, malabsorption
Consider:
a) Higher prednisolone dose+ Azathioprine
2mg/kg/day
b) Prednisolone + Tacrolimus
c) Discuss with a transplant centre
Severe azathioprine side effects
•Prednisolone 10mg/day +
Azathioprine 2mg/kg/day OR
•Use other agent
Maintenance strategy
No fall in AST
Switch to Budesonide 9mg/day
Severe steroid side effects
Fall in AST
Histological 
remission
AST/ALT 
elevated
AST/ALT normal
Persisting hepatitis
Autoimmune liver disease in children 
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6.3.1. Recurrence of autoimmune hepatitis after liver transplantation 
Although LT is a highly successful mode of treatment for AIH, primary disease 
recurs in ~30% of the patients (Neuberger et al. 1984, Gautam et al. 2006). Diagnosis of 
recurrent AIH is based on biochemical abnormalities, the presence of autoantibodies, 
interface hepatitis on liver histology and/or steroid dependence (Demetris et al. 2006, 
Manns et al. 2010a). Awareness of its existence and subsequent appropriate 
management has led, during the last few years, to a decrease in its frequency, and more 
importantly to a better outcome in patients diagnosed with this condition (Rowe et al. 
2008). In this regard, it is of particular importance to be cautious when weaning 
immunosuppression off in patients who underwent LT for AIH since corticosteroid 
discontinuation may increase the risk for recurrent disease. 
Additionally, it has been reported that AIH can also arise de novo following LT 
for non-autoimmune liver diseases. This form of graft dysfunction, called de novo 
autoimmune hepatitis, is characterised by features identical to those of classical AIH, 
namely hypergammaglobulinaemia, positivity for autoantibodies and interface hepatitis 
(Kerkar et al. 1998, Liberal et al. 2012). This condition, though reported in adults, 
seems to be much more prevalent in children (see section 7.3.) 
 
7. Autoimmune liver disease in children 
In children, there are two liver disorders in which liver damage is likely to arise 
from an autoimmune attack: “classical” AIH and AIH-sclerosing cholangitis overlap 
syndrome (also termed autoimmune sclerosing cholangitis). A possible autoimmune 
pathogenesis has also been postulated in the case of de novo autoimmune hepatitis 
following LT.  
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7.1. Comparison between AIH-1 and AIH-2 
The distinction between type 1 and type 2 AIH is particularly relevant in 
paediatrics, since anti-LKM-1-positive disease is rare, though not absent, in adults 
(Gregorio et al. 1997, Oettinger et al. 2005). Anti-LKM-1-positive patients present with 
higher levels of bilirubin and transaminases than those who are ANA/SMA positive; in 
addition, AIH-2 presents significantly more frequently with fulminant hepatic failure 
compared to AIH-1. Apart from children with fulminant presentation, a severely 
impaired hepatic synthetic function, as assessed by the presence of both prolonged 
prothrombin time and hypoalbuminemia, is more common in ANA/SMA-positive than 
in anti-LKM-1-positive patients. The vast majority of patients have increased levels of 
IgG, but some 20% do not, thus normal IgG levels do not exclude the diagnosis of AIH. 
Partial IgA deficiency is more common in AIH-2 than in AIH-1 (Gregorio et al. 1997). 
The severity of interface hepatitis at diagnosis is similar in both types, but cirrhosis on 
initial biopsy is more frequent in AIH-1 than AIH-2, suggesting a more chronic course 
of the disease in the former (Gregorio et al. 1997).  
 
7.2. Autoimmune sclerosing cholangitis  
In recent years, it has become increasingly evident that in children and young 
adults, sclerosing cholangitis is often associated with florid autoimmune features, 
including elevated titres of autoantibodies, especially ANA and SMA, 
hypergammaglobulinaemia, and interface hepatitis on liver biopsy (Table 1.9.).  
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Parameter AIH-1 AIH-2 AISC
Median age in years 11 7 12
Mode of presentation (%)
Acute hepatitis 47 40 37
Acute liver failure 3 25 0
Insidious onset 38 25 37
Complication of chronic liver disease 12 10 26
Associated immune-diseases (%) 22 20 48
Inflammatory bowel disease (%) 20 12 44
Abnormal cholangiogram (%) 0 0 100
ANA/SMA (%) 100 25 96
Anti-LKM-1 (%) 0 100 4
pANNA (%) 45 11 74
Anti-SLA (%) 58 58 41
Interface hepatitis (%) 66 72 35
Biliary features (%) 28 6 31
Cirrhosis (%) 69 38 15
Table 1.9. Clinical presentation of childhood autoimmune liver disease. 
 
 
 
 
 
 
 
 
 
 
 
ANA, anti-nuclear antibodies; SMA, anti-smooth muscle antibodies; anti-LKM-1, anti-liver 
kidney microsomal type 1 antibody; pANNA, peripheral anti-nuclear neutrophil antibodies; SLA, 
soluble liver antigen; IgG, immunoglobulin G.  
From Gregorio GV, Portmann B et al. Hepatology.2001; 33: 544-553 
 
Since these features are shared with AIH and are often not accompanied by 
elevated alkaline phosphatase or gamma glutamyl transpeptidase (GGT) levels at 
disease onset, the diagnosis of sclerosing cholangitis relies on cholangiographic studies. 
In childhood, this condition is called autoimmune sclerosing cholangitis (AISC) and is 
as prevalent as AIH type 1, as shown in a prospective study conducted over a period of 
16 years (Gregorio et al. 2001). In this study, all children with serological – positive 
autoantibodies and high IgG levels – and histological – interface hepatitis – features of 
autoimmune liver disease underwent a cholangiogram at time of presentation. 
Approximately half of them had bile ducts changes characteristic of sclerosing 
cholangitis (Figure 1.9. and 1.10.), though these were generally less advanced than 
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those observed in adult PSC, and were therefore diagnosed as having AISC (Gregorio et 
al. 2001). Importantly, a quarter of the children with AISC, despite abnormal 
cholangiograms, had no histological features pointing to a bile duct involvement, and 
the diagnosis of AISC was only possible because of the cholangiographic studies 
(Figure 1.11.). Virtually all AISC patients were seropositive for ANA and/or SMA. In 
contrast to AIH, which is a predominantly a female disease, AISC affects equally boys 
and girls (Gregorio et al. 2001). 
Figure 1.9. Endoscopic retrograde cholangiopancreatography (ERCP) in autoimmune 
sclerosing cholangitis. ERCP showing widespread bile duct strictures and dilatations in a child 
with autoimmune sclerosing cholangitis. 
 
In the 16-year follow-up study it was shown that the mode of presentation of 
AISC was similar to that of AIH-1. Concomitant presence of IBD was, however, more 
frequent in AISC (45%), than in AIH-1 (20%). At the time of presentation, liver 
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AIH AISC
Bilirubin (nv < 20 mmol/L) 35 (4-306) 20 (4-179)
Albumin (nv > 35 g/L) 35 (25-47) 39 (27-54)
AST (nv < 50 IU/L) 333 (24-4830) 102 (18-1215)
INR (nv < 1.2) 1.2 (0.96-2.5) 1.1 (0.9-1.6)
GGT (nv < 50 IU/L) 76 (29-383) 129 (13-948)
AP (nv < 350 IU/L) 356 (131-878) 303 (104-1710)
AP/AST ratio 1.14 (0.05-14.75) 3.96 (0.20-14.20)
function tests did not help in discriminating between AIH and AISC, though AP/AST 
ratio was significantly higher in AISC (Table 1.10.). pANNA was present in 74% of 
children with AISC vs 45% in AIH-1 and 11% in AIH-2 (Gregorio et al. 2001). 
Clinical, laboratory, and histological features of AIH-1, AIH-2 and AISC are compared 
in Table 1.9.  
 
Table 1.10. Biochemical presentation of childhood autoimmune liver disease. 
 
 
 
 
 
 
 
 
 
 
 
 
AST, aspartate aminotransferase; INR, international normalised ratio; GGT, gamma 
glutamyltranspeptidase; AP, alkaline phosphatase; nv, normal values 
From Gregorio GV, Portmann B et al. Hepatology.2001; 33: 544-553 
 
The same study also showed that AISC is more common than sclerosing 
cholangitis without autoimmune features, autoantibody-negative sclerosing cholangitis 
having been observed in only 9 children referred over the 16-year study period. 
 In the absence of a cholangiography, AISC patients are diagnosed and treated as 
AIH, though evidence of bile duct damage can become apparent during follow-up. 
AISC responds to immunosuppression in terms of reduction of parenchymal 
inflammation, but bile duct disease progresses despite treatment in 50% of patients. 
Following favourable reports in adult PSC (Mitchell et al. 2001), UDCA is usually 
added to the regimen, though there are no data regarding its efficacy in arresting disease 
progression. The medium-term prognosis is good, with a reported 7-year survival of 
100%, though 15% of patients require LT during follow-up (Gregorio et al. 2001). 
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B
A
Figure 1.10. Magnetic resonance cholangiopancreatography (MRCP) in autoimmune 
sclerosing cholangitis. MRCP showing only gross (A), and both gross and subtle biliary 
changes (B) in children with autoimmune sclerosing cholangitis. 
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A
B
Figure 1.11. Histology of autoimmune sclerosing cholangitis. Interface hepatitis without 
obvious biliary changes in a patient with autoimmune sclerosing cholangitis (upper panel). 
Interface hepatitis with abundant plasma cell infiltration and clear bile duct damage in another 
child with autoimmune sclerosing cholangitis (bottom panel). 
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Criteria
Elevated transaminases
Positivity for circulating autoantibodies
• ANA and/or SMA (titre ≥ 1:20) = AIH-1 or AISC
• Anti-LKM-1 (titre  ≥ 1:10) = AIH-2
• Anti-LC-1 = AIH-2
Elevated immunoglobulin G (in 80% of cases)
Liver biopsy:
• Interface hepatitis
• Multilobular collapse
Exclusion of viral hepatitis
Exlusion of Wilson s disease
Exclusion of non-alcholic steatohepatitis
Cholangiogram:
• Normal = AIH
• Abnormal = AISC
Evolution from AIH to AISC has been documented suggesting that AIH and 
AISC are part of the same nosological spectrum (Gregorio et al. 2001). 
Whether childhood AISC and adult PSC belong to the same disease spectrum 
remains undefined, since no prospective study in a large cohort of patients has 
investigated the presence of bile duct damage at disease onset in adults with features of 
autoimmune liver disease. Interestingly, in a retrospective study, a high proportion of 
adults initially diagnosed as having AIH-1 were found to have sclerosing cholangitis on 
magnetic resonance cholangiography (Abdalian et al. 2008).   
Criteria for the diagnosis of childhood autoimmune liver disease are depicted in 
Table 1.11. An algorithm for the treatment decision of children with autoimmune liver 
disease is provided in Figure 1.12. 
 
Table 1.11. Criteria for the diagnosis of autoimmune liver disease in childhood. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIH, autoimmune hepatitis; AISC, autoimmune sclerosing cholangitis; ANA, anti-nuclear 
antibodies; SMA, anti-smooth muscle antibodies; anti-LKM-1, anti-liver kidney microsomal 
type 1 antibody; anti-LC-1, anti-liver cytosol type antibody 
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•Elivated transaminases and IgG
•Autoantibody positivity
•Compatable histology
Cholangiogram
3 year treatment
AIH AISC
Prednisolone  Azathioprine
Add UDCA to all future 
treatment regimens
Attempt withdrawal
AbnormalNormal
Prednisolone  MMF
Prednisolone  CyA
(Or Tacrolimus)
Liver transplant when liver decompensates
Sustained 
remission
Normal transaminases and IgG
Neg/low autoantibody titre
No inflammation on biopsy
No response
Frequent relapse
No response
No response
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.12. Algorithm for treatment decision in children with autoimmune liver disease. 
IgG, immunoglobulin G; AIH, autoimmune hepatitis; AISC, autoimmune sclerosing cholangitis; 
UDCA, ursodeoxycholic acid; MMF, mycophenolate mofetil; CyA, cyclosporine A; neg, 
negative 
Adapted from Mieli-Vergani G, Vergani D. Best Pract Res Clin Gastroenterol. 2011; 25: 783-
795 
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7.3. De novo autoimmune hepatitis after liver transplantation 
Post-transplant de novo AIH (d-AIH) was initially described in 1998, and in 
contrast to the recurrence of the disease in patients transplanted for AIH, this condition 
affects patients transplanted for disorders other than AIH. In the first report of d-AIH, 
over a 5-year period, seven children (4% of 180 LT recipients) developed a form of 
graft dysfunction with features identical to those of classical AIH, namely 
hypergammaglobulinaemia, positivity for circulating autoantibodies (one ANA, two 
ANA and SMA, one gastric-parietal-cell antibody, and three atypical anti-LKM-1), and 
histological features of chronic hepatitis with portal and periportal inflammation (Figure 
1.13.).  
 
Figure 1.13. Histology of de-novo autoimmune hepatitis. The portal tract is densely infiltrated 
by mononuclear cells with a conspicuous presence of plasma cells, that extend and disrupt the 
limiting plate. 
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The index case did not respond to a short course of high dose steroids for 
rejection, but only to the classical treatment of AIH. None of the children were 
transplanted for autoimmune liver disease, none were hepatitis C virus positive, and all 
had serum concentrations of cyclosporine A or tacrolimus within therapeutic anti-
rejection levels at the time of diagnosis of d-AIH (Kerkar et al. 1998). Since that report, 
several other groups have reported the occurrence of d-AIH after LT. Its prevalence in 
children ranges from 2.35% to 6.2% ; the indications for LT so far reported include: 
extra-hepatic biliary atresia, Alagille syndrome, acute liver failure, -1-antitrypsin 
deficiency, primary familial intra-hepatic cholestasis, PSC, and Budd-Chiari syndrome 
(Hernandez et al. 2001, Gupta et al. 2001, Andries et al. 2001, Spada et al. 2001, 
Miyagawa-Hayashino et al. 2004, Venick et al. 2007) 
Awareness that treatment with prednis(ol)one alone or in combination with 
azathioprine or MMF is successful in d-AIH has led to excellent graft and patient 
survival (Salcedo et al. 2002). It is of interest that these patients do not respond 
satisfactorily to short courses of high dose steroids for cellular rejection, making it 
essential to reach an early diagnosis to avoid graft loss. 
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1. The immune system  
The word immunity, which derives from the Latin immunis – meaning exempt 
or free from burden – refers to the mechanisms used by the body as protection against 
foreign agents. The immune system is therefore an organized network of cells and 
molecules with specialised roles in defending against infection. 
Immunity requires the recognition and elimination or containment of infectious 
organisms. This is achieved by two different types of response. Innate (natural) immune 
responses depend on invariant receptors recognising conserved constituents of 
pathogens, and are activated immediately upon encounter of them. Though crucially 
important, innate responses can be overcome by pathogens and they do not lead to 
immunological memory, occurring to the same extent after each subsequent exposure. 
In contrast, the acquired (adaptive) immune system can recognise a specific molecular 
feature of a pathogen and provides enhanced protection against reinfection (Delves and 
Roitt 2000a). 
The hallmark of adaptive immunity in advanced vertebrates is the existence of 
lymphocytes, which execute and regulate immune responses. Adaptive immunity can be 
classified into humoral – the antibody response produced by B cells – and cellular or T 
cell-mediated immune responses (Delves and Roitt 2000b).  
 
1.1. Humoral immune response  
B lymphocytes, which are responsible for antibody production, are the key 
mediators of the humoral immune response (Delves and Roitt 2000a). These cells 
obtained their name from early experiments on antibody production in birds, in which 
surgical removal of a lymphoid organ known as bursa de Fabricius resulted in a 
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complete inability to produce antibody. These antibody-producing cells then became 
known as bursa-derived, or B cells (Warner et al. 1962, Cooper et al. 1966, Moore and 
Owen 1966). In contrast to birds, mammals do not have a bursa; rather, B cells originate 
and mature within the bone-marrow before being released into the circulation. During 
foetal life, the liver is also an important site for B lymphocyte development (Delves and 
Roitt 2000b). B cells bear on their surface the B cell antigen receptor (BCR), which is a 
membrane bound form of the antibody that the B lymphocyte will secrete upon 
activation and differentiation into plasma cells (Ollila and Vihinen 2005). Antibodies 
can contribute to immunity in three main ways: firstly, antibodies can bind pathogens or 
their toxic products, thereby preventing their access to cells that they might infect or 
destroy, in a process known as “neutralisation”; secondly, antibodies bound to and 
facilitate the uptake of the pathogen by phagocytic cells that are specialised to destroy 
ingested bacteria (“opsonisation”); lastly, antibodies binding to a surface of a pathogen 
can activate the proteins of the complement cascade, which can ultimately lead to the 
formation of pores in the targeted pathogen and to its direct destruction. Altogether, 
neutralisation, opsonisation, and complement activation will eventually result in the 
scavenging and degradation of the pathogen or its toxic products by macrophages 
(MacLennan et al. 2003). Other than producing antibodies, another major role of B cells 
is that to present antigens and provide activation signals to T cells (see section 2.). 
 
1.2. Cellular immune response 
Seminal studies performed during the 1950s demonstrated that lymphocytes 
were responsible for two measurable immune responses: antibody production and graft 
rejection (Gowans 1957, Simonsen 1957). Later, it was shown that mice thymectomised 
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immediately after birth were defective at rejecting a tissue graft (Martinez et al. 1962); 
thus the lymphocytes that were thought to derive from the thymus were called thymus-
dependent (T) lymphocytes or T cells.  
T cells develop from progenitors derived from pluripotent hematopoietic stem 
cells in the bone marrow. These migrate through the blood to the thymus, where a 
stepwise rearrangement of genes encoding their unique receptor for antigen takes place. 
Viable T cells at an immature stage then leave the thymus to populate the lymph nodes. 
These naive T cells may become activated in the lymph node by antigens presented to 
them by antigen-presenting cells (APCs). The activated lymphocytes then proliferate, 
forming a clonally derived battalion of cells with specificity for the invader, and 
differentiate into functionally polarised lymphocyte subsets. Depending on its function 
and the type of cytokines produced, the cell is referred to as effector or regulator. 
 
2. Generation of T cell responses  
2.1. T cell activation 
The initiation of an adaptive immune response requires the recognition of 
specific peptides, presented by APCs, by the T cell receptor (signal 1), as well as 
additional co-stimulatory signals, also provided by the APC (signal 2). A third signal, 
comprising cytokines produced by the APC, or otherwise present in the environment, 
also contributes to T cell differentiation. 
 
2.1.1. Signal 1 – antigen recognition by T cells 
T cells are defined by the surface expression of a receptor for antigen – the T 
cell receptor (TCR), composed of two different polypeptide chains, termed the TCR 
Introduction to the present study 
 
 
[104] 
 
and TCR chains, which are linked by a disulfide bond. A minority of T cells (about 
5% in humans) bear an alternative receptor composed of polypeptide chains designated 
and (Davis and Bjorkman 1988). The two subgroups are typically known as  and 
 T cells respectively. The function of the  TCR in immune responses is not entirely 
clear. For the purpose of this thesis the term TCR and T cell will be adopted to mean the 
 receptor and  T cell respectively. 
Unlike immunoglobulins, which act as antigen receptors for B cells, TCRs 
cannot bind an antigen in its native (natural) state. In contrast, TCRs recognise short 
sequences of amino acids derived by intracellular proteolysis of the antigen. These 
peptides are then transported to the cell surface and presented to the TCR by a major 
histocompatibility complex (MHC) molecule (Konig 2002). MHC molecules are highly 
polymorphic glycoproteins encoded by genes within the major histocompatibility 
complex (MHC). There are two classes of MHC molecules – MHC class I and MHC 
class II. Under physiological conditions, peptides derived from proteins synthesised 
endogenously are presented via MHC class I molecules, whereas exogenous antigens, 
which are first endocytosed and then processed by proteolytic enzymes, are presented in 
association with MHC class II molecules (Delves and Roitt 2000b).  
Two main T cell subsets can be defined by the expression of the cell-surface 
accessory molecules, CD4 and CD8. A third of T cells express CD8. As these cells are 
typically associated with target cell killing, the term cytotoxic T lymphocyte (CTL) is 
often used. Two thirds of T cells express the related glycoprotein CD4 on their surface. 
Since the function of mature CD4 T cells is primarily to induce activation of other 
immune cells, they have been termed T helper (Th) cells. The CD4 and CD8 accessory 
molecules have specific functions. While CD8 binds to an invariant part of MHC class I 
Generation of T cell responses 
 
 
[105] 
 
molecules, recognising antigens presented by them, CD4 binds to and recognises 
peptides presented by MHC class II molecules. MHC class I expression by all nucleated 
cells enables infected cells to signal their condition to CD8 T cells and to establish 
cellular contacts that ultimately results in the death of the infected cell and its 
pathogenic content. In contrast, MHC class II molecules are expressed only by few 
specialised APCs (macrophages, dendritic cells and B cells), since recognition of 
peptides embraced by MHC class II molecules leads CD4 T cells to produce cytokines 
and govern the type and the extent of an adaptive immune response (Delves and Roitt 
2000b). 
In addition to the TCR, which interacts with the peptide-MHC complex, without 
itself possessing any intrinsic signalling properties, there are other cell surface 
molecules critically involved in T cell activation. Among these are the CD3, CD3, 
and CD3 protein chains that in association with a disulfide linked chain homodimer 
constitute the CD3 complex (Werlen and Palmer 2002). Each CD3 complex molecule 
contains an immunoreceptor tyrosine-based activation motif (ITAM). ITAMs comprise 
tyrosine residues, which upon phosphorylation by associated kinases, lead ultimately to 
the transcriptional activation of various gene sequences (Guy and Vignali 2009). This 
interaction between peptide-MHC and TCR, which is transduced by the CD3 complex, 
is generally designated ‘signal 1’ in the process of T cell activation. 
 
2.1.2. Signal 2 – role of co-stimulation 
Signalling through the TCR complex is not by itself sufficient to lead to the 
activation of a naive T cell. A second signal, known as ‘signal 2’ or co-stimulation, is 
also required and is provided by APCs (Lafferty et al. 1980). Signalling in the absence 
Introduction to the present study 
 
 
[106] 
 
of co-stimulation results in T cell anergy, a phenomenon that renders T cells unable to 
respond to subsequent antigen exposure (Schwartz et al. 1989, Jenkins et al. 1990). 
Thus, co-stimulation is pivotal in determining whether the encounter of a T cell with the 
antigen results in activation or anergy.  
The best characterised and most effective T cell co-stimulatory pathway 
involves the CD28 receptor, and its two co-stimulatory ligands CD80 and CD86 (also 
known as B7-1 and B7-2 respectively; Greenwald et al. 2005; Figure 2.1.). While CD28 
is constitutively expressed on all T cells in mice and on 95% of CD4 and 50% of CD8 T 
cells in humans, CD80 and CD86 are expressed mainly on APCs. Engagement of CD28 
by CD80 or CD86 leads to the phosphorylation of a tyrosine in the cytoplasmic tail of 
CD28, and to the activation of the phosphotidylinositol 3-kinase (PI3K) pathway (Rudd 
et al. 2009). Together with the TCR signal, this pathway ultimately leads to the 
enhancement of interleukin (IL)-2 gene expression, up-regulation of cell-survival genes, 
promotion of energy metabolism (glucose uptake and glycolysis rate), and facilitation of 
cell-cycle progression, therefore resulting in the vigorous expansion and differentiation 
of antigen-stimulated T cells (Sharpe and Abbas 2006).  
Conversely, TCR signalling can be attenuated by inhibitory molecules. These 
include cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed death 1 (PD-1) and 
B and T lymphocyte attenuator (BTLA). Of these, CTLA-4 has been the most 
extensively studied. It shares 30% sequence homology with CD28, binding to the same 
ligands (Alegre et al. 2001). However, CTLA-4 binds CD80/CD86 at a much higher 
affinity than CD28 (Linsley et al. 1991), and delivers an inhibitory signal to the 
activated T cell, by preventing IL-2 production and arresting cell-cycle progression 
(Salomon and Bluestone 2001). Thus, CTLA-4 limits the expansion of activated T cells. 
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 The pivotal role of CTLA-4 as a negative immune regulator is highlighted by 
the observation that mice genetically deficient in CTLA-4 expression develop a fatal 
lymphoproliferative disease characterised by progressive accumulation of T cells in 
peripheral lymphoid organs as well as in solid organs (Waterhouse et al. 1995, Tivol et 
al. 1995). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. Role of CD80/CD86 and CD28/CTLA-4 pathway in T cell activation. Resting 
antigen-presenting cells (APCs) express few or no CD80/CD86 co-stimulatory molecules and 
thus fail to activate naïve T cells (upper panel). Cytokines produced in response to microbes 
activate APCs and lead to up-regulation of co-stimulatory molecules. CD80/86 – CD28 
interaction stimulates the expansion and differentiation of naïve T cells (middle panel). 
Cytotoxic T lymphocyte antigen 4 (CTLA-4), the high affinity receptor for CD80 and CD86, is 
up-regulated on activated T cells. CD80/86 – CTLA-4 interaction inhibits T cell proliferation 
(bottom panel). 
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Although the interaction between CD80⁄CD86 and CD28⁄CTLA-4 molecules 
remains the best characterised (Figure 2.1.), other co-stimulatory and inhibitory 
molecules and their interaction have also been described. These pathways can be 
subdivided into two major categories according to the type of receptors they use: 1) 
members of the immunoglobulin (Ig) superfamily, which comprises the B7⁄CD28, CD2, 
and T-cell Ig and mucin domain (TIM) families (see section 7.3.1.), and 2) members of 
the tumour necrosis factor (TNF) ⁄ TNF receptor (TNFR) family (Sharpe 2009). 
 
2.1.3. Signal 3 – cytokine environment 
Upon activation, naïve T cells differentiate into subsets with specific effector 
functions. This decision is largely determined by the cytokine milieu present at the time 
of T cell activation in the peripheral immune compartment. These cytokines, produced 
either by APCs or T cells, are generally referred to as ‘signal 3’(Gutcher and Becher 
2007).  
 
2.2. Differentiation of effector CD4 T cells 
CD4 T cells play a central role in immune protection. They help B cells to make 
antibodies, enhance CD8 T cell responses, regulate macrophage functions, and recruit 
neutrophils, eosinophils and basophils to sites of infection and inflammation. Through 
their production of cytokines and chemokines, CD4 T cells orchestrate immune 
responses against a vast array of pathogenic microorganisms, and regulate the extent 
and persistence of these immune responses. 
Based on their cytokine profile, two distinct effector CD4 T cell subsets were 
initially proposed: Th1 and Th2 cells (Mosmann et al. 1986). Almost twenty years later, 
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the Th17 cell subset emerged as a third major effector population of cells that could 
derive from their naïve CD4 precursors (Murphy et al. 2003, Aggarwal et al. 2003, Cua 
et al. 2003; Figure 2.2.). Almost simultaneously, an immune-regulatory T cell 
population was generated in vitro from naïve CD4 T cells (Chen et al. 2003, Fantini et 
al. 2004). These cells were labelled peripherally-induced adaptive regulatory T cells to 
distinguish them from the previously described thymus-derived natural regulatory cells 
(Zheng et al. 2004; the role of each regulatory T cell population will be discussed in 
section 5.). More recently, the existence of another two CD4 T cell subsets, namely 
“Th9” (Dardalhon et al. 2008, Veldhoen et al. 2008) and “Th22” T cell subsets (Duhen 
et al. 2009, Trifari et al. 2009) has been postulated, although lineage-specific 
transcription factors are as yet unidentified. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. T helper cell subsets. Cytokine profile, target cell and corresponding types of 
infection are shown for each CD4 T helper (Th) cell subset. 
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2.2.1. Th1 cells 
Th1 cells produce high levels of interferon-gamma (IFN- promoting both 
phagocyte activation and the production of opsonizing and complement-fixing 
antibodies, thus playing an important role in protection against intracellular pathogens 
(Suzuki et al. 1988, Mosmann and Coffman 1989). In humans, Th1 cells play a 
particularly important role against mycobacterial infections (Zhu and Paul 2008). In 
addition to IFN-, their signature cytokine, Th1 cells produce lymphotoxin, TNF-, and 
IL-2 (Mosmann and Coffman 1989, Paul and Seder 1994). 
The full differentiation of Th1 cells requires the cooperation of type 1 
interferons and IL-12 (Parronchi et al. 1992, Manetti et al. 1993). The presence of 
dendritic cell (DC)-derived IFN-α and/or natural killer (NK) cell-derived IFN-γ may 
lead to the activation of the signal transducer and activator of transcription (STAT)-1 in 
naïve CD4 T cells. Activated STAT-1 up-regulates the expression of T box expressed in 
T cells (Tbet; Afkarian et al. 2002), the master regulator for Th1 cell differentiation and 
IFN- production (Szabo et al. 2000). Ectopic expression of Tbet results in the induction 
of IFN--polarised cells, whereas Tbet-deficient cells produce diminished amounts of 
IFN-(Szabo et al. 2002). Although Tbet induces the production of IFN-, it has been 
shown that IFN- itself, through STAT-1 activation, can induce the expression of Tbet, 
highlighting an important autocrine loop that serves as a powerful amplification 
mechanism for IFN- production and Th1 differentiation (Lighvani et al. 2001). 
STAT-4 activation by IL-12 is also critical for Th1 responses. STAT-4-deficient 
mice display impaired Th1 cell differentiation along with an increase in Th2 responses, 
suggesting that STAT-4 acts to suppress Th2-mediated immunity (M. H. Kaplan et al. 
1996b, Thierfelder et al. 1996). Interestingly, it was shown that GATA binding protein 
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3 (GATA-3), the Th2 lineage-specific transcription factor, antagonises Th1 responses 
by down-regulating STAT-4, rather than interacting directly with Tbet (Usui et al. 
2003). The IL-12/STAT-4 pathway also favours Tbet up-regulation, in a similar way to 
the IFN-/STAT-1 pathway (Y. Yang et al. 2007, Usui et al. 2006), although STAT-4 
may also induce IFN- production independently of Tbet (Zhu and Paul 2010). 
At later stages of Th1 differentiation, expression of the IL-18 receptor alpha 
chain (IL-18Rα) is increased. IL-18Rα up-regulation requires the IL-12/STAT-4 
pathway and is further enhanced by IFNγ (Micallef et al. 1996, Robinson et al. 1997, 
Stoll et al. 1998). IL-12 together with IL-18 can induce IFNγ production by Th1 cells in 
the absence of TCR stimulation (Yang et al. 2001). Such antigen-independent cytokine 
production is probably important for amplifying Th1 responses by recruiting other pre-
existing Th1 cells (Smeltz et al. 2002, Okazawa et al. 2002). 
 
2.2.2. Th2 cells 
 Th2 are key participants in the host response against extracellular pathogens, such 
as helminths (Mosmann and Coffman 1989, Romagnani 1991). They produce a vast 
array of cytokines, including IL-4, IL-5, IL-10, and IL-13. IL-4 is the cytokine 
responsible for IgE class switching in B cells (Kopf et al. 1993). Like IFN- for Th1 
cells, IL-4 is the positive feedback cytokine for Th2 cell differentiation (Le Gros et al. 
1990, Swain et al. 1990). IL-5 plays a critical role in recruiting eosinophils (Coffman et 
al. 1989) and IL-10 suppresses Th1 cell proliferation and inhibits DC function (Moore 
et al. 2001). IL-13 is similar in structure and activity to IL-4, enhancing B cell responses 
and augmenting Th2 cell development (Wynn 2003). In addition, IL-13 is considered 
critical for helminth expulsion (Urban et al. 1998). 
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The interaction of IL-4 with its receptor results in the phosphorylation of STAT-
6, which in turn induces the expression of the Th2 master regulator GATA-3, and 
consequently promotes the activation of the Th2 characteristic cytokines IL-4, IL-5 and 
IL-13 (M. H. Kaplan et al. 1996a, Zheng and Flavell 1997, Kurata et al. 1999, Zhu et al. 
2001). GATA-3 may also induce its own expression when its levels reach a certain 
threshold (Ouyang et al. 2000). Th2 differentiation is completely abolished when 
GATA-3 is conditionally deleted in peripheral CD4 T cells (Zhu et al. 2004, Pai et al. 
2004). However, GATA-3 alone is not sufficient to drive IL-4 production. IL-2-
mediated activation of STAT-5 is also necessary (Zhu et al. 2003). Thus, cooperation of 
STAT-5 with GATA-3 accounts for full Th2 differentiation (Zhu et al. 2006, Ho et al. 
2009; Figure 2.3.). Importantly, the mutual regulation of Th1 and Th2 cell polarisation 
is induced not only by IL-4 and IFN-γ respectively, but also by the Th1 and Th2 lineage 
specific transcription factors. Accordingly, GATA-3 can down-regulate STAT-4 (Usui 
et al. 2003), and strong STAT-5 activation inhibits Tbet expression (Zhu et al. 2003). 
Conversely, Tbet can directly suppress GATA-3 expression (Usui et al. 2006) (Figure 
2.3.) 
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Figure 2.3. Cross regulation of T helper 1 and 2 cell differentiation. At the time of T cell 
activation, the cytokines present in the milieu are responsible for the differentiation pathway 
chosen. Cross regulation ensures the efficient expansion of one lineage. In T helper (Th) 1 
differentiation IL-12 induces the activation of signal transducer and activator of transcription 4 
(STAT-4) that induces interferon-γ (IFN-γ) transcription. IFN-γ feeds back positively, activating 
the transcription factor T box expressed in T cells (Tbet) via STAT-1. Tbet promotes IFN-γ 
production and inhibits Th2 cytokine expression via GATA-3. Th1 differentiation is promoted 
in an IL-4 rich milieu. IL-4 activates STAT-6 to increase the expression of GATA-3. GATA-3 
drives the expression of Th2 cytokines while suppressing Tbet and consequently Th1 
development.  
 
2.2.3. Th17 cells 
In recent years, the Th1/Th2 binary model of CD4 effector T cell differentiation 
has been challenged following the discovery of Th cells that produce IL-17 
(consequently named Th17 cells), and exhibit effector functions distinct from Th1 and 
Th2 cells (Langrish et al. 2005).  
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Th17 cells are important mediators of protection against extracellular pathogens 
not effectively handled by either Th1 or Th2 cells (Korn et al. 2009, Weaver et al. 
2006). Produced in large quantities by Th17 cells, IL-17A is responsible for most of the 
Th17-mediated effects, and is therefore considered the prototypic cytokine of the IL-17 
family, which includes five additional members (IL-17 B, C, D, E and F; Kolls and 
Linden 2004). In addition to IL-17A (commonly referred to as IL-17 also in this thesis), 
Th17 cells co-produce IL-17F (Liang et al. 2006). These two cytokines exert 
overlapping effector functions: upon cross-linking of their receptor they both induce 
production of pro-inflammatory cytokines (IL-6, IL-1 and TNF), pro-inflammatory 
chemokines (CXCL-1, CXCL-6 and IL-8) and metalloproteinases, ultimately leading to 
the recruitment of neutrophils to the site of inflammation (Bettelli et al. 2008). Since 
their receptors (IL-17AR and IL-17CR) are expressed on both hematopoietic and non-
hematopoietic cells, IL-17A and IL-17F are able to induce inflammation at several 
levels. Although the majority of Th17 cells express both IL-17A and IL-17F, it is clear 
now that there are Th cells expressing only IL-17A, only IL-17F or both (Liang et al. 
2007, Chang and Dong 2007).  
Besides IL-17A and IL-17F, Th17 cells also produce IL-21 and IL-22, neither of 
which are Th17-exclusive cytokines, although preferentially produced and released by 
Th17 cells (Liang et al. 2006, Korn et al. 2007a, Y. Zheng et al. 2007a). Whereas IL-17 
has broad effects on many cell types, IL-21 acts on other cells such as B lymphocytes 
and further amplifies Th17 responses (Nurieva et al. 2007). IL-22, a member of the IL-
10 family, is produced by activated T cells and NK cells (Wolk and Sabat 2006). It 
mediates its effects through a receptor complex expressed primarily within tissues, 
particularly by epithelial cells of the gastrointestinal tract and skin, but absent on 
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immune cells (Kotenko et al. 2001, Moore et al. 2001). IL-22 is a bifunctional cytokine 
with both pro- and anti-inflammatory effects: while promoting tissue inflammation in 
response to extracellular pathogens (Aujla et al. 2008), it also increases acute-phase 
reactant production by hepatocytes, thus protecting them from acute liver inflammation 
(Zenewicz et al. 2007). 
In contrast to Th1 and Th2 cell differentiation, which is dependent upon their 
respective effector cytokines, Th17 cell differentiation does not require IL-17. Instead, a 
combination of the anti-inflammatory cytokine transforming growth factor beta (TGF-
 and the pro-inflammatory and pleiotropic cytokine IL-6 is required to induce the 
differentiation of a naïve T cell into a Th17 lymphocyte (Mangan et al. 2006, Veldhoen 
et al. 2006, Bettelli et al. 2006). In the absence of IL-6, Th17 cells can also be generated 
by a combination of TGF- and IL-21, but IL-6 is a comparatively stronger inducer of 
Th17 immunity (Korn et al. 2007a, Zhou et al. 2007). IL-21, a member of the IL-2 
family of cytokines, is also produced in large amounts by Th17 cells, therefore acting in 
an autocrine fashion to amplify Th17 differentiation (Nurieva et al. 2007). In addition to 
the factors mentioned above, IL-1 can synergize with IL-6 to induce Th17 cells 
(Acosta-Rodriguez et al. 2007). Lastly, although the differentiation of naïve T cells into 
Th17 cells does not require IL-23, its presence is essential for the expansion and 
maintenance of the Th17 population. Indeed, recent data have shown that T cells 
cultured in the presence of TFG- and IL-6 do not cause tissue inflammation unless also 
cultured in the presence of IL-23 (Stumhofer et al. 2007, McGeachy et al. 2007). On the 
basis of these data, Bettelli et al. proposed a three-step model essential for the full 
differentiation of Th17 cells: induction of Th17 differentiation by a combination of 
TGF- and IL-6, followed by amplification of Th17 cell frequency by IL-21, and lastly 
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IL-23 (Bettelli et al. 2008; Figure 2.4.).  
 
 
 
 
 
 
Figure 2.4. Steps in Th17 cell differentiation. Different factors control the initial 
differentiation, the amplification and the stabilisation of Th17 cells. Whereas transforming 
growth factor-β (TGF-β), together with IL-6, are the differentiation factors for Th17 cells, IL-
21, which is produced by Th17 cells themselves, acts in a positive feedback loop to amplify the 
frequency of Th17 cells. Lastly, IL-23 expands and stabilises Th17 cells to produce their 
effector cytokines. 
 
Analogous to Tbet in Th1 and GATA-3 in Th2 cells, Th17 development relies 
on the presence of a lineage-specific transcription factor, identified as the retinoic acid-
related orphan receptor gamma t (RORt) (Park et al. 2005, Harrington et al. 2005; 
Figure 2.3.). RORt is the master regulator that drives Th17 cell lineage differentiation 
(Ivanov et al. 2006). Its expression is induced in naïve CD4 T cells within 8 hours of 
TCR engagement along with TGF- and IL-6. Over-expression of RORt promotes 
Th17 differentiation, whilst RORt-deficient T cells produce very low levels of IL-17 in 
response to TGF-, IL-6 or IL-21 (Ivanov et al. 2007). The residual IL-17 production by 
RORt-deficient cells is dependent on the activity of a related nuclear receptor, ROR, 
also up-regulated in Th17 cells. Although ROR deficiency results in minimally 
reduced IL-17 production, loss of both RORt and ROR completely abrogates Th17 
differentiation (X. O. Yang et al. 2008). The induction of RORt is dependent on 
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STAT-3, a transcription factor activated by IL-6, IL-21 and IL-23 that has been shown 
to play an important role in the expression of IL-17. Conditional deletion of STAT-3 in 
T cells prevents the development of Th17 cells, and over-expression of an active form 
of STAT-3 increases IL-17 production (X. O. Yang et al. 2007, Harris et al. 2007). 
STAT-3 affects Th17 differentiation by up-regulating RORt, which is upstream of IL-
17; thus both transcription factors seem to cooperate, and the presence of both is 
required for IL-17 production (X. O. Yang et al. 2007, X. O. Yang et al. 2008).  
Cytokines and transcription factors for the differentiation of the three effector Th 
cell subsets are summarised in Figure 2.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5. Cytokines and transcription factors critical for effector T helper (Th) cell 
differentiation. Upon T cell receptor (TCR) activation triggered by antigen-presenting cells 
(APCs), naïve CD4 T cells differentiate into distinct Th lineages depending on the types of 
cytokines present in the environment. The differentiation process involves up-regulation of 
master transcriptional factors and activation of signal transducers and activators of 
transcription (STAT) proteins. At later stages of Th cell differentiation, different Th cells 
preferentially express an interleukin-1 (IL-1) family receptor. Together with a STAT protein, 
the IL-1 family cytokine induces effector cytokine production from Th cells in a TCR-
independent manner. 
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3. Tolerance 
As discussed in the previous section, the immune system is equipped with very 
powerful effector mechanisms that can eliminate a wide variety of pathogens. However, 
during early days of the study of Immunity, Paul Ehrlich realised that these effector 
mechanisms could, if directed against the host, cause severe tissue damage – a 
phenomena that he termed horror autotoxicus. Thus, if unrestrained immune reactions 
directed towards self-tissues do occur, they would result in a wide spectrum of chronic 
syndromes generally coined autoimmune diseases.  
Since the T cell arm of the immune system includes an incredibly large 
repertoire of T cell clones, each containing a unique receptor for antigen, it allows the 
immune system to respond to a almost infinite variety of antigens (Jiang and Chess 
2006). As a consequence, this diverse repertoire contains T cells recognising the body´s 
own antigens – self-reactive T cells – that drive unwanted autoimmune responses.  For 
this reason, the immune system has evolved several mechanisms to restrain such T cells, 
and therefore prevent damage to self tissues. This process that leads to the elimination 
or neutralisation of self-reactive cells is known as tolerance, and a breakdown in the 
working of this system can lead to autoimmunity (Kamradt and Mitchison 2001). 
Immunological tolerance is multi-layered, encompassing a network of mechanisms, that 
allows maintenance of protective immunity while averting autoimmunity (Mathis and 
Benoist 2010). These layers are generally classified into two broad categories: central 
tolerance that shapes the T cell repertoire in the thymus and peripheral tolerance, which 
relates to the regulation of T cell responses in the periphery (Figure 2.6.). 
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Figure 2.6. Mechanisms of immunological tolerance. Haematopoietic precursors migrate to 
the thymus where they undergo positive and negative selection based on the nature of their T 
cell receptor interactions with peptide/major histocompatibility complex. Although the vast 
majority of self-reactive T cells are effectively deleted at this stage, few escape to the periphery 
where they are kept under control by peripheral tolerance mechanisms acting either directly on 
the self-reactive T cell (T cell intrinsic) or indirectly via additional cells (T cell extrinsic). 
 
3.1. Central tolerance 
Central tolerance refers to those events that, occurring during the early life of a 
lymphocyte, focus the adaptive immune system´s attention on pathogens while steering 
it away from healthy tissue. It is induced at the primary sites of lymphocyte 
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development - bone marrow and thymus – and it includes the mechanisms by which 
antigen-receptor recognition of self-antigen at these sites results in self-tolerance 
(Hogquist et al. 2005).  
This process of lymphocyte development begins in the bone marrow, where 
multipotent haemopoietic stem cells (HSCs) commit to one of two lineages, myeloid or 
lymphoid. The first stage of commitment to the lymphoid lineage is represented by the 
common lymphoid progenitor (CLP), which can give rise to T, B and natural killer 
(NK) cells (Kondo et al. 1997). While B cell development continues in the bone 
marrow, further T cell development is preceded by the migration and entry of CLPs into 
the thymus (Graf 2008), an organ that supports the development and repertoire 
generation of T cells (Miller 1961). After commitment to the T cell lineage, which 
depends on Notch receptor signalling, developing lymphocytes pass through a series of 
different phases characterised by changes in the status of their TCR genes (Deftos and 
Bevan 2000), culminating in the expression of a functional TCR. TCR generation 
encompasses a process of somatic recombination, in which non-contiguous gene 
sequences are randomly recombined in order to produce high levels of 
“recombinatorial” diversity (Petrie et al. 1995). The imprecise nature of recombination 
leads to ‘junctional’ diversity, further increasing the TCR repertoire and leading to the 
production of non-functional TCRs and TCRs with specificity for self molecules 
(Goldrath and Bevan 1999). 
After arriving as precursors from the bone marrow, thymocytes lack expression 
of the surface molecules characteristic of mature T cells. At this point these cells lack 
the TCR as well as the CD4 and CD8 co-receptors, thus they are called CD4/CD8 
double negative (DN) thymocytes (Spits 2002, Gill et al. 2003, Ciofani and Zuniga-
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Pflucker 2010). Proliferation and differentiation of DN thymocytes into CD4/CD8 
double positive (DP) cells is driven by a distinct surface receptor, composed of a TCR 
chain and an invariant pre-TCR chain (Rodewald and Fehling 1998). In the thymic 
cortex, cortical thymic epithelial cells (cTECs) and other APCs display a wide variety 
of self-peptide: MHC complexes. About 97% of DP cells fail to recognise any of these 
and since they do not receive a survival signal, they die by neglect (Werlen et al. 2003). 
The remaining DP thymocytes, binding self-peptide: MHC complexes with sufficient 
avidity, are positively selected (Santori et al. 2002), surviving and undergoing the 
programme of differentiation into CD4 or CD8 single positive (SP) thymocytes. Thus, 
the process of positive selection favours the selection of self-reactive T cells 
(Hengartner et al. 1988, von Boehmer and Kisielow 1990, Jiang and Chess 2006).  
However, some of these cells, after entering the thymic medulla, die by clonal 
deletion when they interact with overly high affinity with self-peptide: MHC complexes 
(Palmer 2003), thereby preventing the majority of self-reactive T cells from entering the 
periphery (Takahama 2006). This process of negative selection is made possible by the 
ectopic presentation of tissue-specific antigens by medullary thymic epithelial cells 
(mTECs), dependent at least in part on the transcriptional factor autoimmune regulator 
(AIRE; Zuklys et al. 2000, Derbinski et al. 2005). 
Although clonal deletion is the predominant mechanism by which tolerance is 
maintained, a small proportion of T cells can undergo receptor editing (Nemazee and 
Hogquist 2003) or enter into a state of anergy (Hammerling et al. 1991).  
Despite the numerous mechanisms of central tolerance described above, it is 
clear that self-reactive T cells still escape to the periphery (Williams et al. 1998, 
Bouneaud et al. 2000). A number of possibilities can be invoked to explain this 
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phenomenon : a) some thymocytes simply do not encounter the limited number of APCs 
expressing their cognate ligand as they mature; b) the avidity between the self-reactive 
thymocyte and the self-peptide : MHC complex may be too low to allow deletion 
(Mueller 2010); c) antigens that are developmentally expressed may not be present in 
the thymus during negative selection, resulting in a failure to induce central tolerance 
(Goverman 2011); d) mutations in key signal-transducing molecules can lead to 
disturbances in the balance of positive and negative selection, therefore  allowing T 
cells to escape negative selection (von Boehmer and Melchers 2010); and lastly e) the 
presence of TCRs with unusual binding properties can render their interaction with 
MHC molecules asymmetrical or incomplete, therefore permitting self-reactive T cells 
to escape deletion (Hahn et al. 2005). 
 
3.2. Peripheral tolerance 
Because central tolerance is not always effective, various mechanisms of 
peripheral T cell tolerance fine tune the self-reactive T cell repertoire, being therefore 
essential to prevent autoimmunity. These mechanisms can be divided into those 
intrinsic to the self-reactive T cell, and those implying the intervention of additional 
subsets of cells (Walker and Abbas 2002; Figure 2.7.). 
One way to prevent autoimmune destruction by a given T cell clone is to delete 
that specificity from the repertoire: autoreactive cells with high avidity for self 
molecules die by apoptosis (Mallone et al. 2005), following engagement of death 
receptors such as Fas (a process known as activation induced cell death) or the Bcl-2 
related protein Bim (activated T cell autonomous death; Hildeman et al. 2002, Marrack 
and Kappler 2004).  
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Alternatively, T cell encounter with a self-antigen may lead to functional 
inactivation – a phenomenon termed T cell anergy (Jenkins and Schwartz 1987). This 
may happen due to the intrinsic properties of self-reactive T cells able to escape to the 
periphery that render them less able to initiate an immune response. They are 
characterised by the high surface expression of inhibitory receptors such as CD5 
(Hawiger et al. 2004), CTLA-4 (Eggena et al. 2004), and PD-1 (Nishimura et al. 1999, 
Keir et al. 2006), as well as higher intracellular levels of members of the ubiquitin ligase 
family (Bonnevier et al. 2005, Fathman and Lineberry 2007). These molecules target 
signalling machinery, such as the TCR and the CD28 co-receptor, for destruction 
(Schartner et al. 2007). In some cases this high threshold for activation is coupled with a 
low avidity for self molecules and/or with a lack of co-stimulation provided by APCs.  
A last intrinsic mechanism of peripheral tolerance implicates that self-reactive T 
cells may never encounter their specific self-antigen, therefore remaining in a status of 
ignorance. This may be due to the restricted trafficking patterns of both naïve and 
antigen-experienced T cells. In the latter case, lymphocyte trafficking ability is 
conferred by DCs during antigen presentation and is characterised by the up-regulation 
of tissue-homing molecules (Mora et al. 2005). In the absence of inflammatory signals, 
DCs have tolerogenic properties and are able to prevent T cell migration from the 
lymphoid tissues to peripheral sites (Bianchi et al. 2009). 
In addition to these intrinsic peripheral mechanisms, self-reactive lymphocytes 
are ultimately controlled by a separate subset of CD4 T cells – the regulatory T cells. 
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Figure 2.7. T cell intrinsic mechanisms of peripheral tolerance. Self-reactive T cells may 
never encounter the self-antigen they recognise therefore existing in a state of ignorance (A). 
Encounter of self-reactive T cell with its antigen may result in anergy – a process involving the 
interaction of the T cell molecules cytotoxic T lymphocyte antigen 4 (CTLA-4) or programmed 
death 1 (PD-1) with their ligands, CD80/86 and programmed death ligand (PDL) 1 and 2 
respectively (B). Lastly, self-reactive T cells may be deleted following contact with self-antigen 
by activation-induced cell death involving up-regulation of T cell Fas ligand (FasL) and 
subsequent signalling through the death receptor Fas (C). 
 
3.3. Regulatory T cells 
The concept that T cells could regulate immune responses dates back to the 
1970s, when the existence of cells with suppressor properties was reported. This cell 
population was defined as being able to dominantly avert unwanted autoimmune 
responses (Gershon and Kondo 1970, Benacerraf et al. 1975). During the following two 
decades, the idea of suppressor cells fell out of favour, partly due to some irreproducible 
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and odd functional properties, and mainly to the lack of reliable distinguishing 
molecular markers.  
Fortunately, the field of T “suppressor” cells was reborn by the observations of 
Sakaguchi et al. that a subset of CD4 T lymphocytes constitutively expressing the IL-2 
receptor -chain (known as CD25) possesses potent immunosuppressive functions both 
in vitro and in vivo. These lymphocytes have been re-named “regulatory T cells” 
(Tregs; Sakaguchi et al. 1995). Tregs actively suppress pathological and physiological 
immune responses, thereby contributing to the maintenance of immunological self-
tolerance and immune homeostasis.  
 
3.3.1. Phenotypic characteristics of regulatory T cells 
CD25 
As mentioned in the previous section, the historical and prototypical Treg is 
characterised by the expression of CD25. Although CD25 is not a faithful marker due to 
its up-regulation on cells undergoing activation, it should be emphasised that Tregs 
express the highest levels of CD25 and do so constitutively, whereas expression by 
conventional CD4 T cells is transient and lower.  Moreover, CD4
pos
CD25
high
 T cells 
have been shown to suppress immune responses (Takahashi et al. 1998, Thornton and 
Shevach 1998). Importantly, transfer of T cell suspensions depleted of CD25pos T cells 
produces autoimmune disease in athymic nude mice, whereas co-transfer of a small 
number of CD4
pos
CD25
pos
 T cells inhibits the development of autoimmunity (Sakaguchi 
et al. 1995). The high level of expression of CD25 on Treg cells suggests the 
importance of IL-2 for these cells. Indeed, presence of IL-2 is required for homeostasis 
and metabolic fitness of Tregs (Fontenot et al. 2005), and therefore for maintenance of 
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self-tolerance, as shown by the evidence that IL-2 neutralisation (Setoguchi et al. 2005) 
or deficiency (Kramer et al. 1995) determines a reduction in the number of Tregs, 
leading to a wide spectrum of autoimmune manifestations (O'Shea et al. 2002). Thus, 
CD25 expression is a functional characteristic of Tregs, being commonly used as a 
marker in Treg research. 
 
FOXP3 
The CD25
high
 population is highly enriched in what is still considered the most 
reliable marker for the identification of Tregs, the forkhead winged helix transcription 
factor FOXP3 (Fontenot et al. 2003, Hori et al. 2003). Its importance for the 
development and function of Tregs is highlighted by the fact that mutations in the 
Foxp3 gene in mice result in fatal autoimmune lymphoproliferative disease. In mice the 
spontaneous scurfy mutation, in which a loss of function in the Foxp3 gene is observed, 
results in a complete abrogation of Tregs and death of the mice at 3-4 weeks of age 
(Brunkow et al. 2001). Similarly, humans with immunodysregulation, 
polyendocrinopathy and enteropathy, X-linked syndrome (IPEX), who also show 
mutations in the FOXP3 gene, have a range of symptoms that are consistent with an 
altered suppressive function of Tregs (Wildin et al. 2001).  
Although the mechanisms of action of FOXP3 have not yet been fully 
characterised, recent evidence suggests that it may act as both a transcriptional repressor 
and activator (Marson et al. 2007, Y. Zheng et al. 2007b). The genes regulated by 
FOXP3 are not necessarily targeted by FOXP3 itself; instead its effects is exerted via 
other transcription factors such as nuclear factor of activated T cells (NFAT), nuclear 
factor-κB (NF-κB; Bettelli et al. 2005) and the runt-related transcription factor 1-core 
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binding factor β (Runx1-Cbfβ) heterodimer (Kitoh et al. 2009), leading to the inhibition 
of their target genes expression (among others, the genes coding for IL-4 and IFN-). 
Foxp3 also interacts with Foxo3a and Foxo1, which induce transcription by binding to 
the Foxp3 promoter (Harada et al. 2010).  
Interestingly, several investigators have suggested that the transcription factors 
Tbet (Koch et al. 2009) and interferon regulatory factor-4 (Irf-4; Zheng et al. 2009) are 
differentially expressed in FOXP3
pos
 Tregs following exposure to specific inflammatory 
environments, which may allow for the differential regulation of target genes in an 
adaptive manner. 
 
CTLA-4 and GITR 
Tregs also express high levels of CTLA-4 and glucocorticoid-induced tumour 
necrosis factor receptor family-related protein (GITR; Sakaguchi 2004, McHugh et al. 
2002). In normal mice exposure of Tregs to an anti-CTLA-4 monoclonal antibody leads 
to their functional inactivation (Takahashi et al. 2000), and CTLA-4-deficient mice 
succumb to fatal autoimmune disease (Bachmann et al. 1999).  
GITR, a member of TNFR  superfamily (Nocentini et al. 1997), appears to act as 
a negative regulator of Treg function: its stimulation abrogating Treg-mediated 
suppression (Shimizu et al. 2002); in contrast, it provides positive co-stimulation to 
other effector T cells (Kanamaru et al. 2004). However, and similar to CD25 
expression, CTLA-4 and GITR are also expressed by activated T cells, therefore 
limiting their use as markers of Tregs (Linsley et al. 1992). Nevertheless, several 
molecules have recently been identified that can help to distinguish Tregs from 
activated T cells. 
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Latency associated peptide 
Latency associated peptide (LAP) forms a latent complex with TGF-β1, an 
important cytokine involved in Treg cell development and function (Nakamura et al. 
2004). LAP is not only useful for distinguishing between Tregs and activated FOXP3
neg
 
or FOXP3
pos
 effector T cells (Tran et al. 2009), as its expression characterises a Treg 
subset with high levels of FOXP3, CTLA-4, and GITR (Chen et al. 2008) but LAP can 
also be used as a marker for TGF-β expressing Tregs, which exhibit higher ability to 
suppress compared to the CD4
pos
CD25
pos
LAP
neg
 population. 
While the LAP
pos
 subpopulations suppressive function is TGF-β dependent and 
is mediated by both cell-to-cell contact and soluble factors, the function of LAP
neg
 cells 
is mainly cell contact dependent (Chen et al. 2008). 
 
CD39 
CD39 (ectonucleoside triphosphate diphosphohydrolase-1, ENTPD1), an 
ectoenzyme that degrades adenosine triphosphate (ATP) to adenosine monophosphate 
(AMP), represents another surface marker of Tregs (Borsellino et al. 2007, Deaglio et 
al. 2007). In mice, it is present on virtually all CD4
pos
CD25
pos
FOXP3
pos
 Tregs. In 
humans, CD39 expression is limited to a subset of FOXP3
pos
 regulatory 
effector/memory-like T cells (Dwyer et al. 2007). In addition to CD39, murine and a 
subset of human Tregs also express CD73, an ecto-5'-nucleotidase, which acting in 
tandem with CD39, converts AMP into adenosine (Zimmermann 1992); hence, these 
suppressor cells are eventually able to catalyse ATP/adenosine diphosphate (ADP) into 
the immunosuppressive nucleoside adenosine (Kobie et al. 2006, Borsellino et al. 2007, 
Deaglio et al. 2007). The expression of both CD39 and CD73 therefore serves as a 
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phenotypic signature of Tregs, also having important mechanistic implications for their 
functional suppressive activity by catalyzing the generation of pericellular adenosine 
(Dwyer et al. 2007).  
 
CD127 
Recent studies have shown that functional Tregs express very low levels of the 
IL-7 receptor alpha (CD127), whereas activated CD25
pos
 T were characterised by the 
expression of this marker (Banham 2006). In the same year, another study reported that 
CD127 was down-regulated on all human T cells after activation. While the majority of 
effector and memory T cells were found to re-express it, FOXP
pos
 T cells remained 
CD127
low
 (Liu et al. 2006). A detailed information about CD127 is provided in section 
7.1.1. 
 
3.3.2. Regulatory T cell subsets 
Tregs are normally classified according to their developmental pathway into 
thymus-derived natural Tregs (nTregs) and peripherally-induced adaptive Tregs (iTregs; 
Figure 2.8.). Both nTregs and iTregs share a similar phenotype and have a contact-
dependent mechanism of action that is poorly understood (Horwitz et al. 2008). 
nTregs represent the most common Treg type accounting for 5-10% of and 1-2% 
of peripheral CD4
pos
 T cells in mice (Belkaid et al. 2002) and 1-2% in humans 
(Baecher-Allan et al. 2001). The pivotal role of the thymus in their generation was 
elucidated in early studies showing that mice undergoing thymectomy on day 3 of life 
suffered from T cell-mediated autoimmune disease, which could be reversed by CD4
pos
 
T cell infusion (Nishizuka and Sakakura 1969). A two-step instructive model of nTreg 
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development in the thymus has recently been proposed (Lio and Hsieh 2008). Firstly, 
autoreactive Treg precursors are exposed to strong TCR signals following high affinity 
binding to self-peptide: MHC molecules expressed on the surface of thymic epithelial 
cells (Jordan et al. 2001). This results in the up-regulation of CD25 and other 
components of the proximal IL-2 signalling pathway (Burchill et al. 2008). The second 
step involves co-stimulation mediated by the binding of CD28 present on developing T 
cells with its ligands expressed by thymic APCs (Salomon et al. 2000). Following co-
stimulation, Treg precursors begin to secrete IL-2 and up-regulate their expression of 
CTLA-4, GITR and, most importantly, FOXP3 (Tai et al. 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8. Thymic and peripheral generation of regulatory T cells. Thymus-derived natural 
regulatory T cell (nTregs) differentiate in the thymus and then migrate to peripheral tissues. 
Peripherally-induced adaptive regulatory T cells (iTregs) differentiate in secondary lymphoid 
organs and tissues. The peripheral population of FOXP3
pos 
regulatory T cells (Tregs) comprises 
both nTregs and iTregs. 
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As mentioned earlier, the avidity of TCRs for self-peptide: MHC complexes 
within the thymus determines the fate of the developing thymocytes – death by neglect, 
positive selection, Treg generation and negative selection (Klein et al. 2009). These 
alternative fates can be encompassed by an affinity threshold model (Palmer and Naeher 
2009). It should be noted that the boundaries between these are likely to be flexible in 
vivo and influenced by the number of engaged TCRs and the availability of co-
stimulatory signals (Figure 2.9.). The term “functional avidity” has been coined to 
account for these additional influences (Scherer et al. 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9. The affinity threshold model of central tolerance and regulatory T cell 
generation. Positive selection of T cells occurs upon receipt of “appropriate” levels of T cell 
receptor (TCR) stimulation. Aberrantly high levels of stimulation result in clonal deletion, while 
low levels lead to death by neglect. Regulatory T cell (Treg) generation occurs at levels between 
that of positive and negative selection. 
 
In recent years it became evident that FOXP3
pos
 Tregs can also be generated 
outside the thymus under a variety of conditions (Curotto de Lafaille and Lafaille 2009). 
FOXP3
pos
 iTreg development requires TCR stimulation and the presence of TGF-, for 
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both in vitro and in vivo generation (Chen et al. 2003). Addition of TGF- to TCR-
stimulated naive CD4
pos
 T cells induces transcription of FOXP3, acquisition of anergic 
and suppressive activity. The mechanism responsible for TGF-β-induced transcription 
of FOXP3 involves cooperation of the transcription factors STAT-3 and NFAT at a 
Foxp3 gene enhancer element (Fantini et al. 2004, Josefowicz and Rudensky 2009). 
Using IL-2-deficient mice and IL-2 neutralisation, it has been demonstrated that TGF-β-
dependent generation of iTregs also requires the presence of this cytokine (S. G. Zheng 
et al. 2007). iTregs are known to play an essential role in the gut-associated lymphoid 
tissue (GALT), due to continuous exposure to dietary antigens and commensal gut 
bacteria (Curotto de Lafaille and Lafaille 2009). Within this environment, a subset of 
DCs characterised by the expression the integrin CD103, can convert naïve T cells into 
Tregs via the production of retinoic acid (Coombes et al. 2007).  
A number of studies have provided evidence that shed light on the differences 
between nTregs and iTregs. Both populations express FOXP3 and suppress immune 
responses through contact-dependent mechanisms and by the production of soluble 
factors (Vignali et al. 2008, Sakaguchi et al. 2010). nTregs are stable with respect to 
retaining regulatory function and FOXP3 expression in the periphery. Studies on the 
methylation of CpG motifs in the Foxp3 locus of nTregs identified complete 
demethylation within an evolutionary conserved region upstream of exon 1, named 
Treg-cell specific demethylated region (TSDR; Curotto de Lafaille and Lafaille 2009). 
nTregs are also unique in that they express the transcription factor Helios (Thornton et 
al. 2010). Although iTregs express the same surface markers, they can be distinguished 
from nTregs based on FOXP3 DNA methylation patterns and their lack of Helios 
expression.  
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Besides FOXP3
pos
 Tregs, other adaptive regulatory T cell subsets develop as a 
consequence of antigen exposure in the periphery. Tr1 cells can be generated from 
naïve CD4 T cells by antigenic stimulation in the presence of IL-10, both in vitro and in 
vivo (Roncarolo et al. 2006). These cells produce IL-10 and TGF-, which have been 
demonstrated to be critical for their suppressive effect (Groux et al. 1996). Tr1 cells do 
not express FOXP3, yet some of their properties in vitro are very similar to those of 
FoxP3
pos
 Tregs. Antigen-specific TGF--secreting cells, termed Th3 cells (Weiner 
2001), were originally propagated from animals that became tolerant to orally 
administered protein antigen (Faria and Weiner 2005). Their relationship with other 
regulatory T cell subsets has not been fully characterised, but it has been reported that 
oral tolerance induction generates both CD25
pos
FOXP3
pos
 as well as CD25
neg
FOXP3
neg
 
T cells with regulatory properties (Sun et al. 2006). 
A variety of other T cell subpopulations including CD8
pos
CD28
neg
, 
CD4
neg
CD8
neg
, and  T cells have also been reported to exert immunosuppressive 
activity (Shevach 2006). There is so far little evidence that they play crucial roles in 
natural self-tolerance.   
 
3.3.3. Mechanisms of suppression 
A key issue of current Treg research is to understand their mechanisms of 
suppression (Sakaguchi et al. 2010). Tregs can exert their suppressive function either 
through a contact-dependent mechanism – by directly targeting the function of effector 
T cells as well as by modulating the maturation and/or function of dendritic cells, which 
in turn are required for the activation of the former – and/or through contact-
independent mechanisms (Shevach 2009). From a functional and practical perspective, 
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the suppression mechanisms deployed by Treg cells can be grouped into four “modes of 
action”: suppression by inhibitory cytokines, suppression by cytolysis, suppression by 
metabolic disruption and suppression by modulation of DC maturation or function 
(Vignali et al. 2008; Figure 2.10.). 
 
Suppression by inhibitory cytokines  
The role of TGF- as a suppressor molecule still remains a matter of debate.  
The majority of studies failed to demonstrate that Treg function in vitro could be 
reversed by an anti-TGF-β neutralising antibody (Piccirillo et al. 2002). However, since 
preventing its production leads to the development of an autoimmune inflammatory 
disease in mice , TGF- should contribute, at least in part, to in vivo suppression in this 
mouse model (Sakaguchi et al. 2009a). Though controversial, TGF- may act as a 
mediator of suppression in membrane-bound form (Nakamura et al. 2001). It may 
condition effector T cells to be amenable to suppression, and may contribute to the 
differentiation of other T cells into Treg-like cells (infectious tolerance; Fahlen et al. 
2005, Andersson et al. 2008). In addition to TGF-β, IL-10 production may be utilised by 
Tregs under certain conditions. IL-10 has been shown to be essential for the prevention 
of colitis in mouse models of IBD (Asseman et al. 1999), and allograft rejection (Hara 
et al. 2001, Kingsley et al. 2002).  
More recently, IL-35, a new member of the IL-12 family of cytokines, has been 
shown to be expressed by Tregs and to be required for their maximal suppressive 
activity (Collison et al. 2007). Ectopic expression of IL-35 conferred regulatory activity 
to naïve T cells and recombinant IL-35 suppressed T cell proliferation in vitro (Collison 
et al. 2007, Gavin et al. 2007).   
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Suppression by cytolysis  
Another potential mechanism of Treg-mediated suppression is cell-contact 
dependent cytolysis of target cells mediated by granzymes A and B (Grossman et al. 
2004, X. Cao et al. 2007) in perforin dependent and independent manners (Gondek et al. 
2005). Recently it has been shown that activated Tregs induce apoptosis of effector T 
cells through a tumour-necrosis-factor-related apoptosis-inducing ligand–death receptor 
5 (TRAIL–DR5) pathway. Blockade of TRAIL abrogates cytolysis and suppression 
(Ren et al. 2007). In addition, Galectin-1, which can induce T cell apoptosis, has been 
shown to be highly expressed by mouse and human Tregs. Knock-out and blockade of 
Galectin-1 abrogates Treg suppressive function (Garin et al. 2007).  
 
Suppression by metabolic disruption  
Several mechanisms of Treg suppression have been recently described that can 
be collectively referred to as “metabolic disruption” of effector T cells (Vignali et al. 
2008). Since Tregs are characterised by high expression levels of the high affinity IL-
2R (CD25), they compete with other T cells for local IL-2 consumption (Thornton and 
Shevach 1998, de la Rosa et al. 2004).  Consequently, actively dividing effector T cells 
are deprived of IL-2 and undergo Bim-mediated apoptosis (Pandiyan et al. 2007). 
Another suppressive mechanism employed by Tregs relates to the dual expression of 
CD39 and CD73. These surface ectoenzymes catalyse the degradation of extracellular 
nucleotides (e.g. ATP), leading to generation of pericellular adenosine (Kobie et al. 
2006, Deaglio et al. 2007).  Adenosine suppresses effector T cell function through 
activation of the adenosine receptor 2A, leading to subsequent intracellular cyclic AMP 
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Figure 2.10. Mechanisms of suppression employed by regulatory T cells. The various 
potential mechanisms of suppression employed by regulatory T cells (Tregs) can be grouped 
into 4 modes of action: (A) inhibitory cytokines including interleukin (IL)-10, transforming 
growth factor  (TGF-), and IL-35; (B) cytolysis including granzyme A- and B-dependent and 
perforin-dependent killing mechanisms; (C) metabolic disruption including CD25-dependent 
cytokine deprivation-mediated apoptosis, cyclic AMP (cAMP)-mediated inhibition, and CD39 
and/or CD73-generated adenosine-mediated suppression; (D) targeting dendritic cells (DCs) 
including mechanisms that modulate DC maturation and or function, such as lymphocyte 
activation gene 3 (LAG-3) – MHC class II-mediated suppression of DC maturation and 
cytotoxic T lymphocyte antigen 4 (CTLA-4) – CD80/86-mediated induction of indoleamine 
2,3-deoxigenase (IDO) which is an immunosuppressive molecule made by DCs.  
Adapted from Vignali DAA, Collinson LW et al. Nat Rev Immunol 2008; 8: 523-532. 
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Suppression by targeting DCs  
In addition to the effect on T cell function, Tregs also modulate the maturation 
and function of DCs.  
A core Treg suppressive mechanism is delivered via the surface expression of 
CTLA-4. The importance of CTLA-4 for Treg function has been shown by the use of 
CTLA-4 specific blocking antibodies (Read et al. 2000) or Treg-specific Ctla-4 knock-
out mice (Wing et al. 2008) – in the absence of functional CTLA-4, Treg-mediated 
suppression of effector T cells was reduced, with consequent ensuing of autoimmune 
disease. Mechanistically, CTLA-4 binding leads to the down-regulation and 
sequestration of the co-stimulatory molecules CD80 and CD86 on DCs (Cederbom et al. 
2000, Sakaguchi et al. 2009b). In addition, CTLA-4 binding to CD80/CD86 also leads 
to the up-regulation of the enzyme indoleamine 2,3-dioxygenase (IDO) (Grohmann et 
al. 2002). IDO catabolises the essential amino acid tryptophan, therefore limiting the 
access to this pro-inflammatory resource (Munn et al. 1999, Grohmann et al. 2002). The 
products of tryptophan catabolism are the immunosuppressive kynurenines (Belladonna 
et al. 2007).  
In addition to inducing the production of immunosuppressive molecules by DCs, 
Tregs may also down-modulate the capacity of DCs to initiate immune responses. 
Recent studies have suggested that cell surface lymphocyte activation gene 3 (LAG-3, 
also known as CD233) binds to MHC class II molecules with very high affinity, 
preventing the maturation and the ability of DCs to activate effector T cells (Liang et al. 
2008). The role of LAG-3 for Treg function was highlighted by studies showing that 
LAG-3 deficiency or specific blockade led to a reduced immune-suppressive activity, 
and that its forced expression can confer suppressive capacity on CD4
pos
 T cells (Huang 
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et al. 2004). Lastly, neuropilin (Nrp-1) has been proposed to play a role in Tregs/DC 
cross-talk, by promoting long interactions between Tregs and immature DCs, therefore 
slowing the initiation of an immune response  (Mizui and Kikutani 2008). Given that 
Nrp-1 is differentially expressed by Tregs (Bruder et al. 2004), this may confer to them 
an advantage over naïve T cells in modulating the function of DCs. 
In conclusion, this section has described various cellular and molecular events 
that contribute to overall Treg-mediated suppression. However, it should be pointed out 
that none of these accounts entirely for Treg-mediated suppression. In fact, it is possible 
that various combinations of several mechanisms are operating, depending on the milieu 
and the type of immune response.  In view of their role in the maintenance of immune-
tolerance, it is not surprising that enhanced or reduced Treg number and/or suppressive 
function is implicated in several diseases. 
 
3.3.4. Tregs and disease 
Tregs play an important role in a range of diseases. They are implicated in the 
pathogenesis of allergy (Ling et al. 2004), chronic infection (Belkaid and Rouse 2005), 
and cancer (Beyer and Schultze 2006). They are also required for the maintenance of 
tolerance to self, thus preventing autoimmune disease.  
The role of Tregs in protecting from autoimmunity was first identified in mice in 
which the absence or depletion of Tregs resulted in the development of pan-
autoimmunity, with manifestations of gastritis, thyroiditis, diabetes and IBD (Sakaguchi 
et al. 1995, Brunkow et al. 2001). Subsequent studies in animal models of autoimmune 
disease showed that Treg defects may account for the development of autoimmunity 
and  that the disease could be reversed by the adoptive transfer of Tregs (Sakaguchi and 
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Sakaguchi 2005). Later, it was confirmed the presence of Tregs in human peripheral 
blood and their ability to suppress T cell proliferation in vitro (Baecher-Allan et al. 
2001, Stephens et al. 2001).  
The importance of T cell regulation in human disease is highlighted by the 
severe inflammation and autoimmune manifestations that occurs in individuals who 
suffer from IPEX, the immunodysregulation determined by mutation in the FOXP3 
gene. These individuals develop a broad range of autoantibodies, insulin-dependent 
diabetes, thyroiditis, eczema, haemolytic anaemia and IBD, and in the absence of a bone 
marrow transplant, they die at an early age (Wildin et al. 2001). Defective regulation by 
Tregs has been documented in other, more common autoimmune diseases.  
 
Multiple sclerosis 
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system 
(CNS), characterised by focal demyelination, loss of oligodendrocytes, axonal damage 
and astrogliosis (Hafler 2004). In MS, self-reactive CD4
pos 
T cells target myelin-based 
antigens, have the ability to migrate to the CNS and display unique effector functions 
(McFarland and Martin 2007). Evidence implicating Tregs in the pathogenesis of MS 
derives from studies on both experimental autoimmune encephalomyelitis (EAE), a 
murine model of MS, and human MS.  
First, it has been shown that animals expressing a transgenic TCR specific for 
myelin basic protein (MBP) and lacking recombination-activating genes are deprived of 
Tregs and spontaneously develop EAE, implicating these cells in EAE prevention (Hori 
et al. 2003). Other studies have conversely shown that Treg-depletion resulted in an 
increased susceptibility to EAE, whereas the adoptive transfer of Tregs led to a reduced 
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EAE incidence (Kohm et al. 2002, Hori et al. 2003). The ability of Tregs to suppress 
CNS inflammation once the disease is established is, however, controversial: in spite of 
Treg accumulation in the CNS, effector T cells have been found to be resistant to Treg-
mediated suppression during active disease due to a highly pro-inflammatory micro-
environment (Kohm et al. 2002, Korn et al. 2007b).  
In the human setting, most of the studies have shown no difference in the 
percentage of Treg cells in the peripheral blood between MS patients and healthy 
subjects, irrespective of the disease activity (Viglietta et al. 2004, Haas et al. 2007, 
Michel et al. 2008). In the cerebrospinal fluid (CSF), on the other hand, Treg numbers 
have been found to be increased compared to those observed in the periphery of MS 
patients (Feger et al. 2007, Venken et al. 2008a). To date, only one study has reported a 
decreased number of FOXP3
pos
 Tregs in this condition. This defect was, however, 
limited to those patients with relapsing-remitting MS, and was corrected after treatment 
with IFN-(Venken et al. 2008b). Recent studies, analysing different Treg subsets in 
MS, have identified a decrease in the naive or recent thymic emigrant Tregs, a 
population characterised by the expression of CD31 and CD45RA, and which has been 
associated with a higher ability to suppress (Haas et al. 2007, Venken et al. 2008a). 
Similarly, Fletcher et al. reported a decrease in the population of Tregs expressing 
CD39 (Fletcher et al. 2009), a molecule that has also been associated with Treg 
suppressive function (see section 5.3.3.). Lastly, Tregs from MS have been reported to 
have an increased percentage of CD127
pos
 cells (Michel et al. 2008), which defines an 
activated cell subset deprived of suppressive function. The studies analysing Treg 
function consistently reported an impaired ability of Tregs to suppress the proliferation 
and IFN- secretion by effector T cells in patients with MS (Viglietta et al. 2004, Haas 
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et al. 2005, Michel et al. 2008). Collectively these data suggest that while the studies on 
the frequency and phenotype of Tregs in MS are inconsistent, those on the function of 
these cells consistently show an impaired ability to suppress. 
 
Type 1 diabetes 
Type 1 diabetes (T1D) is a T cell mediated disease that results in inflammation 
and destruction of the pancreatic islet beta cells with consequent loss of insulin 
production, and a lifelong dependency on exogenous insulin (Bluestone et al. 2010). 
Experiments performed in non-obese diabetic (NOD) mice, a spontaneous 
model of T1D, have shown that the development of diabetes is tightly controlled by 
Tregs (You et al. 2008). Indeed, diabetes transfer, which is observed following the 
infusion of T cells from diabetic mice into immune-incompetent syngeneic recipients is 
prevented by co-injection of Tregs from the spleen or the thymus of young prediabetic 
mice (Herbelin et al. 1998, You et al. 2005, You et al. 2007). In addition, treatment of 
young NOD mice with CD25-depleting antibodies accelerated the onset of the disease 
(Billiard et al. 2006). Furthermore, adoptive transfer of Tregs into NOD mice was 
shown to ameliorate the disease (Tang et al. 2004b).  
Many studies have investigated the role of Treg in patients with T1D. Similarly 
to what observed in MS, whether the frequency of Tregs is reduced or normal in 
subjects with T1D remains controversial. Although an initial study has reported a 
significant decrease in terms of Treg numbers in patients with newly diagnosed or 
established T1D (Kukreja et al. 2002), subsequent studies found no difference in the 
number of Tregs in the peripheral blood of individuals with T1D compared with healthy 
subjects (Putnam et al. 2005, Lindley et al. 2005, Brusko et al. 2005, Brusko et al. 
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2007). However, a recent study examining different Treg subsets reported an increase in 
the CD45RA
neg
FOXP3
low
 T cell fraction in subjects with new-onset diabetes compared 
with healthy subjects; this cell subset was characterised by production of high levels of 
IL-17 and  absence of suppressive function (Marwaha et al. 2010), suggesting that early 
disease is associated with a reduced number of functional Tregs. Akin to Treg numbers, 
several groups have shown that Tregs isolated from patients with T1D are functionally 
impaired (Putnam et al. 2005, Lindley et al. 2005, Brusko et al. 2005, Tree et al. 2006). 
Recent studies have demonstrated that in addition to intrinsic Treg defects, impaired 
immunosuppression in T1D is, in part, due to the resistance of effector T cells to Treg-
mediated suppression (Schneider et al. 2008, Lawson et al. 2008). 
  
Rheumatoid arthritis 
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterised by 
progressively destructive joint inflammation, destruction of articular cartilage and bone 
and synovial hyperplasia (McInnes and Schett 2011). 
As observed in other autoimmune condition, collagen-induced arthritis (CIA), an 
experimental model of RA, is exacerbated by Treg depletion (Morgan et al. 2003). 
However, at variance with MS and T1D, the diseased tissue in RA patients, i.e. the 
synovium, can be obtained, this enabling analysis of Treg number and function in the 
target tissue and comparison with the peripheral blood. 
Analyses of Treg frequency in the peripheral blood of subjects with RA resulted 
in contradictory observations. Several studies have reported decreased (Cao et al. 2004, 
Lawson et al. 2006, Sempere-Ortells et al. 2009) or normal (Ehrenstein et al. 2004, Liu 
et al. 2005, Lin et al. 2007) Treg frequencies, whereas other groups have shown an 
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increase in the number of Tregs in the periphery of RA patients (van Amelsfort et al. 
2004, Kao et al. 2007, Han et al. 2008). Despite these differences, there is general 
consensus that the frequency of Tregs cells is higher in the synovial fluid of patients 
with RA than in controls (Cao et al. 2004, Mottonen et al. 2005, Lawson et al. 2006). 
The evaluation of the suppressive function of Tregs in RA has also resulted in 
heterogeneous findings. While initial studies showed that Tregs isolated from either the 
blood or the synovium of RA patients maintained their ability to suppress the 
proliferation of effector cells (Cao et al. 2003, Mottonen et al. 2005, Lawson et al. 
2006), Ehrenstein et al. reported that Tregs in RA were unable to suppress the responder 
cells´ production of IFN- and TNF- (Ehrenstein et al. 2004). This functional defect 
could be, however, corrected after disease control with anti-TNF- specific agents. 
 
Systemic lupus erythematosus 
SLE is a systemic autoimmune disease characterised by the presence of 
autoantibodies and immune complexes that target multiple organ systems, including the 
skin, joints, kidneys and CNS (Tsokos 2011). Although SLE is thought to be largely 
mediated by B cells (Tsokos 2011), Treg deficiency results in the development of lupus-
like features,  including nephritis and positivity for DNA-specific antibodies (Sakaguchi 
et al. 1995), thus suggesting that impairment of Treg-mediated suppression may have a 
role in the pathogenesis of SLE.  
Numerous studies have evaluated the frequency and phenotype of circulating 
Tregs in SLE. Most of them reported a decreased frequency of Tregs in the peripheral 
blood of SLE patients (Crispin et al. 2003, Miyara et al. 2005, Mellor-Pita et al. 2006, 
Suen et al. 2009). However, other groups have reported normal (Alvarado-Sanchez et 
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al. 2006, Venigalla et al. 2008) or increased (Suarez et al. 2006) frequencies of 
circulating Tregs in patients with SLE. Phenotypic analysis showed that Tregs isolated 
from active SLE patients were characterised by a more activated phenotype and by 
significantly lower expression of FOXP3 compared to patients with inactive disease 
(Valencia et al. 2007, Bonelli et al. 2008). 
From a functional point of view, several groups reported that Tregs isolated 
from active SLE patients were defective at suppressing the proliferation and cytokine 
production of effector T cells, while Tregs obtained from inactive SLE exhibited normal 
suppressive function (Valencia et al. 2007). However, Venigalla et al. showed that 
Tregs lacking CD127 expression were quantitatively and qualitatively normal 
(Venigalla et al. 2008). The authors of these studies have further shown that responder 
cells isolated from patients with active SLE were less sensitive to the suppressive 
function of autologous or normal donor Tregs than those from patients with inactive 
SLE (Venigalla et al. 2008), suggesting that the defect in T cell suppression observed in 
active SLE was due to the resistance of effector cells to Treg mediated suppression and 
not to abnormal regulatory T cell function. In summary, defects in the number and 
function of Treg cells, as well as resistance of effector T cells to suppression have been 
established in patients with SLE. The observations of numerous possible regulatory 
defects may reflect the systemic character of this disease (Buckner 2010).  
 
Inflammatory bowel disease 
The idiopathic IBD comprises two types of chronic intestinal disorders: Crohn´s 
disease (CD) and ulcerative colitis (UC).  Despite pathological differences, both 
diseases are thought to be orchestrated by T cells and to result from a breakdown of 
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immune-tolerance in the gut (Abraham and Cho 2009). The key contribution of Tregs to 
immune-tolerance maintenance in the gut is best exemplified by the occurrence of 
wasting disease and gastritis observed in Treg-depleted mice, and by the amelioration of 
disease following adoptive transfer of Tregs (Sakaguchi et al. 1995). A role for Tregs in 
the regulation of human bowel inflammatory disease is supported by the finding that 
individuals with IPEX syndrome develop severe bowel inflammation as a component of 
their illness (Wildin et al. 2002). 
Similar to RA, studies focusing on the role of Tregs in IBD have benefited from 
the possibility to sample and examine the frequency and function of these cells not only 
in the peripheral blood but also in the target organ. As for the conditions described 
above, the studies evaluating the frequency of Tregs in the peripheral blood of patients 
with IBD have given contradictory results. While two studies reported an increase in the 
number of circulating Tregs (Takahashi et al. 2006, Saruta et al. 2007), other studies 
demonstrated that Tregs were decreased in number in patients with IBD compared to 
controls (Maul et al. 2005, Li et al. 2010, Eastaff-Leung et al. 2010). Notwithstanding 
the differences found in the periphery, analysis of the target organ consistently showed 
an increase in the percentage of FOXP3
pos
 cells in the lamina propria and in the 
mesenteric lymph nodes, particularly in and near the inflamed tissue (Maul et al. 2005, 
Li et al. 2010, Eastaff-Leung et al. 2010, Rahman et al. 2010).  However, two groups 
have reported that this increase in the frequency of infiltrating Tregs is also observed in 
other non-related inflammatory conditions, such as in diverticulitis and infectious 
enteritis (Maul et al. 2005, Uhlig et al. 2006), indicating that the increased frequency of 
Tregs in IBD is similar to that accompanying all types of gut inflammation. 
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Functional studies performed with Tregs cells obtained from peripheral blood, 
mesenteric lymph nodes or lamina propria of IBD patients pointed to a similar 
suppressive activity compared to that exerted by Tregs obtained from healthy 
individuals. Interestingly, however, treatment of IBD patients with anti-TNF- 
antibodies resulted in an increase in the number and function of Tregs, suggesting that 
control of disease activity is associated with the presence of functional Tregs.   
In summary, though there is still controversy whether the number and/or 
phenotype of Tregs are altered in autoimmune diseases, defects in Treg suppressive 
function has been consistently reported. Similarly, loss of tolerance to hepatic self-
antigens leading to liver autoimmunity has been shown to be accompanied by 
impairment in Treg immune-regulation. 
 
4. Breaking tolerance – pathogenesis of autoimmune liver disease 
4.1. Liver as an immunological organ 
The liver is regarded as a unique anatomical and immunological organ, 
continuously exposed to antigen-rich blood (containing pathogens, toxins, tumor cells 
and self-antigens) from the gastro-intestinal tract (Racanelli and Rehermann 2006). The 
liver is highly enriched in phagocytic cells, APCs and lymphocytes and is an active site 
for the production of cytokines, complement components and acute phase proteins 
(Mackay 2002). Within the liver, many cell populations can act as APCs, namely 
endothelial cells, subendothelial stellate cells, hepatocytes, and dendritic cells (Crispe 
2009; Figure 2.11.). Infiltrating liver lymphocytes are present throughout the 
parenchyma, as well as in the portal tracts; these include cells of the innate (NKT and 
NK cells) and adaptive immune systems (B and T cells; Racanelli and Rehermann 
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2006). Immune-regulatory mechanisms are required to determine whether an antigen 
encounter will result in immunological tolerance or reactivity. Liver autoimmunity 
ensues when self-tolerance is lost (Vergani and Mieli-Vergani 2008). 
Figure 2.11. Liver as an immunological organ. Immune cells in the liver comprise those 
belonging to the innate arm of the immune system, namely hepatocytes, liver sinusoidal 
endothelial cells (LSEC), hepatic stellate cells (HSC), Kuppfer cells, dendritic cells (DCs), 
natural killer (NK) cells; and those belonging to the adaptive immune system, such as B and T 
cells. LSECs separate the blood stream from hepatocytes forming the space of Dissé. 
 
4.2. Genetics of AIH 
Genetic studies have identified a number of genes conferring susceptibility to 
AIH.  
AIH is a “complex trait” disease, therefore not following any Mendelian pattern 
of inheritance. Its mode of inheritance is unknown, though like other human complex 
trait disorders, it involves one or more genes that, acting alone or in concert, and 
interacting with environmental factors, increase or reduce the risk of the trait 
(Donaldson 2004b). 
In AIH, the strongest genetic associations relate to genes located within the 
MHC – the human leukocyte antigen (HLA) region – on the short arm of chromosome 6 
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(Table 2.1.), particularly those encoding DRB1 alleles (Donaldson 2002, Donaldson 
2004a, Donaldson 2004b). The role of class II MHC molecules is to present peptide 
antigens to CD4 T cells, suggesting that HLA class II antigen presentation and T cell 
activation are involved in the pathogenesis of AIH (Vergani et al. 2002). In Europe and 
North America, the alleles conferring susceptibility to AIH-1 are DRB1*0301 and 
DRB1*0401 which encode the HLA DR3 and DR4 antigens respectively (Donaldson et 
al. 1991, Strettell et al. 1997). Both heterodimers contain a K (lysine) residue at position 
71 of the DRB1 polypeptide and the hexameric amino acid sequence L (leucin) L 
(leucin) E (glutamic acid) Q (glutamine) K (lysine) R (arginine) at position 67-72 
(Donaldson 2002, Donaldson 2004a).  Amongst many associations reported to date, the 
presence of either HLA DR3 or DR4 are the only associations considered strong enough 
to positively point towards the diagnosis of AIH according to the revised diagnostic 
scoring system elaborated by the IAIHG (Alvarez et al. 1999). In Japan, Argentina and 
Mexico, susceptibility is linked to DRB1*0405 and DRB1*0404, alleles encoding R 
(arginine) rather than K (lysine) at position 71, but sharing the motif LLEQ-R with 
DRB1*0401 and DRB1*0301 (Czaja and Donaldson 2000). Thus, K or R at position 71 
in the context of LLEQ-R may be critical for susceptibility to AIH, favouring the 
binding of autoantigenic peptides, complementary to this hexameric sequence (Czaja et 
al. 2002).  However, an alternative model based on valine/glycine dimorphism at 
position 86 of the DR- polypeptide has been proposed, better representing the key 
HLA associations in patients from Argentina and Brazil (Donaldson 2002, Donaldson 
2004a). In a study from Japan, AIH-1 patients were found to have DRB1 alleles which 
encode histidine at position 13 (Donaldson 2004b).  
Breaking tolerance – pathogenesis of autoimmune liver disease 
 
 
[149] 
 
Taken together, these data indicate that different populations show distinct 
genetic associations and that the peptides presented by MHC class II molecules to the T 
cell receptors are distinct and may derive from different antigens. Thus, these HLA 
associations are potentially indicative of the prevailing environmental insults triggering 
AIH-1 in different environments. In this regard, it is interesting to note that in South 
America possession of HLA DRB1*1301 allele, which predisposes to paediatric AIH-1 
in this population, is also associated with persistent infection with the endemic hepatitis 
A virus (Vergani et al. 2009). 
Recently, a meta-analysis study, aiming to identify common HLA class II alleles 
conferring susceptibility to AIH-1 in Latin America, reported that the serological group 
DQ2 constitutes a risk factor, whilst the possession of DR5 or DQ3 is associated with 
protection against AIH occurrence (Duarte-Rey et al. 2009). 
Susceptibility to AIH-2 is conferred by the possession of HLA DR7 
(DRB1*0701) and DR3 (DRB1*0301), patients positive for DRB1*0701 having a more 
aggressive disease and more severe prognosis (Ma et al. 2006). Another study has 
suggested that the possession of HLA-DQB1*0201 is the major genetic determinant for 
children with AIH-2, although HLA-DQB1*0201 is in linkage disequilibrium with 
DRB1*0701 and DRB1*0301, both associated with AIH-2 (Djilali-Saiah et al. 2004). In 
AIH-2, HLA alleles have also been found to influence the autoantigenic humoral 
response, with DRB1*0301 being associated with seropositivity for both anti-LKM-1 
and anti-LC-1 antibodies and DRB1*0701 predominant amongst patients seropositive 
for anti-LKM-1 only. Additionally, children positive for DRB1*0701 develop anti-
LKM-1 antibodies characterised by a more restricted specificity compare to children 
positive for DRB1*0301 (Djilali-Saiah et al. 2006).  
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HLA locus Allele association AIH-1 AIH-2
HLA-B B8 LD with DRB1*0301
Severe disease course
Relapse after drug withdrawl
More frequent requirement for LT
HLA-C Cw7 Susceptibility in United Kingdom (LD with
DRB1*0301
HLA-DRB1 DRB1*0301 Susceptibility in Europe and North America
Younger age at onset, higher rate of treatment
failure, relapse after drug withdrawl, and
requirement for LT than DR4
More expression of SLA/LP
Susceptibility in children
Associated with seropsitivity for
both anti-LKM-1 and anti-LC-1
DRB1*0401 Susceptibility in Europe and North America
Later age at onset than DR3
Higher frequency in women
Associated with concurrent immunological
diseases
Low frequency of progression to hepatic failure
and death
Higher frequency of ANA positivity
DRB1*0404 Susceptibility in Mexico
DRB1*0405 Susceptibility in Japan and Argentina
DRB1*0701 Susceptibility in Europe and in
Brazil
Predominant amongst patients
positive for only anti-LKM-1
Aggressive disease course and
worse prognosis
DRB1*1301 Susceptibility in South America and in
DR3/DR4-negative North American patients
Early age at onset in Brazil
DRB1*1401 Susceptibility in India
DRB1*1501 Protection in United Kingdom
HLA-DQ DQB1*0201 Susceptibility in United Kingdom and South
America
Susceptibility in Europe and in
North America (LD with
DRB1*0301 and DRB1*0701)
DQB1*0301 Protection in South America
DQB1*0601 Susceptibility in Brazil (LD with DRB1*1301) Susceptibility in Germany
Table 2.1.  HLA associations in autoimmune hepatitis.  
HLA, human leukocyte antigen; AIH, autoimmune hepatitis; LD, linkage desiquilibrium; LT, 
liver transplantation; SLA/LP, soluble liver antigen/liver pancreas; anti-LKM-1, anti-liver 
microsomal antibody type 1 antibodies; anti-LC-1, anti-liver cytosol type 1 antibodies; ANA, 
anti-nuclear antibodies 
 
Other genes within the HLA region and shown to be associated with AIH 
susceptibility include the IgA and complement factor 4A (C4A) genes (Gregorio et al. 
1997). IgA deficiency, frequently found in patients with AIH, is genetically linked to 
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the MHC locus, particularly with HLA-DR1 and DR7 (Vorechovsky et al. 1999, De la 
Concha et al. 2002). Moreover, low levels of C4a are present in 69% of children with 
AIH, this deficiency being genetically determined (Vergani et al. 1985). 
A number of genes outside the MHC may also be involved in susceptibility to 
AIH.  As mentioned earlier, CTLA-4 (also known as CD152) is a molecule present on 
the surface of T cells, which interacts, in competition with CD28, with CD80 and CD86 
ligands on APCs, transmitting an inhibitory signal to T cells. A transition from A 
(adenine) to G (guanine)  in exon 1 of the CTLA-4 gene has been shown to confer 
susceptibility to several autoimmune diseases, including AIH-1 in caucasians from 
North America (Agarwal et al. 2000); however, this finding was not confirmed in 
Brazilian patients with AIH-1 or AIH-2 (Bittencourt et al. 2003). A polymorphism at 
position 308 in the tumor necrosis factor  gene promoter (TNFA) occurs more 
frequently in patients with AIH-1 from Europe and North America than in healthy 
subjects and is associated with a poorer response to steroids (Czaja et al. 1999b), a 
finding that was not observed in Japanese patients (Yoshizawa et al. 2005). A 
polymorphism at position 670 in the FAS gene promoter was found to influence AIH 
susceptibility and progression, leading to a more aggressive disease with an early 
development of cirrhosis (Agarwal et al. 2007). Polymorphisms in the vitamin D 
receptor – capable of activating macrophages and monocytes, preventing dendritic cells 
differentiation, and inhibiting Th1 cell function – were shown to contribute to the 
development of autoimmune liver disease (Vogel et al. 2002).  
A form of AIH resembling AIH-2 has been described in some 20% of patients 
with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). 
This condition, also known as autoimmune polyendocrine syndrome 1, is a monogenic 
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autosomal recessive disorder, and is characterised by a variety of organ-specific 
autoimmune diseases, the most common of which are hypoparathyroidism and primary 
adrenocortical failure, accompanied by chronic mucocutaneous candidiasis (Liston et al. 
2005, Mathis and Benoist 2009). At variance with many other autoimmune diseases, 
APECED is associated with mutations of a single gene – designated autoimmune 
regulator 1 (AIRE1). The AIRE1 gene sequence consists of 14 exons containing 45 
different mutations, with a 13-bp deletion at nucleotide 964 in exon 8 accounting for 
more than 70% of APECED alleles in the United Kingdom (Simmonds and Gough 
2004). AIRE1, which codifies a transcription factor, is highly expressed in medullary 
epithelial cells and other thymic stromal cells involved in clonal deletion of self-reactive 
T cells. Interestingly, APECED has a high level of variability of symptoms, especially 
between populations. Since various gene mutations have the same effect on thymic 
transcription of ectopic genes in animal models, it is likely that the clinical variability 
across human populations relates to environmental or genetic modifiers. Of the latter, 
the most likely to synergise with AIRE mutations are polymorphisms in the HLA 
region. HLA molecules are not only highly variable and strongly associated with 
multiple autoimmune diseases but they are also able to affect thymic repertoire selection 
of self-reactive T cell clones (Longhi et al. 2010). Carriers of a single AIRE1 mutation 
do not develop APECED. However, although the inheritance pattern of APECED 
indicates a strictly recessive disorder, there are anecdotal reports of mutations in a 
single copy of AIRE being associated with human autoimmunity of a less severe form 
than classically defined APECED (Simmonds and Gough 2004, Liston et al. 2005). The 
role of AIRE1 heterozygote status in the development of AIH remains to be defined. 
AIRE1 mutations have been reported in three children with severe AIH-2 and extra-
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hepatic autoimmune manifestations (Lankisch et al. 2005), and in four children with 
AIH-1 and a family history of autoimmune disease (Lankisch et al. 2009). 
 
4.3. Molecular mimicry 
In patients with increased genetic susceptibility to AIH, immune responses to 
liver autoantigens may be triggered by molecular mimicry, a process where immune 
responses to external pathogens become directed toward structurally similar self-
components  (Vento et al. 1984, Bogdanos et al. 2001).  
Autoimmunity is a common feature during chronic HBV and HCV infections, 
where 50% of patients eventually develop autoantibodies such as ANA and SMA 
(Gregorio et al. 1999, Gregorio et al. 2003). In addition, 10% of chronic HCV patients 
are positive for LKM-1, this positivity being correlated with disease severity and 
adverse reactions to interferon treatment (Lenzi et al. 1999). Thus, HBV and HCV 
infection may play a role in the initiation of the autoimmune process; however, a strong 
link between autoimmunity and viral hepatitis has been shown only for HCV. 
Interestingly, reactivity against CYP2D6193-212, identified as a major B-cell epitope in 
AIH-2, is also found in 50% of HCV infected patients with seropositivity for anti-LKM-
1 antibodies (Bogdanos et al. 2001). In HCV-positive/anti-LKM-1-positive patients the 
presence of cross-reactivity between antibodies directed against homologous regions of 
HCV (NS5B HCV2985-2990) and cytomegalovirus (exon CMV130-135; Kerkar et al. 2003) 
has been demonstrated. Moreover, Manns et al. reported a sequence homology between 
CYP2D6254-271 and the amino acid (aa) sequence 310-324 of E1 HCV and the aa 
sequence 156-170 of IE1 75 Herpes Simplex Virus 1 (HSV-1). As anti-LKM-1 
antibodies cross-react with homologous regions of CYP2D6, HCV, CMV and HSV, a 
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“multi-hit” mechanism for the generation of these antibodies and possibly of AIH-2 
may be envisaged (Manns et al. 1991, Bogdanos et al. 2001). According to this model, 
sequential exposure to common viral pathogens like CMV or HSV may establish 
permissive immunologic conditions by priming a cross-reactive subset of T cells in a 
genetically predisposed host. Depending on the level of exposure and the degree of 
genetic susceptibility, a minority of recurrently infected individuals may progress to 
autoimmune disease. It is therefore conceivable that an as yet unidentified virus 
infection may be part of the origin of the autoimmune attack in AIH (Vergani et al. 
2009).  
Further support of this model has been provided by an interesting case-report 
describing a 10-year-old girl who acquired HCV infection following LT for end-stage 
liver disease caused by α1-anti-trypsin deficiency. Two weeks after HCV infection 
IgM anti-LKM-1 appeared, followed by IgG anti-LKM-1, a finding suggesting HCV as 
a trigger of a primary anti-LKM-1/anti-CYP2D6 autoimmune response (Mackie et al. 
1994).  
A link between HCV infection and breakdown of immune tolerance has also 
been postulated by a recent study by Agmon-Levin et al., who reported that serum anti-
HCV antibodies were found in up to 8.7% of patients with autoimmune diseases, 
including cryoglobulinaemia, Hashimoto's thyroiditis and IBD (Agmon-Levin et al. 
2009).  
In addition to these environmental and genetic factors, there is increasing 
evidence that a failure of mechanisms maintaining tolerance to liver autoantigens is 
central to the development of AIH. 
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4.4. Mechanisms of autoimmune liver damage 
The mechanisms leading to autoimmune liver damage have been a focus of 
intense investigation over the past three decades. However, the initial trigger of centred  
autoimmunity remains elusive.  
The histological picture of interface hepatitis (see Chapter I, section 4.4.), the 
hallmark of the disease and composed of lymphocytes, plasma cells, and macrophages 
was the first to suggest that an autoaggressive cellular immune attack was the basis of 
this condition. Whatever the initial trigger, this massive recruitment of activated 
inflammatory cells is likely to cause damage. Immunohistochemical studies performed 
in the early 1990s have identified a predominance of T lymphocytes expressing the  
T cell receptor (Senaldi et al. 1992). Amongst T cells, the majority are positive for the 
CD4 helper/inducer phenotype, and a sizeable minority for the CD8 cytotoxic 
phenotype. Lymphocytes of a non T cell lineage are fewer and include NK cells, 
macrophages, B cells and plasma cells (Senaldi et al. 1992). 
Regardless of the factors triggering the autoimmune process, the pathogenic 
mechanism leading to liver damage is part of a complex scenario, which requires the 
intervention of both innate and adaptive arms of the immune system. 
Liver damage is probably orchestrated by CD4
pos
 lymphocytes that recognise a 
self-antigenic peptide. The autoimmune response is initiated after the peptide is 
embraced by a HLA class II molecule and presented to a naïve CD4
pos
 T helper cell 
(Th0) by an APC, in the presence of the appropriate co-stimulatory signals, induced by 
the interaction of CD28 on Th0 and CD80/CD86 on APC. Once activated, and 
depending on the type of cytokines present in the microenvironment and on the nature 
of the antigen, Th0 cells can differentiate into Th1, Th2 and Th17 cells. These effector 
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cells initiate a cascade of immune reactions largely determined by the cytokines they 
produce:  
a) Th1 cells secrete mainly IL-2 and IFN-;  IFN-isconsidered the main 
orchestrator of tissue damage since it not only stimulates CD8 cells, enhances the 
expression of HLA class I, and induces expression of HLA class II molecules on 
hepatocytes (Lobo-Yeo et al. 1990, Senaldi et al. 1991), but also activates 
monocytes/macrophages, which in turn release IL-1 and TNF-;  
b) Th2 cells produce IL-4, IL-10 and IL-13, cytokines that induce the maturation 
of B cells into plasma cells, with consequent production of autoantibodies; 
c) Th17 cells, which arise in the presence of TGF- and IL-6, produce IL-17, IL-
22, TNF- and CCL-20 (Bettelli et al. 2006). In both mice and humans Th17 immunity 
has been recently associated with autoimmune disease (Miossec et al. 2009). Th17 cells 
have also been implicated in the pathogenesis of another autoimmune liver disease, 
PBC (Harada et al. 2009). Although their contribution to liver damage in AIH is still 
under investigation, a recent paper showed an increased number of Th17 cells in both 
the peripheral blood and liver of patients with AIH compared to healthy controls (Zhao 
et al. 2011). 
If Tregs are numerically and functionally impaired in AIH (see section 4.5.), 
effector responses are perpetuated with consequent liver cell destruction by the direct 
action of CTL, cytokines released by Th1, and possibly Th17 cells and 
monocytes/macrophages, complement activation or engagement of natural killer cells 
by autoantibodies bound to the hepatocyte surface (Vergani and Mieli-Vergani 2008). 
Mechanisms leading to and/or perpetuating the autoimmune liver attack in AIH are 
depicted in Figure 2.12. 
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Figure 2.12. Autoimmune attack to the liver cell. An autoantigenic peptide is presented to an 
uncommitted T helper (Th0) lymphocyte within the HLA class II molecule of an antigen-
presenting cell (APC). Th0 cells become activated and, according to the cytokines present in the 
microenvironment and the nature of the antigen, differentiate into Th1, Th2, or Th17 cells, 
initiating a series of immune reactions determined by the cytokines they produce: Th2 secrete 
mainly IL-4, IL-10 and IL-13, and direct autoantibody production by B lymphocytes; Th1 
secrete IL-2 and IFN-γ, which stimulate T cytotoxic lymphocytes (CTL), enhance expression of 
class I and induce expression of class II HLA molecules on hepatocytes and activate 
macrophages; activated macrophages release IL-1 and tumour necrosis factor alpha (TNF-α). If 
regulatory T cells do not oppose, a variety of effector mechanisms are triggered: liver cell 
destruction could derive from the action of  CTL; cytokines released by Th1 and recruited 
macrophages; complement activation or engagement of Fc receptor-bearing cells such as natural 
killer (NK) lymphocytes by the autoantibody bound to the hepatocyte surface. The role of the 
recently described Th17 cells, which arise in the presence of transforming growth factor beta 
(TGF-β) and IL-6, is under investigation. 
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4.4.1. Humoral immune response 
Several autoantibodies have been reported to contribute to liver damage in AIH. 
The titres of anti-liver-specific membrane lipoprotein (LSP) antibody, as well as 
antibodies to the LSP components ASGPR and alcohol dehydrogenase (ADH) correlate 
with biochemical and histological indices of disease severity (Jensen et al. 1978, 
McFarlane et al. 1986). The role of these autoantibodies in the autoimmune liver attack 
has been suggested by the finding that hepatocytes, isolated from patients with AIH, are 
coated with immunoglobulins and are susceptible to cytotoxicity when exposed to 
autologous Fc receptor bearing mononuclear cells (Vergani et al. 1979, Vergani et al. 
1987). More recently, anti-SLA antibodies, targeting the UGA suppressor tRNP-
associated antigenic protein (tRNP
(ser)sec
; Wies et al. 2000, Palioura et al. 2009), were 
found in 50% of AIH-1 and AIH-2 patients, defining a disease course more severe 
compared to seronegative patients (Ma et al. 2002a).  
In AIH-2, the evidence that anti-LKM-1 antibodies are involved in liver damage 
stems from studies showing that CYP2D6 is also expressed on the surface of 
hepatocytes, and therefore may be susceptible to recognition by anti-LKM-1 antibodies 
(Muratori et al. 2000). Following the identification of CYP2D6 as the target antigen of 
LKM-1, the search for B cell epitopes within CYP2D6 has been the focus of intensive 
research. In AIH-2 anti-LKM-1 antibodies recognise linear regions (autoepitopes) of 
CYP2D6 in a hierarchical manner. Thus, the main linear B cell epitope, CYP2D6193-212 
is recognized by 93% of the patients, CYP2D6257-269 by 85%, CYP2D6321-351 by 53%, 
and two additional minor epitopes CYP2D6363-389 and CYP2D6410-429 are recognized by 
7% and 13% respectively (Kerkar et al. 2003). Using the expression of both full-length 
and a series of truncated CYP2D6 proteins in an eukaryotic system, Ma et al. have 
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provided a conformational epitope mapping of CYP2D6, showing that the antigenicity 
is confined to the C terminal portion of the molecule and that it increases stepwise 
towards the C terminal (Ma et al. 2002b). 
 
4.4.2. Cellular immune response 
Early investigations of the cellular immune mechanisms involved in the 
pathogenesis of autoimmune liver damage concluded that AIH patients had circulating 
lymphocytes “sensitised” to liver antigens and able to kill target cells in vitro. Studies 
performed using T and non-T cell subsets obtained from the peripheral blood of AIH 
patients and xenogenic target cells demonstrated that cytotoxic cells were present in the 
non-T cell subpopulation (Vergani et al. 1979). Involvement of an antibody-dependent 
cell-mediated cytotoxicity (ADCC) in the autoimmune liver attack has been suggested 
by experiments showing that cytotoxic lymphocytes were located within the non-T cell 
compartment and that aggregated IgG were able to block cytotoxic activity. Such 
involvement was later confirmed by the observation that hepatocytes carrying IgG on 
their surface were susceptible to damage by lymphocytes from healthy individuals 
(Vergani et al. 1987). In the early 90s, clonal analysis studies showed that cytotoxicity 
against liver-specific antigens could also be detected within the T cell compartment 
(Wen et al. 1990). 
Subsequent studies conducted by Wen et al. demonstrated that children with 
AIH display a 10-fold higher frequency of liver antigen-specific precursors in their 
circulation when compared to healthy subjects (Wen et al. 2001).  Experiments of clonal 
analysis revealed a high frequency of CD4 T cells expressing the HLA-DR molecule 
amongst IL-2R positive cells. Neutralization of HLA-DR, CD4 and IL-2R led to the 
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conclusion that these clones follow the classical rules of immune recognition, being able 
to recognize antigens in the context of class II HLA molecules (Wen et al. 1990). 
Subsequent investigations showed that in AIH the largest numbers of clones generated 
from the peripheral blood are CD4
pos
 T cells bearing the  T cell receptor. In contrast, 
the highest proportion of clones obtained from liver biopsies of the same patients are 
CD4
neg
CD8
neg
 T cells bearing the  T cell receptor or CD8pos  T cells. Both types of 
liver-derived clones are able to proliferate in response to liver-specific antigens, such as 
ASGPR and ADH; clones that proliferate in the presence of ASGPR are also able to 
induce the production of ASGPR-specific autoantibodies from B lymphocytes in vitro 
(Wen et al. 2001). 
 
CD4 T cell immune responses 
CD4 T cell immune responses have mainly been studied in AIH-2, where the 
target autoantigen is known. The evidence that autoantibodies to CYP2D6 belong to the 
IgG isotype – thus implicating a CD4-dependent class switch – and, that the majority of 
T cells infiltrating the liver in AIH are CD4 lymphocytes, suggested a role for these 
cells in AIH pathogenesis. CYP2D6262-285 specific T cell clones generated from liver 
tissue and peripheral blood express a Th1 CD4 phenotype (Lohr et al. 1991, Lohr et al. 
1992). To define the specificity of ex vivo CYP2D6-reactive T cells in AIH-2, 
overlapping peptides covering the whole CYP2D6 molecule were constructed; this 
study showed that T cells from HLA DRB1*0701 positive patients recognise seven 
CYP2D6 regions, four of which are also partially recognized by T cells of DRB1*0701 
negative patients (Ma et al. 2006). Whilst distinct peptides induce production of IFN-, 
IL-4, or IL-10, peptides inducing IFN- and proliferation were found to overlap. An 
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overlap between sequences inducing T and B cell responses has also been observed. 
The number of epitopes and the quantity of cytokine produced by T cells have been 
reported to correlate with biochemical and histological markers of disease activity. 
These results indicate that the T cell response to CYP2D6 in AIH-2 is polyclonal, 
involves multiple effector types targeting different epitopes, and is associated with 
hepatocyte damage (Ma et al. 2006). 
 
CD8 T cell immune responses 
In the early 1990s CD8 T cell clones specific for ASGPR were described in AIH 
patients (Wen et al. 1990). More recently, CYP2D6-specific CD8 T cells, capable of 
producing IFN- and of exerting cytotoxicity upon recognition of CYP2D6 epitopic 
sequences in an HLA class I restricted fashion, have been identified. Involvement of 
CYP2D6-specific CD8 T cell immune responses in the liver damage is suggested by the 
correlation between the extent of CYP2D6-specific CD8 T cell immune responses and  
indices of disease activity and by the presence of self-reactive CD8 T lymphocytes 
within the portal tracts (Longhi et al. 2007). 
 
  T cells 
 T cells bear a TCR composed of rearranged  and  chains instead of the 
conventional  heterodimeric TCR (Kreslavsky et al. 2010).  Although representing a 
small proportion of circulating lymphocytes,  T cells are abundant in the liver (Girardi 
2006). According to the rearranged V chain, two  T cell subsets are generally 
recognised: V1 and V2 cells. While the former are highly abundant among 
intraepithelial lymphocytes but scarcely represented in the peripheral blood, the latter 
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constitute up to 80% of the whole circulating  T cell population. In terms of function, 
V1 cells are known to possess both regulatory and effector function, whereas V2 cells 
are mainly effectors and involved in the defence against pathogens and tumours (Girardi 
2006).  
In the early 1990s, Wen et al. reported a higher frequency of  T cells in 
children with AIH compared to controls. Later, the same authors showed that a higher 
number of  T cell clones could be obtained from liver biopsy specimens of AIH 
patients than from their peripheral blood. Moreover, they showed that these  T cells, 
in comparison to those bearing the  TCR, are more cytotoxic against liver-derived 
cell-lines, therefore suggesting a role for these cells in the autoimmune liver attack. 
A paper by Ferri et al. has recently renewed interest in  T cells and in 
understanding their contribution to liver damage in AIH, showing that the number of 
these cells is elevated during the active phases of disease. Moreover,  T cells not only 
display an inverted V1/V2 ratio, but are also more frequently positive for IFN- and 
granzyme B than normal controls. The frequency  T cells positive for granzyme B 
correlated with transaminase and bilirubin levels, a finding that suggests a role for these 
cells in the initiation and/or perpetuation of liver injury (Ferri et al. 2010). 
 
Monocytes 
Monocytes/macrophages represent a major component of the portal/periportal 
cellular infiltrate in AIH. Compared to health, monocytes isolated from the peripheral 
blood of children with AIH, displayed more vigorous spontaneous migration, and 
produced more TNF-α over IL-10, and expressed higher levels of Toll-like receptor 4 
(TLR-4) – a molecule that, like other members of the Toll-like receptor family, 
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recognises pathogen-associated molecular patterns, and whose engagement is key to the 
initiation of adaptive immune responses  (Hoshino et al. 1999). Marked monocytes´ 
activation during active disease suggests active participation of these cells in liver 
damage, possibly promoted by autoreactive cells belonging to the adaptive arm of the 
immune system (Longhi et al. 2009). 
Collectively the studies described above indicate an involvement of both 
humoral and cellular immune responses in the pathogenesis of AIH, involvement which 
is likely to be permitted by a failure of immune homeostatic processes. 
 
4.5. Impairment of regulatory T cells 
Occurrence of autoimmune diseases is determined by the breakdown of 
immune-regulatory mechanisms that in health are responsible for maintaining 
immunological tolerance against self-antigens (see section 3.3.). In the context of AIH, 
seminal studies conducted during the 1980s were able to a) demonstrate an impairment 
of cells with “suppressor” function, which would eventually revert following in vitro 
exposure of therapeutic doses of steroids (Hodgson et al. 1978, Nouri-Aria et al. 1982, 
Vento et al. 1984), and to b) show that this defect involved a subpopulation of T 
lymphocytes controlling immune responses against a liver-specific membrane 
autoantigen (Vento et al. 1984). Those were the seeds for a series of subsequent studies, 
that almost 20 years later, clearly indicated that impairment in regulatory T cells is 
essential to the loss of immune tolerance in AIH and to the emergence of uncontrolled 
effector immune responses (Longhi et al. 2004, Longhi et al. 2005, Longhi et al. 2006, 
Longhi et al. 2008, Ferri et al. 2010, Longhi et al. 2011).  
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Among the multiple T cell subsets with suppressive function, the regulatory T 
cells (Tregs), defined by the expression of CD4, the IL-2 receptor  chain (CD25), and 
the transcription factor FOXP3, have emerged as having a central role in maintaining 
immune-tolerance to autoantigens (Sakaguchi et al. 1995, Sakaguchi et al. 2010; see 
section 5.3.).  
Both children and adults with AIH display a reduced frequency of 
CD4
pos
CD25
high
 Tregs that, compared to healthy subjects, express lower levels of 
FOXP3 (Longhi et al. 2004, Longhi et al. 2005, Ferri et al. 2010). This defect partly 
relates to the liver disease stage, being more evident at presentation and at relapse than 
during drug-induced remission. The observation that the frequency of Tregs is inversely 
correlated with anti-SLA and anti-LKM-1 antibody titres, suggest that Treg reduction 
favours the serologic manifestations of AIH (Longhi et al. 2004).  
Tregs isolated from patients with AIH are also functionally impaired as they fail 
to restrain the proliferation and IFN- production of CD4 and CD8 effector T cells 
(Longhi et al. 2004, Longhi et al. 2005), and are also defective at inducing a regulatory 
milieu that would support and enhance their own function (Longhi et al. 2006). When 
considering their interaction with innate immune cells, Tregs from AIH patients have 
been found to aberrantly enhance the activation of monocytes (Longhi et al. 2009). 
The observation that corticosteroid therapy can partially restore Treg indicates 
that in AIH these cells, though impaired, have the potential to expand and regain their 
function (Longhi et al. 2004, Longhi et al. 2005). 
 Using a polyclonal T cell stimulation strategy (that engages the T cell receptor 
via CD3 and the co-stimulatory molecule CD28, while providing exogenous IL-2; a key 
cytokine for Treg survival and growth), Tregs can be expanded from circulating 
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CD4
pos
CD25
pos
 Tregs, and generated de novo from non-regulatory CD4
pos
CD25
neg
 T 
cells in healthy subjects and, though to a lesser extent, also in patients with AIH 
(Longhi et al. 2008). Interestingly, expanded Tregs express higher levels of FOXP3, and 
therefore suppress more efficiently when compared to freshly isolated Tregs (Longhi et 
al. 2008).  
Since the expansion strategy mentioned above provides strong TCR signals, it 
may tend to preferentially expand effector rather than regulatory T cells; thus, it will be 
essential in view of future clinical application to either expand highly purified and 
consequently highly effective Tregs; or, alternatively, to create the right environment in 
which Tregs can perform at their best, namely through the inhibition of the 
aforementioned IL-17 expression (Longhi et al. 2012).  
Studies conducted in mice have shown that Tregs with autoantigen specificity 
suppress more efficiently than their non-antigen-specific counterparts. In contrast to 
AIH-1, were reactivity to a univocal autoantigenic target is lacking, in AIH-2 not only is 
the key autoantigen known (CYP2D6; Gueguen et al. 1988), but  also the antigenic 
regions (CYP2D6217-260 and CYP2D6305-348), targeted by  B, CD4 and CD8 T cells is 
well characterised (Kerkar et al. 2003, Longhi et al. 2007). Thus, AIH-2 seems to be the 
ideal model for attempting reconstitution of self-tolerance by specific immunological 
intervention. In this regard, antigen-specific Tregs from patients with AIH-2 have been 
found to suppress CD4 and CD8 T cell responses more potently than polyclonally 
expanded Tregs. The most efficient suppression of autoreactive T cells was achieved 
when Tregs exposed to CYP2D6 peptides were co-cultured with semi-mature dendritic 
cells loaded with the same peptide (Longhi et al. 2011). For this reason autoantigen-
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Evidence Reference
AIH-1
Impairment of “suppressor” cell function, which recovers after in vitro exposure of steroids Nouri-Aria et al., 1982
Defect in a T cell population that controls immune reponses against a liver-specific antigen Vento et al., 1984
Tregs are defective in number and function Longhi et al., 2004, Longhi et al., 2005
Tregs fail to restrain the proliferation and IFN- production by CD4 and CD8 T cells Longhi et al., 2004, Longhi et al., 2005
Tregs are defective at promoting secretion of regulatory cytokines by their targets Longhi et al., 2006
Tregs aberrantly enchance activation anf function of monocytes Longhi et al., 2009
NKT cells are reduced in number Ferri et al., 2010
NKT cells contain low frequencies of IL-4-producing cells Ferri et al., 2010
AIH-2
Tregs are defective in number and function Longhi et al., 2004, Longhi et al., 2009
Tregs fail to restrain the proliferation and IFN-production by CD4 and CD8 T cells Longhi et al., 2004, Longhi et al., 2005
specific Tregs would represent an optimal tool for achieving a tailored immne-tolerance 
reconstitution in AIH. 
Among other cells with suppressive potential, NKT cells, a subset of T cells that 
co-express NK cell markers and that are highly represented within the liver (see section 
4.1.), have been suggested to play an important role in regulating immune responses in 
the context of autoimmune liver diseases (Santodomingo-Garzon and Swain 2011).  
NKT cells are numerically reduced in the peripheral blood of AIH patients, particularly 
during the active phases of disease and this number is partially restored during drug-
induced remission; their behaviour, therefore, mirrors that of CD4
pos
CD25
high
 regulatory 
T cells (Ferri et al. 2010). In addition, NKT cells from AIH patients produce lower 
quantities of the regulatory cytokine IL-4 compared to healthy controls (Ferri et al. 
2010). Evidence of impaired immune-regulation in AIH is summarised in Table 2.2. 
 
Table 2.2.  Evidence of impaired immune-regulation in AIH. 
AIH, autoimmune hepatitis, Tregs, regulatory T cells; IFN-, interferon gamma; NKT cells, 
natural killer T cells; IL-4, interleukin-4 
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4.6. Animal models of AIH 
Animal experiments have contributed much to the understanding of pathogenic 
mechanisms of several conditions. In AIH, the ideal model should be characterised by a 
well-defined initiating event followed by chronic inflammation leading to fibrosis. 
Although several murine models of AIH have been reported so far, none of them 
faithfully reproduces the human condition.  
Since in AIH-2 the autoantigen is well defined, researchers have focused their 
attention in this disease subtype. One model  is based on the immunisation of C57BL/6 
female mice with a plasmid containing the cDNA for the antigenic region of human 
CYP2D6 and formimino-transferase cyclodeaminase,  targets of anti-LKM-1 and anti-
LC-1 respectively, together with the end of the terminal region of murine CTLA-4 
(Lapierre et al. 2004). Only after three immunisations and when a plasmid containing 
the cDNA encoding IL-12 was also used, antigen specific autoantibodies were 
produced, and a modest liver damage accompanied by portal and periportal infiltration 
of CD4, CD8 T and, B cells was observed. When the same immunisation protocol was 
used in different mouse strains, no inflammatory changes were observed highlighting 
the importance of a specific genetic background in the development of the disease 
(Lapierre et al. 2004). More recently the same group demonstrated that in the same 
model the severity of the disease depends on the age at the time of the xeno-
immunisation as 7-week-old females of C57BL/6 background developed more severe 
disease with higher levels of serum alanine aminotransferase and autoantibody titre than 
younger and older females (Lapierre et al. 2010).  Another model of AIH-2 was 
generated after infecting CYP2D6 transgenic mice with an Adenovirus-CYP2D6 vector 
(Holdener et al. 2008). While focal hepatocyte necrosis was seen both in mice treated 
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with the Adenovirus-CYP2D6 vector and control mice treated with Adenovirus alone, 
only the former developed chronic histological changes, including fibrosis, reminiscent 
of AIH. The hepatic lesion was associated to a specific immune response to an 
immunodominant region of CYP2D6 and a cytotoxic T cell response to Adenovirus-
CYP2D6 vector infected target cells. Though these two experimental approaches 
provide useful information on the possible pathogenic mechanisms leading to AIH-2, a 
model faithfully reproducing AIH in humans is still missing. 
The role of antigen-specific T cells in the induction and perpetuation of 
experimental hepatitis has recently been provided by a transgenic mouse model, 
characterised by the expression of chicken ovalbumin (OVA) on the surface of 
hepatocytes (Buxbaum et al. 2008). Repeated injections of OVA-specific T cells 
resulted in chronic hepatitis characterised by lobular and portal inflammation. Hepatic 
damage was determined by CD8 OVA-specific T cells and was enhanced by OVA-
specific CD4
pos
 T cell help (Buxbaum et al. 2008). In contrast, Robinson et al. reported 
that in Tgf-b
-/-
 mice, a model characterised by the development of fulminant hepatitis, 
CD4
pos
 T cells are the most important source of IFN- relevant to pathology, with no 
significant contribution from CD8
pos
 T cells  (Robinson et al. 2009). Taken together, it 
is possible that involvement of different immune-mediated mechanisms may determine 
different types of disease presentation and outcome. 
To elucidate the roles of immune-regulatory mechanisms involved in the 
development of AIH, Kido et al. recently developed a mouse model of spontaneous AIH 
by inducing a concurrent loss of two controlling mechanisms, namely FOXP3
pos
 
regulatory T cells and the PD-1-mediated signalling. Following neonatal thymectomy, 
which is associated with a dramatic reduction in the number of nTregs in the periphery,  
Causes of regulatory T cell impairment in autoimmune liver disease 
 
 
[169] 
 
PD-1 deficient mice developed fatal AIH characterised by severe CD4
pos 
and CD8
pos
 T 
cell infiltration and massive lobular necrosis, and elevated titres of ANA. Importantly, 
adoptive transfer of Tregs was able to suppress the progression of fatal hepatitis after 
AIH initiation, confirming the role of self-reactive T lymphocytes in the development of 
AIH liver damage as well as that of Tregs in maintaining tolerance (Kido et al. 2008). 
Further evidence implicating Tregs in AIH pathogenesis, was provided by the work of 
Lapierre et al. mentioned above, which showed that xeno-immunised C57BL/6 male 
mice developed minimal liver inflammation which was associated with a higher 
percentages of FOXP3
pos
 Tregs both in peripheral blood and liver compared to 
immunised female mice. 
In summary, both human and animal studies have provided wide evidence that 
in AIH the effector functions of CD4 and CD8 T cells are pathogenically important and 
associated with defective Tregs. However, what causes Treg defects in AIH remains 
largely unknown.  
 
5. Causes of regulatory T cell impairment in autoimmune liver disease 
As shown in section 3.3.4., autoimmunity can result from a loss of Treg 
immune-regulation due to: 1) reduced numbers of Tregs; 2) intrinsic defects in Treg 
function; and/or 3) effector cell resistance to Treg suppression. 
 
5.1. Inadequate numbers of Tregs 
An obvious first step in determining whether Treg defects contribute to human 
autoimmunity is to assess whether there is an inadequate number of functional Tregs, 
thereby leading to impaired immune-regulation.  
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Although it has been shown that the frequency of CD4
pos
CD25
pos
 cells are 
significantly reduced in AIH patients (see section 4.5.), studies conducted in other 
human autoimmune diseases have demonstrated that the pool of Tregs defined by the
expression of CD25 are frequently contaminated by effector T cells, rendering difficult 
the precise quantification of functional Tregs. In the past few years, the identification of 
new markers has allowed a more refined Treg quantification and has enabled the 
distinction of bona fide Tregs from effector cells. One of these molecules is the IL-7 
receptor (IL-7R) or CD127.  
 
5.1.1. CD127 
CD127, the IL-7R, has recently been reported to be useful in discriminating 
between CD25
pos
 Tregs and CD25
pos
 activated T cells (Seddiki et al. 2006), because 
many non-regulatory T cell subsets are IL-2-independent and IL-7-dependent (von 
Freeden-Jeffry et al. 1995). However, Tregs, which require IL-2 for survival, do not 
require neither IL-7 nor the IL-7R. Down-regulation of CD127 on Treg cells was 
confirmed by using microarray gene-expression profiling studies of CD4
pos
CD25
high
 and 
CD4
pos
CD25
neg
 T cells, and by using quantitative polymerase chain reaction to confirm 
CD127 mRNA reduced expression (Liu et al. 2006).  
A link between CD127 and FOXP3 has also been suggested based on the 
observation that Foxp3 physically interacts with the promoter region of CD127, which 
could explain the down-regulation of CD127 characteristic of Tregs (Liu et al. 2006). In 
addition, it has been shown that the CD127
neg
 population is characterised by high 
suppressive activity, in contrast to the non-suppressive CD127
pos
 subset (Seddiki et al. 
2006).  
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Codarri et al. have recently explored the role of CD127 expressing cells in the 
context of solid organ transplantation (Codarri et al. 2007), where it is known that 
activated allospecic CD4 T cells and Tregs play a key role by either participating  in 
allograft rejection or promoting tolerance (Graca et al. 2002, Benghiat et al. 2005). The 
authors reported that the CD4
pos
CD25
pos
 T cell population in kidney and liver transplant 
recipients were frequently CD127
pos
, whereas in healthy subjects the majority of these 
cells were CD127
neg
. They have further shown that this cell population contained 
allospecic CD4 T cells and secreted effector cytokines such as TNF-α and IFN-γ, being 
substantially more expanded in patients with documented chronic rejection than in the 
peripheral blood of stable transplant recipients. Moreover, in patients with chronic 
rejection CD127
pos
 cells accounted for 50% of the total CD4 T cells infiltrating the 
allograft, clearly indicating an association between CD127 expression by 
CD4
pos
CD25
pos
 cells and T cell effector functions (Codarri et al. 2007). 
Analysis of the functional properties of CD4
pos
CD25
high
CD127
neg
 Tregs have 
been provided by a study in relapse-remitiing MS patients (Michel et al. 2008), a 
condition associated with defective Treg function (see section 3.3.4). The authors 
showed that, at variance with CD4
pos
CD25
high
, the regulatory potency of 
CD4
pos
CD25
high
CD127
low
 cells was similar in patients and in age-matched control 
subjects. Conversely, the CD4
pos
CD25
high
CD127
pos
 T cell population in MS patients 
proliferated more vigorously and produced higher quantities of effector cytokines, 
explaining, at least in part, the previous observation of an impaired suppressive capacity 
of CD4
pos
CD25
high
 cells in MS patients (Michel et al. 2008).  
Taken together these studies highlight the importance of reduced CD127 
expression as a marker of bona fide Treg cells. I have thus hypothesised that 
Introduction to the present study 
 
 
[172] 
 
unrestrained effector mechanisms in autoimmune liver disease are permitted by a 
reduced number of functional Tregs, i.e. those characterised by absent expression of 
CD127. 
 
5.2. Intrinsic defect in Treg function 
Akin to cell numbers, another possible cause for impaired immune-regulation in 
autoimmunity setting is represented by defects in the Treg cell function that are intrinsic 
to these cells. In this regard, the galectin family of molecules has recently received 
attention, given its role in immune-regulation and because of the association of some of 
its members with Treg´ mechanisms of suppression. 
 
5.2.1. Galectins 
Lectins are non-enzymatic and non-immunoglobulin proteins that bind 
carbohydrates. Galectins, previously termed S-type lectins, are a family of 
evolutionarily conserved animal lectins that bind N-acetyllactosamin-containing glycans 
(Cooper and Barondes 1999, Rabinovich and Toscano 2009). They have pleiotropic 
roles in immune responses, being involved in pathogen recognition, in shaping the 
course of adaptive immune responses and in fine-tuning inflammatory responses 
(Rabinovich et al. 2007b, R. Y. Yang et al. 2008).  
Fifteen galectins have been identified in mammals, 11 of which are also present 
in humans – galectins 1-4, 7-10, and 12-14 (Liu and Rabinovich 2005). Structurally, 
galectins share a common basic fold and at least one conserved carbohydrate 
recognition domain (CRD) of approximately 130 amino acids responsible for 
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Prototype
Galectin-1
Chimera type
Galectin-3
Tandem repeat type
Galectin-9
carbohydrate binding (Leffler et al. 2004). Galectins are traditionally classified in three 
different groups on the basis of structural similarities:  
a) prototype galectins, which have one CRD and exist as monomers or dimers 
(galectin-1, galectin-2, galectin-5, galectin-7, galectin-10, galectin-11, galectin-13, 
galectin-14 and galectin-15); 
 b) tandem-repeat type galectins, which  contain two different CRDs separated 
by a linker of up to 70 amino acids (galectin-4, galectin-6, galectin-8, galectin-9 and 
galectin-12); 
 c) the chimera-type galectin-3, which contains a CRD connected to a non-lectin 
amino-terminal region (Figure 2.13.).  
 
 
 
 
 
 
Figure 2.13. Representation of the structure of different members of the galectin family. 
Galectins can be subdivided into 3 groups: prototype galectins, which contain one carbohydrate 
recognition domain (CRD) and can form homodimers; tandem-repeat type galectins, which 
contain two distinct CRDs in tandem connected by a linker of up to 70 amino acids and are 
inherently bivalent; and the unique chimera-type galectin-3, which consists of unusual tandem 
repeats of proline- and glycine-rich short stretches fused onto the CRD. 
 
Although galectins have features of cytosolic proteins, they are found not only 
intracellularly but also in the extracellular space. The mechanism of secretion is not 
clear since galectins lack the signal sequences required for classical secretory pathway 
via the endoplasmic reticulum (ER) and vesicles of the Golgi apparatus, and are 
therefore released through an unusual route that requires intact carbohydrate-binding 
activity of the secreted protein (Hughes 1999).  
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Once outside the cells, galectins bind to, and cross-link multiple glucoconjugates 
found on the cell surface or in the extracellular matrix, translating glycan-coded 
information into immune cell activation, differentiation and homeostatic programmes 
(Cooper and Barondes 1999).  
Like many other receptor-ligand systems, galectins can trigger a cascade of 
transmembrane signalling events; through this mechanism, they can modulate processes 
that include apoptosis, cytokine secretion, and cell adhesion and migration (Rabinovich 
et al. 2007a). However, such interactions are limited to galectins that are secreted; some 
of the family members remain associated with cell membranes or function within the 
intracellular compartment, participating in processes that are essential for basic cellular 
functions such as pre-mRNA splicing, regulation of cell cycle progression and cell 
growth, and modulating apoptosis via interaction with Bcl-2 family members in the 
cytoplasm (Liu et al. 2002, Wang et al. 2004). These functions are typically independent 
of their sugar-binding activities and rather rely on protein-protein interactions 
(Rabinovich et al. 2002). Interestingly, the same member – e.g. galectin-3 – may exert 
paradoxical effects depending on whether it acts from the outside or inside the cell. If in 
the former it triggers cell death, in the latter it protects the cell from apoptosis (Nangia-
Makker et al. 2007, Liu and Rabinovich 2005). 
Although the majority of galectins have a wide tissue distribution, some of them 
are expressed with restricted tissue specificity (Rabinovich et al. 2002). Within the 
immune system, galectins are expressed by virtually all immune cells, either 
constitutively or in an inducible fashion, and are significantly up-regulated by activated 
B and T cells, activated macrophages, and DCs (Blaser et al. 1998, Rabinovich et al. 
1998, Zuniga et al. 2001). Recently, studies using gene expression arrays have indicated 
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high expression of galectins in Tregs (Sugimoto et al. 2006, Ocklenburg et al. 2006, 
Garin et al. 2007). 
 The expression of galectins is regulated during the activation and differentiation 
of immune cells, and may be significantly altered under several pathological conditions 
(Rabinovich et al. 2007a). Moreover, the expression of galectins may be modulated by 
cytokines, chemokines and hormones (Camby et al. 2006). 
 
5.2.2. Galectins and tolerance 
Galectins play a vital role in central and peripheral tolerance (Dhirapong et al. 
2009; Figure 2.14.). Since a more detailed description of the biological functions of 
galectin-9 (GAL-9) will be provided later, this section will primarily focus on other 
members, particularly galectin-1 (GAL-1) and galectin-3 (GAL-3) that along with 
GAL-9 are each representative of the different subfamilies mentioned above. 
A key feature of the galectin family members is their influence on T cell 
development, function and homeostasis. The best studied family member, GAL-1, has 
been shown to control T cell growth and apoptosis during thymic development and after 
stimulation in the periphery (Perillo et al. 1995). GAL-1 is expressed on thymic 
epithelial cells (Baum et al. 1995), where it promotes clonal deletion of thymocytes 
(Perillo et al. 1997), and therefore contributes to central tolerance by eliminating self-
reactive lymphocytes. In the periphery, GAL-1 induces apoptosis of activated, but not 
of naïve T cells (Blaser et al. 1998).  
In addition to its pro-apoptotic properties, GAL-1 is known to elicit IL-10 
production (van der Leij et al. 2004) and to boost the suppressive activity of Tregs. 
Indeed, exposure to GAL-1 promoted the differentiation of Tregs in vitro (Juszczynski 
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et al. 2007). Moreover, in a mouse model where colitis is induced by 2,4,6-
trinitrobenzene sulfonic acid (TNBS), administration of GAL-1 resulted in expansion of 
IL-10-producing cells, which successfully suppressed autoimmune inflammation 
(Santucci et al. 2003). In this regard, proteomic analysis of human Tregs have identified 
galectin-10 (GAL-10) as a putative marker of Tregs, since it was expressed only by 
CD4
pos
CD25
pos 
cells and treatment with GAL-10-specific small-interfering RNA 
(siRNA) resulted in complete abrogation of Treg suppressive activity (Kubach et al. 
2007).  
As mentioned earlier, GAL-3 has the unique ability of acting in a dual manner – 
it can either prevent or induce apoptosis of T cells depending on its intra or extracellular 
localisation respectively (Hsu et al. 2009). While intracellular GAL-3 protects from 
apoptosis induced by Fas ligation or a broad spectrum protein kinase inhibitor 
staurosporine (Yang et al. 1996), the same protein located exogenously may promote 
cell death, as exemplified by its apoptotic effect on T cells (Fukumori et al. 2003). It 
should be noted, however, that most studies to date point to a pro-inflammatory role of 
GAL-3. Indeed, elevated levels of serum GAL-3 have been reported in various 
inflammatory conditions, such as rheumatoid arthritis (Ohshima et al. 2003) and 
Behcet´s disease (Lee et al. 2007). Also, a role for GAL-3 in the development of airway 
inflammation in a murine model of asthma has been demonstrated (Zuberi et al. 2004, 
Lopez et al. 2006). Furthermore, GAL-3-deficient mice consistently developed fewer 
inflammatory cell infiltrations following thioglycollate injection in the peritoneal cavity 
than the wild-type mice, thus supporting GAL-3 as a positive regulator of inflammatory 
responses (Hsu et al. 2000). 
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Figure 2.14. Contributions of galectins to central and peripheral tolerance. In the thymus 
galectin-1, galectin-3 and galectin-9 induce apoptosis in double negative (CD4
neg
CD8
neg
) or 
double positive (CD4
pos
CD8
pos
) thymocytes, suggesting a role for the these galectins in 
regulating central tolerance (A). Once in the periphery, galectin-9 blocks early T cell receptor 
(TCR)-mediated activation signals and prolongs the survival of naïve T cells. Galectin-3 forms 
lattices with complex N-glycans to limit TCR clustering, thus increasing agonist threshold for 
TCR signalling. Following T cell activation, galectin-1, galectin-3 and galectin-9 bind to 
particular glycosylated receptors and trigger distinct intracellular events to induce T cell death. 
In addition, galectin-1, galectin-9 and galectin-10 may contribute to the suppressive activity of 
regulatory T cells (Tregs). 
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5.2.3. Galectin-9 
GAL-9, also known as ecalectin, belongs to the tandem-repeat class of galectins, 
consisting of two homologous but distinct CRDs (N-terminal, 148 amino acids; C-
terminal, 149 amino acids) connected by a linker peptide (Hirabayashi et al. 2002, 
Wada and Kanwar 1997). Frame-shift mutations leading to a truncated product with 
only one functional CRD were found in the coding sequence of GAL-9 in some cancer 
cells (Lahm et al. 2000). Three isoforms arising from alternative splicing of the original 
transcript and differig in the length of the linker region, have been identified (Chabot et 
al. 2002). The full-length protein may also be post-transcriptionally cleaved by enzymes 
such as thrombin (Nishi et al. 2006). To date, there is little or no information as to 
whether these GAL-9 isoforms exhibit different biological functions.  
GAL-9 was first identified as a selective eosinophil chemoattractant, inducing 
superoxide production and prolonging cell survival (Matsumoto et al. 1998). 
Subsequent studies revealed that, similar to other galectins, GAL-9 modulates a variety 
of biological functions such as cell aggregation and adhesion and apoptosis of 
eosinophils, cancer cells and T cells (Wada et al. 1997, Saita et al. 2002, Kageshita et al. 
2002). It can be localised both intracellularly and, albeit unusual for a galectin, on the 
cell surface. Release from the cell surface to a soluble form requires the action of certain 
matrix metalloproteinases (Hirashima et al. 2004). Almost simultaneously, GAL-9 was 
also described as a urate transporter in the kidney, where it functions as a voltage-sensor 
and mediates transport of urate (Lipkowitz et al. 2004).  
GAL-9 has also been shown to possess a broad array of immunological 
activities. Firstly, it was demonstrated that GAL-9 was involved in the regulation of 
thymic epithelial cell–thymocyte interactions, promoting apoptosis of the latter (Wada 
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et al. 1997). Subsequent studies using several different cell lines have shown that GAL-
9 preferentially induced cell death of activated CD4
pos
 T cells through the calcium-
influx-calpain-capsase-1 pathway (Kashio et al. 2003).   
In 2005, Zhu and colleagues identified GAL-9 as the ligand of T-cell-
immunoglobulin-and-mucin-domain-3 (TIM-3), a protein selectively expressed on 
terminally differentiated Th1 but not Th2 cells (Zhu et al. 2005).  
Functional studies conducted within the same investigation suggested that GAL-
9 induces cell death in Th1 but not in Th2 cells and that Gal-9-induced cell death is 
dependent on TIM-3. In the context of EAE, in vivo administration of GAL-9 in mice 
immunised with myelin oligodendrocyte glycoprotein (MOG) immunodominant peptide 
specifically reduced the numbers of MOG-specific IFN--producing Th1 cells. 
Moreover, treatment with GAL-9-specific siRNA during the induction of EAE resulted 
in blunting of disease (Zhu et al. 2005). Thus, GAL-9 engagement of TIM-3 serves to 
negatively regulate Th1 immunity.  
Interestingly, GAL-9 expression is itself up-regulated by IFN-(Imaizumi et al. 
2002, Asakura et al. 2002). This fact introduces a paradigm whereby IFN-, responsible 
for tissue inflammation, also induces an inhibitory ligand – GAL-9 – which then 
selectively deletes Th1 cells and thereby preventing protracted inflammation in the 
target organ. Since loss of IFN- would disrupt the feedback loop, this could be the 
underlying mechanism that explains why IFN- deficient mice develop a more severe 
form of EAE (Ferber et al. 1996). 
Seki et al. showed that exogenous administration of GAL-9 significantly 
suppressed CIA in a dose-dependent manner (Seki et al. 2008). Interestingly, GAL-9 
treatment resulted in a dramatic reduction of IL-17 levels in the joint, which was 
Introduction to the present study 
 
 
[180] 
 
mirrored by an increase in the percentage of Tregs. On the other hand, GAL-9-deficient 
mice became susceptible to CIA, presumably due to a decreased number of Tregs. 
Furthermore, GAL-9 treatment prevented the differentiation of Th17 cells from naïve T 
cells, when these were cultured in the presence of TGF- and IL-6 – cytokines that 
drive the differentiation of Th17 cells. The same in vitro study showed that GAL-9 up-
regulated both FOXP3 mRNA expression and Treg differentiation in the presence of 
TGF-(Seki et al. 2008). In line with this, further evidence supporting a role for GAL-9 
in regulating immune responses has been provided by Sehrawat et al. in the context of 
experimental allergic conjunctivitis (Sehrawat et al. 2009), and Lv et al. using a mouse 
model of viral myocarditis (Lv et al. 2011). In both studies, administration of exogenous 
GAL-9 resulted in disease recovery, not only by promoting apoptosis of CD4
pos
 effector 
cells, but also by inducing FOXP3
pos
 Treg conversion and limiting Th17 generation in 
vitro.  
In the human setting, a role for GAL-9 in the differentiation of human FOXP3
pos
 
Tregs was provided later in patients with HCV infection. In this study, GAL-9 treatment 
consistently resulted in the expansion of Tregs, contraction of effector CD4 T cells, and 
apoptosis of HCV-specific CTLs (Mengshol et al. 2010). 
Human GAL-9 was first cloned from tissue of a patient with Hodgkin´s disease 
(Tureci et al. 1997) and was found to be widely distributed (Wada and Kanwar 1997). 
Indeed, GAL-9 can be potentially expressed on almost all cells.  
Within the immune system, GAL-9 is predominantly expressed on naïve CD4
pos
 
effector T cells and Tregs. Upon T cell activation, GAL-9 is down-regulated on the 
effector compartment, but importantly maintained on Tregs (Sabatos et al. 2003, 
Sanchez-Fueyo et al. 2003).  
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In this thesis I aim to explore whether GAL-9 expression by Tregs relates to 
their suppressive function and whether Treg impairment in AIH results from a defective 
GAL-9 expression.  
 
5.3. Effector cell resistance to Treg suppression 
A third mechanism that may contribute to an impaired immune-regulation 
relates to the susceptibility of effector T cells to Treg control (Walker 2009). Resistance 
of effector T cells to Treg action has been observed in several animal models of 
autoimmunity, in which inflammation and tissue destruction progress despite the 
presence of functional Tregs at the site of inflammation (Gregori et al. 2003, Monk et 
al. 2005, Korn et al. 2007b, D'Alise et al. 2008). Importantly, the same trend is now 
emerging from human studies, especially from those in the context of SLE (Venigalla et 
al. 2008, Vargas-Rojas et al. 2008). Amongst the possible ways by which effector T 
cells may become resistant to suppression one may depend on TIM-3. TIM-3 is a 
member of the TIM family of proteins and has been recently linked with effector cell 
susceptibility to Treg control.  
 
5.3.1. TIM family of proteins 
In 2001, the Tim family of genes was cloned from within the Tapr (the T cell 
and airway phenotype regulator) locus as a novel allergy and asthma susceptibility gene 
(McIntire et al. 2001). Since then, there has been increasing evidence indicating that this 
family play a crucial role in the regulation of immune responses, not only in allergy and 
asthma, but also in the response to viral infections, transplant tolerance, and 
autoimmunity (Su et al. 2008, Rodriguez-Manzanet et al. 2009). The family consists of 
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eight members (Tim-1 to Tim-8) on mouse chromosome 11B1.1, and three ortholog 
members (TIM-1, TIM-3, and TIM-4) on human chromosome 5q33.2, a region that has 
been repeatedly associated with asthma, allergy and autoimmunity (Marsh et al. 1994, 
Encinas and Kuchroo 2000, McIntire et al. 2004). Each of these genes encode a type 1 
membrane protein with similar structure, consisting of an N-terminal Ig-like domain, a 
mucin-like domain, a single transmembrane domain, and an intracellular tail (Meyers et 
al. 2005b). While the intracellular tails of TIM-1 and TIM-3 contain tyrosine 
phosphorylation motifs that are involved in transmembrane signalling, TIM-4 has a 
short intracellular tail devoid of tyrosines (Kuchroo et al. 2003; Figure 2.15.).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.15.  Schematic representation of human TIM domain protein structures. 
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These molecules are involved in several important immunological functions, 
including T cell activation, induction of T cell apoptosis and T cell tolerance, and the 
clearance of apoptotic cells (Freeman et al. 2010).  Although this thesis focuses on 
TIM-3, a brief overview of the other TIM family members expressed in humans is given 
in the next section. 
 
5.3.2. TIM-1 
TIM-1 was first identified in monkeys (G. Kaplan et al. 1996) and then in 
humans (Feigelstock et al. 1998) as the hepatitis A virus cellular receptor (HAVCR), the 
receptor exploited by hepatitis A for viral entry. Later, TIM-1 was identified as a cell 
surface protein highly expressed on proximal tubular epithelial cells after acute kidney 
injury – and therefore termed kidney injury molecule-1 (KIM-1; Ichimura et al. 1998). 
TIM-1 is also up-regulated in urine and tissue samples of patients with renal cell 
carcinoma (Vila et al. 2004). 
Within the immune system, TIM-1 is expressed on activated but not naïve 
CD4
pos
 T cells (Umetsu et al. 2005). Upon CD4 T cell differentiation, it is preferentially 
expressed on Th2 cells, since Th1 and Th17 cells express little or no TIM-1 (Meyers et 
al. 2005a, Nakae et al. 2007b). It is now clear that TIM-1 is also expressed by other 
immune cells, namely mast cells (Nakae et al. 2007a), invariant NKT cells (Khademi et 
al. 2004), and a subpopulation of B cells (Sizing et al. 2007).  
Several ligands for TIM-1 have been identified including TIM-4 (Meyers et al. 
2005a), TIM-1 itself (Santiago et al. 2007), IgA(Tami et al. 2007), and 
phosphatidylserine (PtdSer; Kobayashi et al. 2007).  
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Given the association of TIM-1 polymorphisms with allergic disease both in 
humans and in mouse models (McIntire et al. 2003), a number of studies have sought to 
elucidate the role of TIM-1 in these processes. In vitro treatment with anti-TIM-1 
monoclonal antibodies (mAb) provided a potent co-stimulatory signal that increased T 
cell proliferation and IL-4 cytokine production (Umetsu et al. 2005). In vivo, the 
administration of the mAb along with antigen also resulted in the increase of antigen-
specific T cell proliferation and production of IL-4 and IFN-(Umetsu et al. 2005). 
Moreover, agonistic TIM-1 mAb prevented respiratory tolerance, providing further 
support that TIM-1 co-stimulation activates T cells. 
 Recently, it has been shown that TIM-1 co-stimulation abrogates allogeneic 
transplant tolerance by reducing the expression of FOXP3, and thereby preventing Treg 
development (Degauque et al. 2008). Since the induction of respiratory tolerance to 
antigen is also associated with generation of antigen-specific Tregs, TIM-1 co-
stimulation may prevent tolerance induction not only by enhancing Th cell 
development, but also by hindering Treg development (Rodriguez-Manzanet et al. 
2009). 
Interestingly, different TIM-1 mAbs, which recognise distinct epitopes of TIM-
1, result in different outcomes.  While TIM-1 mAbs recognising exon 4 of the mucin 
domain exacerbated inflammation and increased production of Th2 cytokines, a mAb 
reactive with the Ig domain had an anti-inflammatory effect in a mouse model of 
asthma (Sizing et al. 2007).  In addition, alternative outcomes may also derive from 
different levels of signal strength provided by TIM-1 engagement. In this regard, 
administration of the agonistic high-affinity TIM-1 mAb during the induction of 
autoimmunity enhanced pathogenic Th1 and Th17 responses and increased the severity 
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of EAE, whereas a lower affinity mAb, increased Th2 responses and inhibited the 
development of EAE. Thus, TIM-1 has been proposed to have both activating and 
inhibitory effects in immune responses (Xiao et al. 2007). However, the precise 
mechanisms that regulate the different outcomes of TIM-1 signalling by different mAbs 
are not yet known (Freeman et al. 2010). 
 
5.3.3. TIM-4 
The role of TIM-4, another TIM molecule present in mice and humans, is less 
clearly defined. In contrast to TIM-1 and TIM-3, TIM-4 is not expressed on T cells but 
is primarily found on APCs, including DCs, macrophages, and peritoneal B cells 
(Meyers et al. 2005a, Kobayashi et al. 2007).  
Although initially identified as the ligand for TIM-1 (Meyers et al. 2005b), it is 
now unclear whether direct interaction occurs (Sizing et al. 2007). Both mouse and 
human TIM-4 are receptors for PtdSer, being capable of binding and engulﬁng 
apoptotic bodies (Kobayashi et al. 2007). However, TIM-4 may also have other 
unidentified ligands.  
Current evidence shows that the interaction between TIM-4 and its putative 
ligand results in promotion of Th2 responses. Several studies suggest that TIM-4 may 
play a role in maintaining oral tolerance and in the prevention of food allergy. TIM-4 
up-regulation on murine intestinal mucosa DCs, following exposure to Staphylococcus 
enterotoxin B, promoted Th2 polarisation and intestinal allergic responses – which were 
inhibited in mice pre-treated with TIM-4 mAb (P. C. Yang et al. 2007). However, the 
results of in vitro studies, in which TIM-4 Ig fusion proteins have been used, are 
contradictory. High concentrations of TIM-4 Ig led to an increased T cell proliferation; 
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on the other hand, lower doses mediated an inhibitory signal (Meyers et al. 2005b). 
TIM-4 Ig has also been shown to both activate and inhibit naïve T cells, while treatment 
of pre-activated T cells enhances activation (Mizui et al. 2008). Since in these studies, T 
cells were stimulated with anti-CD3/anti-CD28 in the absence of APCs, it is difficult to 
translate such conclusion to an in vivo model. This is particularly relevant considering 
that TIM-4 can act as PtdSer receptor, simply because the absence of APCs eliminates 
the process of apoptotic body engulfment (Freeman et al. 2010).  
 Importantly, TIM-4, in contrast to other members of the family, does not 
contain any tyrosine phosphorylation motifs in its intracellular tail, hence raising the 
question of whether it can directly mediate transmembrane signalling (Rodriguez-
Manzanet et al. 2009). 
 
5.3.4. TIM-3 
TIM-3 was originally discovered as a result of generation and screening of a 
panel of 20.000 mAbs in an attempt to distinguish Th1 and Th2 cells based on cell 
surface expression profiles (Monney et al. 2002). Expression of TIM-3, a 281 amino 
acid cell surface protein, was detectable on CD4 and CD8 T cells only after several 
rounds of antigenic stimulation in the presence of Th1 polarising conditions (ie. IL-12 + 
anti-IL-4). Up-regulation of TIM-3 in vivo also required several rounds of cell division, 
being closely associated with IFN- production. In contrast, TIM-3 was neither 
expressed by naïve T cells nor Th2 cells (Monney et al. 2002, Sanchez-Fueyo et al. 
2003). Later, TIM-3 was also shown to be expressed on murine Th17 cells (Nakae et al. 
2007b). 
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In humans, TIM-3 is expressed on terminally differentiated Th1 cells, on Th17 
cells, and on some CD8
pos
 T cells (Hastings et al. 2009). However, TIM-3 expression is 
not limited to cells of the adaptive immune system. Indeed, subsets of cells belonging to 
the innate arm also express TIM-3, including human NK cells, monocytes (Khademi et 
al. 2004), and DCs (Anderson et al. 2007).  
In addition to the full-length, cell-surface expressed protein, a splice variant of 
TIM-3 was found in mice that lacks the mucin and transmembrane domains and is 
thought to be a soluble form of TIM-3 (Sabatos et al. 2003, Geng et al. 2006). Although 
it seems to possess the binding specificity of the full-length protein, little is known 
about how this alternate TIM-3 splice form influences immune responses (Rodriguez-
Manzanet et al. 2009).   
 
TIM-3, a negative regulator of T cell responses 
Initial studies of the functional role of TIM-3 in the regulation of T cell 
responses showed that it acts as an inhibitory molecule. Administration of an anti-TIM-
3 mAb during induction of EAE worsened disease progression, leading to increased 
mortality and to an atypical and acute form of the disease, characterised by high 
numbers of inflammatory foci in the central nervous system (CNS; Monney et al. 2002). 
Histological examination of the CNS of anti-TIM-3 mAb treated mice showed high 
numbers of activated macrophages in the demyelinating lesions, concurrent with the 
expansion of the monocytes population in the peripheral blood (Monney et al. 2002). In 
addition, polymorphisms in TIM-3 gene have been associated with the development of 
RA in humans (Chae et al. 2004), and airway hyper-reactivity in mice (McIntire et al. 
2001). 
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To better understand the mechanisms by which TIM-3 operates in vivo, fusion 
proteins (TIM-3.Ig) containing either the full length or soluble extracellular forms of 
TIM-3 fused to a human Fc tail were generated (Sabatos et al. 2003, Sanchez-Fueyo et 
al. 2003). The administration of TIM-3.Ig to ovalbumin-immunised mice resulted in a 
Th1 cell hyperproliferation similar to that observed following treatment with anti-TIM-
3 mAb. Interestingly, administration of TIM-3.Ig also led to the production of massive 
quantities of Th1 cytokines (IFN- and IL-2; Sabatos et al. 2003). Moreover, in NOD 
mice, administration of either anti-TIM-3 mAb or TIM-3.Ig fusion protein similarly 
resulted in the acceleration of diabetes onset and progression (Sanchez-Fueyo et al. 
2003).  
As mentioned above, GAL-9 was later identified as a ligand of TIM-3. GAL-9 
triggering of TIM-3 on Th1 cells was shown to induce calcium flux, cell aggregation 
and cell death in vitro.  
In contrast to TIM-3.Ig treatment, in vivo administration of GAL-9 caused 
selective loss of IFN--producing cells and led to the amelioration of EAE, providing 
further support for TIM-3 as a negative regulator of Th1 responses (Zhu et al. 2005).  
Collectively, these data demonstrate that the interaction between TIM-3 and 
GAL-9 serves as a mechanism to dampen Th1 immunity by selective deletion of TIM-
3
pos
 Th1 cells. Thus, the TIM-3/GAL-9 pathway may have evolved to control 
population expansion of Th1 cells in the immune compartment and to prevent 
prolonged inflammation in target tissues (Zhu et al. 2005, Anderson and Anderson 
2006; Figure 2.16.). 
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Figure 2.16. TIM-3-mediated immune-regulation. Th1 cells produce IFN-, which up-
regulates galectin-9 and consequently triggers cell death in T cell immunoglobulin and mucin 
domain 3 (TIM-3)-positive cells, leading to termination of Th1 responses at tissues sites (A). In 
disease states, low levels of TIM-3 may allow Th1 cells to escape galectin-9 induced cell death. 
Similarly, Th17 cells, reported to express lower levels of TIM-3, may be less susceptible to 
galectin-9-mediated suppression (B). 
 
TIM-3 and T cell exhaustion 
Virus-specific T cells in human immunodeficiency virus (HIV), hepatitis B virus 
(HBV) and HCV chronic infections progressively develop a range of functional 
impairments in cytokine production, cytotoxic activity, and proliferative capacity – a 
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phenomenon termed “exhaustion” (Klenerman and Hill 2005, Freeman et al. 2006). 
Exhaustion of CD4
pos
 and CD8
pos
 T cells had initially been associated with sustained 
expression of the inhibitory molecule PD-1, which results in the inhibition of T cell 
proliferation and cytokine production. Blockade of the PD-1/PDL-1 pathway resulted in 
a partial restoration of T cell function in vitro (Day et al. 2006, Urbani et al. 2006, 
Wherry et al. 2007). However, since not all exhausted cells expressed PD-1, and hence 
were not rescued by blockade of the PD-1/PDL-1 pathway (D'Souza et al. 2007), it was 
likely that other molecules contributed to the exhaustion associated with chronic 
infections (Hafler and Kuchroo 2008). In this regard, relatively recent studies have 
implicated TIM-3 in mediating T cell exhaustion during the course of chronic viral 
infections.  
Jones et al. reported the up-regulation of TIM-3 on both CD4
pos
 and CD8
pos
 T 
cells from individuals with acute and progressive chronic HIV infection, but not in 
chronically infected individuals who had controlled the infection or in healthy subjects. 
Interestingly, TIM-3-expressing cells did not overlap with the PD-1
pos
 population, 
suggesting that TIM-3 and PD-1 expression mark distinct subsets of exhausted T cells. 
The frequency of TIM-3
pos
 cells correlated positively with viral load and inversely with 
CD4
pos
 T cell counts. HIV-specific T cells expressing high levels of TIM-3 proliferated 
less and produced reduced levels of cytokines compared to their TIM-3
neg
 counterparts. 
Lastly, the demonstration that the blockade of TIM-3 pathway with a mAb or TIM-3.Ig 
enhances virus-specific T cell responses ex vivo clearly shows that  TIM-3 plays a 
critical role in suppressing the overall T cell response to HIV (Jones et al. 2008). 
In the context of HCV chronic infection, it has been shown that TIM-3 
expression is also increased on CD4
pos
 and CD8
pos
 T cells. However, in contrast to HIV, 
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expression of TIM-3 by T cells highly overlapped with that of PD-1. The proportion of 
dually PD-1/TIM-3 expressing cells was greatest in liver-resident T cells, and 
significantly more in HCV-specific than in cytomegalovirus-specific T cells used as 
controls. TIM-3-expressing cells were characterised by a senescent phenotype, a central 
rather than an effector memory profile, and lower production of IFN- and TNF- 
compared to the TIM-3
neg
 population. Treatment with anti-TIM-3 mAb strongly 
enhanced T cell proliferation and IFN- production and decreased IL-10 production in 
response to HCV peptide antigen (Golden-Mason et al. 2009).  
In an attempt to identify patients at risk of developing viral persistence during 
and after acute HCV infection, McMahan et al. have analysed the impact of TIM-3 and 
PD-1 co-expression on T cells in the outcome of patients with acute HCV infection. 
They have shown that the level of dual TIM-3 and PD-1 expression on HCV-specific 
CD8
pos
 cells predated the development of viral persistence, providing greater prognostic 
information than single expression and viral load. Higher expression of these inhibitory 
molecules correlated with impaired IFN- production and reduced cytotoxic activity. 
Importantly, while blockade of either TIM-3 or PD-1 pathways enhanced HCV-specific 
CD8
pos
 T cell proliferation to a similar extent, hepatocyte-directed cytotoxicity was 
increased predominantly after TIM-3 blockade, leading the authors to speculate that 
TIM-3 and PD-1 may be associated with distinct steps that mediate functional T cell 
exhaustion (McMahan et al. 2010).  
 
TIM-3 and tolerance  
The TIM-3/GAL-9 pathway is also suggested to play an important role in 
establishing tolerance. Long-lasting tolerance to allogeneic grafts can be achieved by 
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donor-specific transfusion (DST) and CD154 (CD40L) mAb treatment, an effect 
mediated by enhanced donor-specific Treg suppression. However, blocking TIM-3 
mediated immune-regulation by the concurrent administration of TIM-3.Ig 
compromised the function of donor-specific Tregs, and prevented the induction of 
tolerance (Sanchez-Fueyo et al. 2003). Similarly, TIM-3 deficient mice were also 
refractory to tolerance induction with DST and anti-CD154 mAb. Indeed, both TIM-
3.Ig treated and Tim-3 deficient mice exhibited increased T cell proliferation, and 
production of IL-2 after administration of high-dose aqueous antigen compared to 
controls (Sabatos et al. 2003). The exact mechanisms by which TIM-3 mediates 
tolerance induction remain to be elucidated.  
 
TIM-3 and autoimmunity 
The role of TIM-3 in the modulation of human autoimmune disease has been 
most thoroughly studied in MS. CD4
pos
 T cell clones derived from the CSF of MS 
patients expressed lower levels of TIM-3, despite producing higher quantities of IFN- 
than those from the CSF of control subjects. In vitro Th1 polarisation significantly 
enhanced IFN- secretion but not TIM-3 expression among clones from patients relative 
to those from controls. Treatment of normal CD4
pos
 T cells or Th1 cells with TIM-3 
specific siRNA reduced TIM-3 expression and resulted in increased proliferation and 
IFN- secretion (Koguchi et al. 2006). These data are in agreement with the 
observations mentioned in the above section that TIM-3 up-regulation on exhausted T 
cells in chronic viral infections leads to less T cell activation (Sakuishi et al. 2011). 
Collectively, these observations suggest that dysregulated expression of TIM-3 in MS 
may render effector cells refractory to inhibition, thereby causing immunopathology.  
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Another study performed in patients with MS aimed at assessing TIM-3 
expression and function on ex vivo CD4
pos 
T cells isolated from the periphery. CD4 cells 
from control subjects expressed higher levels of TIM-3 mRNA compared to untreated 
MS patients. The authors also demonstrated that during T cell stimulation, the presence 
of anti-TIM-3 mAb enhanced IFN- production in healthy subjects, but not in untreated 
patients, demonstrating a defect in TIM-3 immune-regulation. Interestingly, treatment 
with glatiramer acetate or IFN- – effective treatments in reducing the frequency of 
relapses in MS patients – increased TIM-3 mRNA and reversed the functional defect, 
providing a potential mechanistic explanation for the lack of immune-regulation 
associated with self-reactive T cells in MS (Li Yang et al. 2008). 
To date, it remains unclear whether Th1 cells in MS are somehow selected for 
lower TIM-3 expression or whether there is a genetic deficiency in up-regulation of 
TIM-3 (Anderson and Anderson 2006, Li Yang et al. 2008).  
However, regardless of the mechanism, lower TIM-3 expression on Th1 cells 
prevent the resolution of tissue inflammation, possibly contributing to chronic disease 
states. Moreover, IL-17-producing Th17 cells have been demonstrated in murine 
models to be highly pathogenic, and recently these cells have been shown to express 
TIM-3 (Nakae et al. 2007b), raising the possibility that TIM-3 may play a role in the 
regulation of this subset (Figure 2.13.). 
In this thesis I will explore whether altered TIM-3 expression enables 
pathogenic T cells to avoid Treg control in patients with AIH. 
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6. Hypotheses and aims 
The main aim of this thesis is to investigate possible causes of functional Treg 
impairment in patients with autoimmune liver disease. I will explore whether Treg 
reduced ability to suppress results from a primary Treg defect or by a low susceptibility 
of responder cells to Treg control.  
Given the role played by Tregs in the maintenance of immune-tolerance , I plan 
to determine the frequency of CD4
pos
CD25
high
 Tregs expressing low levels of the 
activation molecule CD127 (CD127
low 
Tregs), and to investigate to what extent absence 
or low levels of CD127 impact on Treg ability to suppress. 
Because of the pivotal role played by the interaction between GAL-9 and TIM-3 
in controlling effector immune responses while maintaining tolerance, I plan to evaluate 
the GAL-9 expression in Tregs and to assess whether this expression is associated to 
Treg ability to suppress. I will then determine the expression of TIM-3 by responder 
cells and evaluate whether this expression relates to the responsiveness of effector cells 
to Treg control. 
The following hypotheses will be tested (Figure 2.17): 
Hypothesis 1: CD4
pos
CD25
pos
CD127
neg
 Tregs are numerically reduced in patients with 
autoimmune liver disease.  
Hypothesis 2: Reduced GAL-9 expression leads to defective Treg function and to 
suboptimal control of effector immune responses. 
Hypothesis 3: impaired TIM-3 expression by effectors results in low susceptibility to 
Treg control. 
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Figure 2.17. Hypotheses of the present study. Schematic representation of the three 
hypotheses that will be tested in this thesis. Impaired Treg suppression could derive from: 1) 
low numbers of regulatory T cells, particularly those characterised by low or absent expression 
of CD127 (see Chapter 4); 2) intrinsic defects in Treg cell function – i.e. defective Gal-9 
expression (see Chapter 5); 3) low responsiveness of effector cells to Treg due to low TIM-3 
expression (see Chapter 6). 
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1. Preparation of peripheral blood mononuclear cells (PBMCs) 
PBMCs were isolated from heparinised blood by standard density gradient 
centrifugation. Ten to 20 mL of peripheral blood was venesected from each patient and 
healthy subject and mixed in a sterile syringe containing preservative free heparin at a 
final concentration of 10 U/mL. Aliquots of heparinised blood were subsequently 
layered on the top of an equal volume of Lymphoprep
TM
 (Ficoll) density gradient 
solution (Amersham Pharmacia Biotech, Ltd., Little Chalfont, United Kingdom) in a 50 
mL sterile tube ensuring that a distinct interface between the two layers was maintained. 
The blood was then centrifuged at 500×g for 21 minutes at 20 ºC without brake, to 
ensure separation of the PBMCs from the denser Ficoll/erythrocyte layer below, and the 
less dense dilute plasma layer above. After centrifugation, the mononuclear cell layer 
was collected with a sterile pipette, transferred into a fresh tube and washed twice with 
Roswell Park Memorial Institute 1640 (RPMI 1640) medium (Invitrogen Life 
Technologies, Paisley, United Kingdom) at 300×g for 5 minutes with brake applied. 
After the second wash, PBMCs were resuspended in RPMI 1640 medium, 
supplemented with 2 mM L-glutamine, 25 mM HEPES, 100 U/mL benzyl penicillin, 
0.1 mg/mL streptomycin, and 2.5 mg/mL amphotericin B with heat inactivated foetal 
calf serum (FCS, hereafter denoted “supplemented RPMI 1640”). 
Cells were counted using a haemocytometer and lymphocyte viability was 
determined by Trypan-blue exclusion.  This method is based on the principle that live 
(viable) cells will not take up the dye, whereas dead (non-viable) cells will (Hoskins et 
al. 1956). Equal volumes of 0.4% Trypan-blue solution and lymphocyte suspension 
were mixed, then put on a Neubauer haemocytometer and examined under a light 
microscope. Cell viability was calculated as follows: % of viable cells = (number of 
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viable [non-stained] cells / number of total cells) x 100. The viability of freshly isolated 
cells always exceeded 98%.   
 
2. PBMCs cryopreservation 
After isolation from peripheral blood, PBMCs that were not used immediately 
were frozen in a solution containing 90% FCS and 10% dymethyl sulphoxide (DMSO, 
Sigma Aldrich Ltd., Gillingham, Dorset, United Kingdom) – a cryoprotectant that 
reduces  the amount  of  ice  present  during  freezing,  thus  reducing  ionic  stress 
(Pegg 2007). 
Briefly, the cell suspension obtained after PBMCs isolation was centrifuged at 
300×g for 5 minutes. The pellet obtained was then resuspended in 1 mL of 
cryoprotective solution per 5-10x10
6
 cells prior to being transferred into sterile 
cryotubes. Immediately after the cryotubes were placed in pre-warmed Nalgene
TM
 
cryocontainer (Nalgene, Nalge Europe Ltd., Hereford, United Kingdom) that had been 
filled with 70% isopropanol according to the manufacturer’s instructions to freeze to -
70 ºC at a cooling rate of 1 ºC per minute. After 24 hours, vials were transferred into a -
140 ºC freezer.  
 
3. Thawing of cryopreserved PBMCs  
If not properly thawed, lymphocytes´ viability and recovery may be affected and 
their function compromised.  In general, cells should be thawed quickly but diluted 
slowly to remove DMSO.  Cells with DMSO intercalated into their membranes are very 
fragile, and must be pelleted and handled gently (Pegg 2007). 
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Cryopreserved cells were thawed quickly (< 1 minute) by immersion and gentle 
shaking of the cryotubes in a 37 ºC water bath. Warm RPMI 1640 was then dropwise 
added into the cryotube until a final volume that was twice that of the cell suspension. 
The diluted cell suspension was transferred to 50 mL sterile tube containing 8 mL of 
warm RPMI 1640 for every cryotube of cells added.  Cells were pelleted by 
centrifugation at 300×g for 7 minutes. After discarding the supernatant and gently 
flicking the tube to break up the pellet, 10 mL of RPMI 1640 were added for a second 
wash and centrifugation was carried out as above. After this second wash, cells were 
resupended in 1 mL of supplemented RPMI 1640 and cell number and viability was 
determined by Trypan-blue exclusion.   
Although it has been suggested that cryopreservation of PBMCs may result in 
attenuation of their functionality (Tree et al. 2004, Axelsson et al. 2008), preliminary 
experiments where cell preparations from the same patients were tested before and after 
cryopreservation showed no significant difference in viability and behaviour in culture 
when assessed for proliferation and cytokine production in the case of effectors and 
ability to suppress in the case of regulatory T cells. 
 
4. Flow cytometry 
Flow cytometry is a technique that permits measurement and analyses of optical 
and fluorescence characteristics of particles of interest (e.g. cells), termed “events”, as 
they flow in a fluid stream through a beam of light (Brown and Wittwer 2000). These 
characteristics are determined using a flow cytometer – an optical-to-electronic 
coupling system – which records how the cell scatters an incident laser light and emits 
fluorescence (Virgo and Gibbs 2012). It is composed of three main systems: fluidics, 
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optics, and electronics. The ﬂuidics system transports particles in a stream to the laser 
beam for interrogation. Then, the optics system, which consists of lasers and optical 
filters, illuminates the particles in the sample stream and directs the resulting light 
signals to the appropriate detectors (Watson 1999). Lastly, the electronics system 
converts the detected light signals into electronic signals that can be processed by the 
computer (Recktenwald 1993). Additionally, some instruments can be equipped with a 
cell-sorting device (Herzenberg et al. 2002); in these, the electronics system is also 
capable of performing sorting decisions by charging and deﬂecting particles (see section 
6.2.2.). 
When the cells pass through the laser beam, they scatter its light. Two scatter 
parameters are measured: forward scatter (FSC) and side scatter (SSC). FSC is 
proportional to the cell size; thus, lymphocytes have smaller FCS than monocytes and 
granulocytes. On the other hand, SSC, which is measured at an angle of 90º to the FSC, 
relates to the cells´ granularity and nuclear complexity/lobularity. For this reason, 
monocytes and granulocytes have a higher SSC than lymphocytes (Figure 3.2.). 
Additionally, antibodies conjugated to fluorescent dyes can bind specific proteins on 
cell membranes or inside cells. Once the cells pass through the light source, the 
fluorescent molecules are excited to reach a higher energy state. Upon returning to their 
resting states, the fluorochromes emit light energy at higher wavelengths. The use of 
multiple fluorochromes, each with similar excitation wavelengths but different emission 
wavelengths (or “colours”), allows several individual cell markers to be detected 
simultaneously (De Rosa et al. 2003, Perfetto et al. 2004). 
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Figure 3.1. How the flow cytometer works. Fluorochrome-labelled monoclonal antibodies are 
added to a cell suspension. The labelled cell suspensions are passed through the flow cell of a 
flow cytometer. Each cell passes through the laser beam of the flow cytometer, a process termed 
single cell analysis. The fluorochrome of each labelled monoclonal antibody bound to the cell is 
excited by the laser light and emits fluorescence of a certain wavelength. The cells also scatter 
light at multiple angles. Photodetectors placed at forward angle and at right angles to the axis of 
the laser beam collect the emitted or scattered light. The signals from each photodiode are 
digitised and passed to a computer for storage, display, and analysis. A variety of histograms for 
visual display can be generated automatically or at the discretion of the operator. 
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Figure 3.2. Analysis of lysed whole blood. Forward (FCS) and side scatter (SSC) 
characteristics allow the gating of three different populations: granulocytes (yellow), monocytes 
(green), and lymphocytes (red).  
 
In the current study, flow cytometry was performed on a two lasers Becton-
Dickinson (BD) FACSCanto
TM
 II. BD FACSDiva
TM
 software was used for analysis. 
 
4.1. Surface antigens 
Multi-colour flow cytometry was performed on fresh and/or frozen PBMCs, 
gated using unstained cells in order to exclude dead cells, granulocytes and monocytes. 
3.5×10
5
 unfractioned PBMCs were used for each experiment. Cells were resuspended in 
200 mL of 1× phosphate buffered saline (PBS) containing 1% FCS (PBS/1% FCS). 
Cells were then stained with different combinations of ﬂuorochrome-conjugated 
monoclonal antibodies (mAbs), including anti-CD4, anti-CD25, anti-CD127, anti-
CD45RO, anti-CD45RA, anti-CCR7, and anti-TIM-3 (Table 3.2.). Cells were incubated 
at 4ºC in the dark for 30 minutes. Following incubation, PBMCs were washed once with 
400 mL PBS/1% FCS at 300×g for 5 minutes, then resuspended in 500 mL, and stored at 
4ºC until analysis.  
 
Flow cytometry 
 
 
[205] 
 
Specificity Fluorchrome Clone Volume (mL/test) Company
CD4 APC-Cy7 RPA-T4 1.5 BD Biosciences1
CD25 PE-Cy7, APC, FITC, PE M-A251 2 BD Biosciences1
CD127 PE, FITC HIL-7R-M21 1 BD Biosciences1
TIM-3 PE, APC 344823 4 R&D Systems2
CD45RO PE-Cy7, PE UCHL1 2 BD Biosciences1
CD45RA FITC OX-33 2 BD Biosciences1
CCR7 PE-Cy7 3D12 2 BD Biosciences1
Galectin-9 N/A ECA8 1.2 MBL3
IgG1 PE A85-1 0.5 BD Biosciences1
CTLA-4 APC BNI3 5 BD Biosciences1
FoxP3 APC, FITC, PE PCH101 5 eBioscience4
T-bet PerCP-Cy5.5, PE 4B10 5 eBioscience4
GATA-3 PE-Cy7 L50-823 5 BD Biosciences1
RORC APC, PE AFKJS-9 0.8 eBioscience4
IL-10 APC, PE JES5-16E3 5 BD Biosciences1
TGF-1 PerCP 27232 5 R&D Systems2
IFN- APC, PE 45-15 3 IQ Products5
IL-2 APC MQ1-17H12 0.8 BD Biosciences1
IL-17 FITC, PE 64DEC17 5 eBioscience4
Table 3.1. Antibodies used for flow cytometry.  
 
3.5×10
5
 cells were used per test 
APC, allophycocyanin; Cy7, Cychrome 7; PE, phycoerythrin; FITC, flourescein isothiocyanate; 
PerCP, peridinin-chlorophyll-protein complex; Cy5.5, cychrome 5.5 
1
 Oxford, UK; 
2
 Abingdon, UK; 
3
 Nagoya, Japan; 
4
 Hatfield, UK; 
5
 Groningen, The Netherlands 
 
4.2. Intracellular staining 
The percentage of cells positive for FOXP3, Tbet, GATA-3, RORC 
(transcription factors of Tregs, Th1, Th2 and Th17 cells respectively), and CTLA-4 was 
determined by intracellular staining. PBMCs were first suspended in PBS/1%FCS and 
stained with mAbs directed against surface markers, as described above. After 30 
minutes incubation, cells were washed once, and then incubated at 4ºC for 20 minutes 
with 100 mL of BD Cytofix/CytopermTM (BD Biosciences) – a formaldehyde and 
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saponin-containing solution that can be used for the simultaneous fixation and 
permeabilisation of cells, allowing the mAbs to penetrate into the cell and detect the 
intracellular protein (Tay et al. 1999).  After one wash, cells were resuspended in 100 µl 
BD Perm/Wash
TM
 buffer solution containing a pre-determined optimal concentration of 
fluorochrome-conjugated anti-FOXP3, anti-Tbet, anti-GATA-3, anti-RORC, and anti-
CTLA-4 mAbs. After a further 30 minutes incubation at 4ºC in the dark, cells were 
washed, resuspended in 500mL PBS/1%FCS, and analysed by flow cytometry.  
Since a fluorochrome-conjugated mAb is not available, expression of GAL-9 
was determined by an indirect method (Asakura et al. 2002, Saita et al. 2002). Briefly, 
following fixation/permeabilisation (see above), cells were washed and initially 
incubated with IgG1 anti-human GAL-9 mAb (MBL, Nagoya, Japan) at 4ºC in the dark. 
Following 30 minutes incubation, cells were counter-stained with PE-conjugated anti-
IgG1 secondary antibody and incubated for further 30 minutes. Cells were finally 
washed and analysed by flow cytometry. 
For intracellular cytokine staining (ICCS), PBMCs were seeded in 96-round 
bottom plates at 3.5×10
5
 cells/well, and cultured in supplemented RPMI 1640. Phorbol 
12-mystrate 13-acetate (PMA) (10 ng/mL) and ionomycin (500 ng/mL) were added to 
the culture to induce cytokine production by T cells (Pala et al. 2000). After incubation 
at 37 ºC and 5% CO2 for 1 hour, Brefeldin A was added at a final concentration of 20 
mg/mL, in order to prevent the transport of cytokines from the endoplasmic reticulum to 
the Golgi apparatus and hence to favour their intracellular accumulation (Dinter and 
Berger 1998). Following 5-hour incubation, PBMCs were transferred into FACS tubes, 
washed with 400 mL of PBS/1%FCS at 300×g for 5 minutes, then stained with 
antibodies for surface markers, fixed and permeabilised as described previously.  
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Finally, cells were counter-stained with fluorochrome-labelled anti-IFN-, anti-
IL-17, anti-IL-2, anti-TGF- and anti-IL-10 mAbs (Table 3.1.). Flow cytometry was 
performed as above. 
 
5. Cell purification 
5.1. Regulatory T cell subsets 
5.1.1. Magnetic sorting 
CD4
pos
CD25
pos 
(henceforth denoted as “Tregs”) cells were isolated from PBMCs 
using immunomagnetic beads (Dynal Invitrogen, Oslo, Norway). This method includes 
two sequential steps: the negative selection of total CD4
pos
 cells is followed by the 
positive selection of CD25
pos 
cells.  
In brief, PBMCs were resuspended in 500 µl supplemented RPMI 1640 and 200 
µl Antibody Mix Human CD4 per 100×10
6
 cells. This antibody mixture contains 
murine anti-human antibodies specific for CD14, CD16, CD56, CDw123, Glycophorin-
A, CD36, CD8, and CD19 marking monocytes, DCs, granulocytes, NK cells, platelets, 
erythrocytes, CD8
pos
 T cells, and B cells for depletion. Cells were incubated at 4⁰C in 
the dark for 20 minutes, washed and loaded with 1 mL depletion beads coated with an 
Fc-specific human immunoglobulin G4 antibody (Depletion MyOne Beads) per 
100×10
6
 cells. Cells were incubated at room temperature for 15 minutes with rolling 
and tilting. The tube was placed in a magnetic stand for 6 minutes. All non-CD4
pos
 T 
cells became attached to the wall of the tube as an effect of the magnetic field, thus 
allowing the transfer of the supernatant containing the bead-free CD4
pos
 T cells to a new 
tube. The purity of CD4
pos
 T cells, assessed by flow cytometry at this point, exceeded 
95% (Figure 3.3.).   
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Following CD4
pos
 isolation, the cells were resuspended in supplemented RPMI 
1640 at 15×10
6
 per mL. 200 mL of Dynabeads CD25 – immunomagnetic beads coated 
with anti-human CD25 antibodies – were added to the solution. After 25 minutes 
incubation at 4º C, the tube was placed in the magnet and the supernatant containing 
CD4
pos
CD25
neg
 T cell fraction (see section 6.2.) was collected. Finally, the residual 
beads harbouring the CD25
pos
 population were resuspended in 500 mL supplemented 
RPMI 1640 with DETACHaBEAD (80 mL per 15 x 10
6 
cells), which allows cell 
detachment from the beads.  After 45 minutes incubation at room temperature, the tube 
was placed in the magnet, and the supernatant containing CD4
pos
CD25
pos
 cell fraction 
collected and transferred to a fresh tube. The purity of CD4
pos
CD25
pos
 Tregs was higher 
than 92% (Figure 3.3.). 
CD4
pos
CD25
pos
CD127
neg
 cells (hereafter denoted “CD127neg Tregs”) were 
further puriﬁed from total CDposCD25pos Tregs. Because of the large number of cells 
required, this additional puriﬁcation step was limited to those subjects from whom 
sufficient numbers of CD4
pos
CD25
pos
 T cells were obtained.  
In brief, puriﬁed CD4posCD25pos cells were incubated with PE-conjugated anti-
CD127 monoclonal antibodies at 4 ºC in the dark for 30 minutes. After washing, cells 
were incubated with microbeads conjugated to monoclonal anti-PE antibodies (Miltenyi 
Biotec, Bergisch-Gladbach, Germany) at 4°C for a further 15 minutes. Incubation was 
followed by magnetic separation using MS columns (Miltenyi Biotec). The flow-
through cells were the CD4
pos
CD25
pos
CD127
neg
 cells, while those eluted from the 
column corresponded to the activated CD4
pos
CD25
pos
CD127
pos
 lymphocyte fraction. 
The purity of both subsets, assessed by ﬂow cytometry, exceeded 90% (Figure 3.4.).  
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Figure 3.3. Flow cytometric assessment of CD4
pos
, CD4
pos
CD25
neg
 and CD4
pos
CD25
pos
 T cell 
purity. Dot plot of anti-CD4 fluorescence (Y axis) versus FSC (X axis), showing high purity 
after negative selection of CD4
pos
 cells (upper panel). Dot plots of anti-CD4 fluorescence (X 
axis) versus CD25 fluorescence (Y axis), after negative and positive selection of CD25
neg
 
(bottom left) and CD25
pos
 (bottom right) populations respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Flow cytometric assessment of CD4
pos
CD25
pos
CD127
neg
 and 
CD4
pos
CD25
pos
CD127
pos
 T cell purity. Dot plots of anti-CD127 fluorescence (X axis; arbitrary 
units, log scale) versus CD25 fluorescence (Y axis; arbitrary units, log scale) in a representative 
autoimmune hepatitis patient. Highly pure CD25
pos
CD127
neg
 (left panel) and CD25
pos
CD127
pos
 
(right panel) population are seen in the respective quadrants. The purity of the two 
subpopulations is indicated as percentage of CD4 cells in the respective quadrant.  
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5.1.2. FACS sorting 
CD4
pos
CD25
pos
 cells were also sorted into CD4
pos
CD25
high
 and CD4
pos
CD25
low
 
populations using fluorescence-activated cell sorting (FACS
TM
, Figure 3.5.).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. Purity of FACS-sorted regulatory T cell populations. Cells were sorted 
according to CD25 expression using BD FACSAria
TM
. Dot plots showing high purity for both 
CD4
pos
CD25
high
 (right top) and CD4
pos
CD25
low
 (right bottom) populations after sorting in a 
representative healthy subject.  
 
PBMCs were washed in PBS/1%FCS and resuspended at a density of 1×10
6
 
cells/ml prior to staining with 25 µl of anti-human CD25 PE and 15 µl of anti-human 
CD4 APC-Cy7 per 1x10
6
 cells. Unstained and single stained control populations were 
used as controls.  
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Cells were then washed twice with PBS/1%FCS, before filtering through 40 µm 
cell strainers (BD Biosciences) and resuspension at 8×10
6
 cells/ ml in PBS. Ice-cold 
cells were sorted into CD25
high
 (corresponding to the top 2% of CD4
pos
 cells displaying 
the brightest CD25 fluorescence) and CD25
low
 (corresponding to the remaining CD4
pos
 
cell population displaying low CD25 fluorescence) cells using a FACSAria
TM
 (Becton 
Dickinson Immunocytochemistry Systems). Sorted lymphocytes were then washed in 
PBS and resuspended in supplemented RPMI 1640. The purity of both CD25
low
 and 
CD25
high
 cells exceeded 98% (Figure 3.6.). 
 
5.2. Responder cells 
CD4
pos
CD25
neg
 cells were isolated from PBMCs by two-step negative selection 
as described in 6.1.1. Their purity exceeded 95% (Figure 3.4.).  
CD4
pos
CD25
neg
 cells were further purified according to the expression of TIM-3. 
In brief, CD4
pos
CD25
neg
 cells were incubated with PE-conjugated anti-TIM-3 mAbs for 
30 minutes, then with microbeads conjugated to monoclonal anti-PE antibodies for 
further 15 minutes at 4˚C. CD4posCD25negTIM-3neg and CD4posCD25negTIM-3pos 
(henceforth “TIM-3neg” and “TIM-3pos”) populations were purified by negative and 
positive selection respectively using MS columns (see section 6.1.2.). Their purity was 
greater than 90% (Figure 3.6.). 
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Figure 3.6. Purity of TIM-3
pos
 and TIM-3
neg
 cell subsets. CD4
pos
CD25
neg
 cells were 
immunomagnetically-sorted according to the expression of TIM-3. Dot plots of anti-CD25 
fluorescence (X axis; arbitrary units, log scale) versus TIM-3 fluorescence (Y axis; arbitrary 
units, log scale) in a representative autoimmune hepatitis patient. Purified CD25
neg
TIM-3
neg
 (top 
panel) and CD25
neg
TIM-3
pos
 (bottom panel) populations are seen in the respective quadrants 
where their percentage of purity is indicated.  
 
6. Proliferation and suppression assays 
6.1. Assessment of suppressive function of regulatory T cells 
Immunomagnetically-purified CD4
pos
CD25
pos
, CD4
pos
CD25
pos
CD127
neg
, 
CD4
pos
CD25
pos
CD127
pos
, and FACS-sorted CD4
pos
CD25
low
 and CD4
pos
CD25
high
 cells 
were added to autologous CD4
pos
CD25
neg
 effector cells at a ratio of 1/8. The 
Treg/effector cell ratio was selected as optimal on the basis of preliminary experiments 
in which ratios of 1/16, 1/8, and 1/4 were compared: 1/8 ratio was chosen as capable of 
exerting detectable regulatory function using the minimum number of cells.  Cells were 
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seeded in a round-bottom 96-well plate and cultured in a humidified incubator at 37ºC 
and 5% CO2 for 5 days in the presence of anti-CD3/anti-CD28 T cell expander capable 
of preserving the original T cell function (CD3/CD28 Dynabeads, Dynal Biotech), at a 
bead/cell ratio of 1/2. Recombinant IL-2 was added at 30 U/mL on day 1. Parallel 
cultures of CD4
pos
CD25
neg
 cells cultured on their own were performed under identical 
conditions and used as controls. All experiments were performed in duplicate. For the 
last 18 hours the cultures were pulsed with 0.25 mCi/well of 3H-thymidine and harvested 
using a multi-channel harvester. The amount of incorporated 
3
H-Thymidine was 
assessed by a -counter (Canberra Packard Ltd., Pangbourne, United Kingdom), and 
expressed as counts per minute (cpm). The inhibition percentage was calculated using 
the formula: Inhibition (%) = (1 – cpm in the presence of Tregs/ cpm in the absence of 
Tregs) x 100. 
 
6.2. Effector CD4 T cell proliferation and responsiveness to Treg control 
To evaluate the responsiveness of effector cells to regulatory T cell-mediated 
suppression, CD4
pos
CD25
neg
, TIM-3
neg
, and TIM-3
pos
 populations, stimulated with T 
cell expander and IL-2 (see section 6.1.), were co-cultured with CD4
pos
CD25
pos
, 
CD4
pos
CD25
pos
CD127
neg
 and CD4
pos
CD25
pos
CD127
pos
 cells under the same conditions 
described in 6.1. Control cultures using CD4
pos
CD25
neg
, TIM-3
neg
 and TIM-3
pos
 cells 
cultured on their own were performed under identical conditions. Following 5-day 
culture, cells were assessed for their proliferative response by 
3
H-thymidine 
incorporation (see section 6.1.).  
Percentage of target cell inhibition was determined using the formula shown in 
the previous section. 
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7. Neutralisation assays 
To assess whether the suppressor function of regulatory T cells is related to the 
release of regulatory and/or effector cytokines, purified mouse monoclonal anti-human-
IL-10 (clone 23278), anti-human-TGF-(clone 9016), anti-human-IFN-(clone 25723), 
and anti-human-IL-17 (clone 41809) neutralising antibodies (all from R&D Systems, 
Abingdon, UK) were added at a final concentration of 10 mg/mL to purified 
CD4
pos
CD25
pos
, CD4
pos
CD25
pos
CD127
neg
 and CD4
pos
CD25
pos
CD127
pos
 T cell 
populations.  After 12 hours, these T cell populations were added to autologous 
CD4
pos
CD25
neg
, TIM-3
neg
 and TIM-3
pos
 cells used as targets. 
Similarly, to investigate whether the susceptibility of the responder cells to Treg 
control is related to the release of cytokines, CD4
pos
CD25
neg
, TIM-3
neg
 and TIM-3
pos
 
cells were exposed to anti-IFN-, anti-IL-17, anti-IL-10, and anti-TGF- neutralising 
antibodies (10 mg/mL) for 12 hours before CD4posCD25pos, CD4posCD25posCD127neg 
cells were added. Cells were cultured under the same conditions described above. 
Following a 5-day culture, cells were tested for their proliferative response.  
 
8. Galectin-9 silencing 
Gene silencing is the most effective strategy enabling evaluation of gene 
function, and it can be evaluated at both transcriptional and post-transcriptional levels. 
At the post-transcriptional level, small interfering RNAs (siRNAs) are one of the most 
recent tools that can be deployed to silence gene expression (Dorsett and Tuschl 2004). 
The RNA interference (RNAi) pathway, which was first described by Andrew Fire and 
Craig Mello in 1998 who observed that the injection of double-stranded RNA (dsRNA) 
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into the nematode Caenorhabditis elegans, led to a potent sequence-specific 
degradation of cytoplasmic mRNAs containing the same sequence as the dsRNA trigger 
(Fire et al. 1998). Following the demonstration that double-stranded siRNAs could 
trigger RNAi pathway in mammalian cells (Elbashir et al. 2001), siRNA has become a 
routine tool to study gene function (Corey 2007).  
Gene  expression can be blocked by either transfecting the siRNA into cells – a 
process in which the siRNA is complexed with lipids or other molecules to facilitate 
passage through cell membranes (Janowski et al. 2006) – or by introducing a vector that 
could express the siRNA within the cells (Tiscornia et al. 2006). Once inside the cell, 
the siRNA is bound by the proteins of the RNA-induced silencing complex (RISC). The 
RISC proteins facilitate the binding of the RNA sequences complementary to one of the 
two strands of the siRNA duplex (Filipowicz 2005). One strand of the siRNA (the sense 
or passenger strand) is lost from the complex, while the other strand (the antisense or 
guide strand) is matched with its complementary RNA target (Figure 3.7.). Recognition 
of mRNA by the antisense strand of the siRNA can cause destruction of the mRNA, 
therefore preventing its translation into a protein and thereby reducing the level of 
protein inside cell (Corey 2007).  
siRNAs have been used to silence specific genes in different cell types with an 
impressive suppression ranging from 70 to 100%. In these cases RNAi-dependent gene 
silencing could be considered a true knock-out technology (Tuschl et al. 1999). 
However, in in vivo assays and cell cultures, it has been shown that siRNAs do not 
completely eliminate the encoded protein; therefore the effect produced by the siRNA 
should be considered a “knock-down” rather than a “knock-out” (Sifuentes-Romero et 
al. 2011). 
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Figure 3.7. How small interfering RNAs work. Small interfering RNAs (siRNAs) enter cells 
and then bind to the RNA-induced silencing  complex (RISC). The RISC proteins unravel the 
duplex and facilitate the search for mRNA sequences that are complementary to one of the RNA 
strands. Upon recognition of a complementary mRNA, RISC cleaves the mRNA and prevents 
translation.   
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8.1. Transfection procedure 
GAL-9-specific siRNA (Invitrogen Life Technologies) used in this study 
contained three different sequences targeting all isoforms. A GAPDH Stealth RNAi and 
a “negative control Stealth RNAi” (Invitrogen Life Technologies) served as positive and 
negative controls for transfection. 
Immunomagnetically purified CD4
pos
CD25
pos
, CD25
pos
CD25
pos
CD127
neg 
and 
CD25
pos
CD25
pos
CD127
pos
, and FACS-sorted CD4
pos
CD25
high
 and CD4
pos
CD25
low
 T 
cells were resuspended in Optimem medium (Invitrogen Life Technologies) at 2-
3×10
6
/ml, and then transfected using 8 ml Lipofectamine RNAiMax (Invitrogen Life 
Technologies). GAL-9-specific stealth siRNAs were used at a final concentration of 3 
nM. GAL-9 stealth siRNA working concentration and Lipofectamine RNAiMax 
volume were determined after performing a series of preliminary experiments where 
stealth siRNA concentrations ranging from 0.75 to 24 nM and Lipofectamine RNAiMax 
volumes ranging from 1 to 16 ml per ml of total cell suspension were tested. A GAL-9 
Stealth RNAi concentration of 3 nM and a Lipofectamine RNAiMax volume of 8 ml 
was the most effective at inducing gene knockdown with minimal toxicity to the cells.  
 
8.2. Assessment of Galectin-9 gene knock-down 
Following overnight incubation at 37˚C and 5% CO2, aliquots of 2.5×10
5
 cells 
were collected to extract RNA and assess GAL-9 expression by real-time PCR. Cells 
were lysed with TRizol reagent (Invitrogen Life Technologies) at a concentration of 0.1 
ml/1 x 10
6
 cells and total RNA was extracted. mRNA was reverse transcribed using 
Oligo-(dT)12-18 primer (Invitrogen Life Technologies) and Omniscript Reverse 
Transcriptase (Qiagen Inc., Chatsworth, CA).  
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GAL-9 transcripts were quantiﬁed by real-time PCR using gene-speciﬁc probes 
and TaqMan Master Mix (Applied Biosystems, Warrington, UK). PCR ampliﬁcation 
conditions were: 50°C for 2 minutes, 95°C for 10 minutes, 40 cycles of 95°C for 15 
seconds, and 60°C for 1 minute. Samples were run in triplicate using a real-time PCR 
thermocycler (ABI Prism 7000 Sequence Detection System, Applied Biosystems, Foster 
City, CA), and results were analysed by matched software. Relative expression of GAL-
9 gene was determined by normalising to GAPDH expression according to the 
manufacturer’s instructions. 
 
8.3. Assessment of suppressive function of siRNA-treated cells 
Following siRNA treatment, cells were washed and resuspended in 
supplemented RPMI 1640, and added to CD4
pos
CD25
neg
, TIM-3
pos
 and TIM-3
neg
 
responder cells at a 1/8 ratio. Parallel cultures where siRNA-untreated CD4
pos
CD25
pos
, 
CD25
pos
CD25
pos
CD127
neg
, CD25
pos
CD25
pos
CD127
pos
, CD4
pos
CD25
high
, and 
CD4
pos
CD25
low
 T cells were added to responder cells served as controls. After a 5-day 
culture, cell proliferation was assessed by 
3
H-thymidine incorporation and the 
percentage of cell proliferation inhibition calculated as detailed above. 
 
9. Immunohistochemistry 
The phenotype of lymphocytes infiltrating the liver tissue was investigated by 
immunohistochemistry in patients with a documented diagnosis of AILD. Liver biopsies 
were performed percutaneously according to the Menghini technique, with a 1.4 mm 
diameter needle. The biopsies were fixed in neutral formalin, embedded in paraffin, cut 
into 5 mm thick sections, and stained for CD4, FOXP3, TIM-3 and GAL-9 (Table 3.2.). 
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Specificity Source Clone Dilution Company
Galectin-9 Polyclonal goat AF2405 1/300 R&D Systems1
TIM-3 Polyclonal goat AF2365 1/50 R&D Systems1
CD4 Monoclonal mouse 4B12 Ready-to-use Dako2
FoxP3 Monoclonal mouse 22510 1/100 Abcam3
Tissue sections were then evaluated by a single pathologist, who graded the biopsies 
quantitatively for histological variables. 
 
Table 3.2. Primary antibodies used for immunohistochemistry. 
 
1
 Abingdon, UK; 
2
 Glostrup, Denmark; 
3
 Cambridge, UK 
 
Different immunohistochemistry methods were employed: 1) standard avidin-
biotin-complex (ABC) method (Vector Laboratories, Burlingame, USA) – used for 
preliminary experiments aiming at determining the optimal dilution of anti-TIM-3, anti-
GAL-9, and anti-FOXP3 primary antibodies; 2) EnVision+ system (Dako Cytomation, 
Glostrup, Denmark) – used for TIM-3 and GAL-9 single immunostaining, and for 
FOXP3/GAL-9 double immunostaining. Furthermore, CD4 and FOXP3 single 
immunostaining was performed using an autostainer (HX System Benchmark, Ventana 
Medical Systems, Tucson, AZ, USA), as per the manufacturer’s instructions.  
 
9.1. Single immunostaining 
9.1.1. ABC method 
ABC method is one of the most widely used staining techniques for 
immunohistochemistry. This technique relies on the high affinity that avidin – a large 
glycoprotein found in chicken eggs – has for the vitamin biotin. Avidin possesses four 
binding sites for biotin, but due to the molecular orientation of the binding sites, fewer 
than four molecules of biotin will actually bind. The biotin molecule is easily 
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conjugated to variety of biological molecules such as antibodies and enzymes (Hsu et 
al. 1981). In this method secondary antibodies are conjugated to biotin and function as 
links between tissue-bound primary antibodies and an avidin-biotin-peroxidase complex 
(Figure 3.8.). 
For this purpose, liver tissue sample sections were first deparaffinised by placing 
them in xylene for 4 minutes, and then in ethanol for additional 4 minutes. After 
rehydration, epitope retrieval was achieved by boiling the sections either in a sodium 
citrate buffer (pH 6.0) or in a trishydroxymethylaminomethane/ethylene diamine 
tetraacetic acid (Tris-EDTA) buffer (pH 9) in a microwave (600 Watts twice for 5 
minutes with a 2-minute interval). After cooling for 15 to 30 minutes, slides were 
placed in PBS for 5 minutes. Endogenous peroxidases were quenched by peroxidase-
blocking solution (DakoCytomation, Denmark) for 30 minutes. Non-specific 
background staining was inhibited by a 10 min incubation of the sections with 5% horse 
serum (Vector Laboratories). Avidin-biotin blocking reagents were applied for 30 min 
to block endogenous biotin. Sections were incubated with polyclonal goat anti-human 
TIM-3, polyclonal goat anti-human GAL-9, and monoclonal mouse anti-human FOXP3 
for one hour at room temperature. 1/10, 1/20, 1/50, 1/100, 1/200, 1/300, 1/500 and 
1/1000 dilutions were tested for each primary antibody. Dilutions giving the strongest 
signal with minimal background were chosen. Thereafter, sections were incubated with 
biotin conjugated secondary antibody (anti-goat IgG, Vector Laboratories, diluted: 1:50) 
for 30 minutes. Immunoreactivity was visualized using avidin-biotin-peroxidase 
complex (ABC) kit reagents (Vector Laboratories), and 3,3´-diaminobenzidine (DAB, 
Dako Cytomation).. Sections were then weakly counterstained with haematoxylin and 
examined under light microscope.  
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9.1.2. Envision+ method 
EnVision Systems are based on dextran polymer technology (Figure 3.9.). This 
detection system permits binding of a large number of enzyme molecules (horseradish 
peroxidase or alkaline phosphatase) to a secondary antibody via the dextran backbone. 
The benefits are many, including increased sensitivity, minimised non-specific 
background staining and a reduction in the total number of steps compared to the ABC 
method (Chilosi et al. 1994). 
 
Figure 3.8. Immunohistochemistry techniques. In the EnVision technique, the primary 
antibody is attached to a dextran backbone which contains an average of 10 molecules of 
secondary antibody and 70 molecules of enzyme (peroxidase). In the ABC technology, the 
avidin-biotin enzyme reacts with the biotinylated secondary antibody.    
 
Antigen unmasking was carried out by microwaving the slides twice in a Tris-
EDTA buffer (pH 9.0) for 5 minutes with a 2-minute interval.  After the endogenous 
peroxidase was blocked, deparaffinised sections were incubated with primary 
monoclonal antibodies for 1 hour at room temperature. The sections were then 
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incubated with goat anti-mouse immunoglobulins conjugated to a peroxidase-labelled 
dextran polymer (EnVision, DakoCytomation) at room temperature for 1 hour. The 
reaction products were developed through the immersion of the sections in DAB 
solution. 
 
9.2. Double immunostaining 
Double immunostaining for GAL-9 with FOXP3 was performed to assess 
whether these two proteins co-localise in the liver tissue. Deparaffinised sections 
intended for were microwaved twice in Tris-EDTA buffer (pH 9.0) for 5 minutes with a 
2-minute interval. 
Staining with the first primary antibody was performed in the same way used for 
single immunostaining, and signals were developed with DAB (brown product). After 3 
washes with trishydroxymethylaminomethane-buffered saline (5 minutes each), the 
second primary antibody was added to the sections, and they were incubated for 1 hour 
at room temperature. 
After they were washed in trishydroxymethylaminomethane-buffered saline, the 
second reaction was developed with an EnVision G\2 System/Alkaline Phosphatase kit 
(DakoCytomation; red product). Nuclei were lightly counterstained with haematoxylin. 
10. Statistical analysis 
Data were analysed using Microsoft Excel 2010 and Prism
®
 5 software 
(GraphPad; San Diego, CA).  
The normality of variable distribution was assessed by the Kolmogorov-Smirnov 
goodness of fit test. When the hypothesis of normality was accepted (p > 0.05) results 
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were presented as mean and standard error of the mean (SEM), used instead of the 
standard deviation to describe the precision of the sample mean. Comparison between 
variables was performed using two-tailed paired or unpaired Student´s t test as 
appropriate. When the hypothesis of normality was rejected (p < 0.05), results were 
expressed as median and range and comparisons between variables were performed 
using two-tailed, non-parametric Wilcoxon or Mann-Whitney U tests for related and 
independent data sets respectively. 
Correlation between variables was determined: by Pearson´s correlation 
coefficient in those cases the data conformed to a normal distribution; or by Spearman´s 
rank correlation coefficient if data were not normally distributed. A p value less than 
0.05 was considered significant; p values ≥0.05 and ≤0.15 were considered to indicate a 
trend to significance. 
 
11. Patients and controls 
The experiments included in this thesis were performed in seventy-seven 
patients with autoimmune liver disease. Thirty healthy subjects, recruited from King´s 
College Hospital staff members, served as normal controls. Details of patients and 
controls included in individual parts of the study are given in the corresponding chapter. 
A table depicting all relevant clinical data from each individual patient is provided in 
Appendix I.  
 
12. Ethics 
In adherence to the Helsinki Principles, informed consent was obtained from all 
subjects whose biological material was used in the present study. Consent was obtained 
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from patients, if older than 16, and from parents/guardians, in cases of patients younger 
than 16. The study protocols were approved by the Ethics Committee of King´s College 
Hospital, London, United Kingdom. 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
CHAPTER IV 
Frequency, phenotype and function of regulatory T cells in 
autoimmune liver disease 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Background 
 
 
[227] 
 
1. Background 
A wealth of data indicates that CD4
pos
CD25
pos
 cells are key players in the 
maintenance of immune-tolerance as they prevent effector cells to react against self-
antigens. Despite the advances made in understanding the mechanisms underlying Treg 
cell lineage commitment and function, purifying Treg cells – for basic and translational 
studies – is still largely reliant upon their CD4 and CD25 expression (Banham 2006). 
However, while in mice CD25 identifies a largely homogeneous regulatory population 
(Takahashi et al. 1998), human CD4
pos
 T cells exhibit a continuous and primarily low 
expression of CD25, in which 2-4% express high levels and up to 30% express low 
levels of CD25 (Baecher-Allan et al. 2001). Further studies have shown that at variance 
with mice where the whole CD4
pos
CD25
pos
 T cell population exhibit regulatory 
function, in humans only the CD4
pos 
cell subset expressing the highest CD25 
fluorescence (the so-called CD25
high
 population) displays a similarly strong regulatory 
function (Baecher-Allan et al. 2001). Since there is no uniformly defined consensus as 
to where the boundary between CD25
high
 and CD25
low
 expression should be drawn, the 
comparison of data deriving from human samples has been difficult, particularly in the 
case of chronic inflammatory conditions where high numbers of activated effector cells 
are present.  
Akin to CD25, other surface markers, including GITR, CD62L, LAG-3 and 
CTLA-4, initially thought to be specifically expressed by Tregs, have been subsequently 
found to be expressed also on effector T cells (Tang et al. 2004a, Ronchetti et al. 2004, 
Banham 2006). Despite being still considered one the most specific Treg markers, the 
lineage specific transcription factor FOXP3 cannot be used to purify Tregs because of 
its intracellular location (Sakaguchi et al. 2010). 
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Recent literature has indicated that the absence or low expression of CD127 is a 
marker of bona fide Tregs that can be readily utilised for their purification in humans. A 
recent study has shown that CD127 was down-regulated on all human T cells after 
activation. Interestingly, while CD127 was then re-expressed on the majority of effector 
and memory T cells, FOXP3
pos
 T cells remained CD127
neg
. Moreover expression of 
CD127 negatively correlated with that of FOXP3, as result of FOXP3 binding to the 
CD127 promoter (Liu et al. 2006). Simultaneously, Seddiki et al. reported that the 
surface expression of CD127, in combination with CD25, can distinguish between 
human regulatory and activated effector CD4
pos
 T cells (Seddiki et al. 2006). The same 
evidence has since been reproduced in other disease states classically associated with 
impaired or enhanced CD4
pos
CD25
high
 Treg number and function, such as MS (Michel 
et al. 2008, McKay et al. 2008), allograft rejection (Codarri et al. 2007) and cancer 
(Shen et al. 2009).  
Given the pivotal role of Tregs in controlling responder cells, my initial 
hypothesis is that unrestrained effector mechanisms involved in autoimmune liver 
damage result from defective Treg number. To test this hypothesis I have performed a 
phenotypic and functional characterisation of circulating CD4
pos
CD25
pos
CD127
neg
 cells 
(“CD127neg Tregs”) in patients with autoimmune liver disease (AILD). 
Specific objectives of the current chapter are: 1) to determine the frequency of 
circulating CD127
neg
 Tregs and activated CD127
pos
 T cells (“CD127pos T cells”) present 
within the conventional Treg population in AILD patients; 2) to assess the cytokine and 
the transcription factor profile of CD127
neg
 Tregs, CD4
pos
CD25
pos
 Tregs and CD127
pos
 
T cells and 3) to purify CD127
low
 Tregs and to test their ability to suppress proliferation 
of responder CD4 T cells. 
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2. Subjects 
For this part of the study thirty-four patients with ANA and/or SMA positive 
AILD were investigated. Seventeen (50%) patients were female. The median age at the 
time of study was 13.4 years, range 5.6-26.7 years. Nineteen patients were studied 
during drug-induced remission (ie, with normal transaminase levels; [R] patients) while 
15 patients had active disease ([A] patients) at the time of investigation. From 6 of 15 
[A] patients, blood was obtained at diagnosis before treatment was started; the 
remaining 9 [A] patients were studied at relapse during immunosuppression tapering. 
A liver biopsy performed at the time or close to diagnosis showed histological 
features of interface hepatitis in all patients. Viral, metabolic, and genetic causes of liver 
disease were excluded by appropriate investigations, all patients being negative for anti-
hepatitis C virus, hepatitis B surface antigen, Epstein-Barr virus, and cytomegalovirus 
serological markers of active infection.  In the group of [A] patients, ANA were present 
in 9 patients and SMA were present in 8 (Table 4.1); Concomitant presence of ANA 
and SMA occurred in 4 individuals. At the time of diagnosis, all 19 [R] patients tested 
positive for ANA and/or SMA whereas at the time of study 11 remained either ANAs 
and/or SMAs positive (one patient tested positive for both) and 8 were autoantibody 
negative. All patients were negative for anti-LKM-1 and anti-LC-1. Relevant 
demographic, clinical and laboratory data are summarised in Table 4.1. 
Fourteen patients had bile duct changes characteristic of sclerosing cholangitis 
on retrograde cholangiography and were diagnosed as having autoimmune 
hepatitis/sclerosing cholangitis (AISC) overlap syndrome (Gregorio et al. 2001); this 
group consisted of 7 [R] and 7 [A] patients, the latter including 2 at presentation. When 
considered together, AIH and AISC are henceforth indicated as autoimmune liver 
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Parameter
AILD
(n=34)
[A] patients
(n=15)
[R] patients
(n=19)
p*
Age in years 13.4 (5.6-26.7) 13.8 (5.6-16.8) 13.0 (8.2-26.7) NS†
Female, n of patients (%) 17 (50%) 10 (67%) 7 (37%) NS†
AST (nv<50 IU/L) 45 (18-1061) 93(51-1061) 28 (18-49) <0.0001‡
GGT  (nv<50 IU/L) 44 (8-503) 74 (17-503) 27 (8-164) 0.0002‡
Total bilirubin (nv<20 mmol/l) 8 (3-127) 13 (3-127) 6 (4-14) 0.009‡
AP (nv<350 IU/L) 189 (68-834) 181 (88-834) 196 (68-344) NS‡
AP/AST ratio 4.31 (0.17-16.38) 2.20 (0.17-4.65) 6.45 (1.58-16.38) <0.0001‡
INR (nv<1.2) 1.05 (0.86-1.78) 1.07 (0.90-1.78) 1.04 (0.86-1.23) NS‡
Albumin (nv>35 g/L) 45 (32-50) 44 (32-50) 46 (40-50) 0.09‡
IgG (nv 6.5-17 g/L) 16.82 (7.51-43.96) 18 (11.66-43.96) 12.99(7.5127.14) 0.03‡
ANA, n of positive patients (%) 16 (47%) 9 (60%) 7 (37%) NS†
SMA, n of positive patients (%) 13 (38%) 8 (53%) 5 (26%) NS†
pANNA, n of positive patients (%) 16 (47%) 9 (60%) 7 (37%) NS†
ASIC, n of positive patients (%) 14 (41%) 7 (47%) 7 (37%) NS†
UC, n of positive patients (%) 12 (35%) 5 (33%) 7 (37%) NS†
disease (AILD). Biochemical and immunological differences between AIH-1 and AISC 
patients investigated in this chapter are depicted in Table 4.2. 
 
Table 4.1. Clinical and laboratory features of AILD patients at the time of study 
 
 
 
 
 
 
 
 
 
 
 
 
Data presented as median (range) unless noted otherwise. 
AILD, autoimmune liver disease; AST, aspartate aminotransferase; GGT, gamma-glutamyl 
transpeptidase; AP, alkaline phosphatase; INR, international normalised ratio; IgG, 
immunoglobulin G; ANA, anti-nuclear antibodies;  SMA, anti-smooth muscle antibodies; 
pANNA, peripheral anti-nuclear neutrophil antibodies;  AISC, autoimmune sclerosing 
cholangitis; UC, ulcerative colitis; nv, normal value; NS non significant 
*
p value when comparing clinical parameters between [A] and [R] patients 
† 
Fisher´s exact test 
‡ 
Mann-Whitney test
 
 
 
Patients were treated with prednisolone (2.5-5 mg daily at remission and 1-2 
mg/kg/day at relapse) either alone or in combination with azathioprine (1-2 mg/kg/day) 
and/or mycophenolate mofetil (MMF, up to 40 mg/kg/day). In those patients diagnosed 
with AISC, ursodeoxycholic acid (UDCA) at a dose of 15-30 mg/kg/day was added to 
the immunosuppressive regimen. Dosage and duration of treatments for each patient are 
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Parameter
AIH-1 patients
(n=20)
AISC patients
(n=14)
p*
Age in years 12.9 (5.6-17.8) 14.4 (8.2-26.7) NS†
Female, n of patients (%) 10 (50%) 7 (50%) NS†
AST (nv<50 IU/L) 38 (18-1061) 49 (21-534) NS‡
GGT (nv<50 IU/L) 34 (8-492) 73 (12-503) 0.02‡
Total bilirubin (nv<20 mmol/l) 7 (4-127) 8 (3-47) NS‡
AP (nv<350 IU/L) 178 (79-669) 209 (68-834) NS‡
AP/AST ratio 4.31 (0.17-15.64) 3.99 (1.56-16.38) NS‡
INR (nv<1.2) 1.08 (0.94-1.30) 1.00 (0.86-1.78) NS‡
Albumin (nv>35 g/L) 45 (39-50) 45 (32-50) NS‡
IgG (nv 6.5-17 g/L) 16.54 (7.51-43.96) 17.08 (11.29-27.14) NS‡
ANA, n of positive patients (%) 8 (40%) 8 (57%) NS†
SMA, n of positive patients (%) 8 (40%) 5 (36%) NS†
pANNA, n of positive patients (%) 6 (30%) 10 (71%) 0.03†
UC, n of positive patients (%) 3 (15%) 9 (64%) 0.005†
Active disease, n of patients (%) 8 (40%) 7 (50%) NS†
shown in Appendix I.  At the time of the study, 3 patients with AIH-1 and 9 with AISC 
had concomitant ulcerative colitis (UC). 
 
Table 4.2. Clinical and laboratory data comparing AIH and AISC patients. 
 
 
 
 
 
 
 
 
 
 
 
Data presented as median (range) unless noted otherwise. 
AIH-1, autoimmune hepatitis type 1; AISC, autoimmune sclerosing cholangitis; AST, aspartate 
aminotransferase; GGT, gamma-glutamyl transpeptidase; AP, alkaline phosphatase; INR, 
international normalised ratio; IgG, immunoglobulin G; ANA, anti-nuclear antibodies;  SMA, 
anti-smooth muscle antibodies; pANNA, peripheral anti-nuclear neutrophil antibodies; UC, 
ulcerative colitis; nv, normal value; NS non significant 
*
p value when comparing clinical parameters between AIH-1 and AISC patients 
† 
Fisher´s exact test 
‡ 
Mann-Whitney test 
 
Fifteen healthy subjects (HS, median age: 28.9 years, range 22.6-35.8, 66% 
female), recruited from King’s College Hospital staff, served as normal controls. The 
disparity between patient and control age derives from ethical constraints in obtaining 
biological specimens from healthy children. To test whether age disparity may account 
for differences, patients were divided into 2 subgroups, (≤14 and >14 years old).
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3. Results 
3.1. Frequency of regulatory T cells 
The frequency and phenotype of regulatory T cells was analysed in 32 AILD 
patients and 14 HS. Gating of PBMCs according to their forward (FSC) and side (SSC) 
scatter characteristics and antibody fluorescence patterns (Figure 4.1.), revealed a 
population of lymphocytes expressing CD4
 and CD25 (“conventional Tregs”, cTregs). 
The proportion of these cells was lower in AILD compared to HS (5.86±0.53% vs 
9.94±0.80%; p<0.001). CD4
pos
CD25
pos
 cells were subsequently subdivided according to 
their CD25 expression into CD25
low
, CD25
medium
, and CD25
high
 subsets and the 
expression of CD127 within those populations was evaluated. 
The percentage of CD127
pos
 cells within cTregs was higher in patients 
(28.18±1.99%) than in HS (14.91±1.34%, p<0.00001), this difference being evident 
also when the CD25
low
 (32.49±2.32% vs 18.90±1.05%, p<0.00001), CD25
med
 
(18.99±1.18% vs 11.29±0.97%, p<0.00001) and CD25
high
 (10.10±0.79% vs 
2.09±0.47%, p<0.0000000001) fractions were analysed separately. 
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Figure 4.1. Gating strategy used to analyse CD127 expression. PBMCs were gated according 
to their forward (FSC) and side (SSC) scatter characteristics (A); lymphocytes were 
subsequently gated according to CD4 expression (B); a population of cells positive for CD25 
was then identified within the CD4 cell population and subdivided according to its CD25 
expression (C). CD127 expression, represented as mean fluorescence intensity on histogram 
plots, was evaluated within CD25
high
(D), CD25
medium
 (E) and CD25
low
 (F) populations. Plots are 
from one representative healthy subject. Values represent the frequency of cells within each 
CD25 population. 
 
Analysis of CD127
neg
 Tregs showed that the frequency of these cells was 
markedly decreased in patients with AILD (4.35±0.45%) compared to HS (8.01±0.69%, 
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p<0.001), this difference being significant both in [A] (2.16±0.21%, p<0.000001) and 
[R] patients (6.06±0.13%, p=0.03; Figure 4.2.). CD127
neg
 Tregs were significantly less 
numerous in [A] than in [R] patients (p<0.000001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. Frequency of CD4
pos
CD25
pos
CD127
neg
 cells.  Plots in Panel A show the frequency 
of CD4
pos
CD25
pos
CD127
neg
 cells in one representative [A] patient, in one representative [R] 
patient and in one representative healthy subject. The graph in Panel B summarises data from 
15 [A] patients, 19 [R] patients and 14 healthy subjects. Error bars represent SEM.  
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In line with this, the frequency of CD127
neg
 Tregs in AILD inversely correlated 
with levels of AST and IgG, and to a lesser extent with SMA titres (Figure 4.3.).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. Correlation between the frequency of CD4
pos
CD25
pos
CD127
neg
 cells and indices 
of disease activity. In AILD patients the percentage of CD4
pos
CD25
pos
CD127
neg
 cells negatively 
correlates with levels of AST (Panel A), IgG (Panel B), and to a lesser extent SMA (Panel C).  
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Within [A] patients no differences in the frequency of CD127
neg
 Tregs were 
observed between those studied at diagnosis and those studied during an episode of 
relapse. Within AILD patients, no differences were found between the two age groups, 
between AIH and AISC, or between those with or without concomitant UC. 
The frequency of cTregs, CD127
neg
 Tregs and CD127
pos
 T cells positive for 
FOXP3 and CTLA-4, classical Treg markers that have been linked to the suppressive 
function of these cells, was investigated in 10 AILD patients and 5 HS. 
The frequency of FOXP3
pos
 cells was higher within CD127
neg
 Tregs than within 
cTregs in both patients (77.83±4.91% vs 43.48±3.99%, p<0.0001), and HS 
(91.20±4.28% vs 66.30±10.53%, p=0.001).  Compared to HS, AILD patients displayed 
a lower percentage of FOXP3
pos
 cells both within cTregs (p=0.004) and CD127
neg
 Tregs 
(p=0.03). In AILD, the frequency of FOXP3
pos
 cells within CD4
pos
CD25
pos
 cells 
inversely correlated with the percentage of CD127
pos
 cells within the same subset (r= –
0.66, p=0.04, Figure 4.4.).  
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Figure 4.4. Frequency of FOXP3
pos
 cells within regulatory T cell populations. The plots 
show that the highest frequency of FOXP3
pos 
cells was within CD127
neg
 Tregs and the lowest 
within CD127
pos
 cells in AILD patients (A) and healthy subjects (B). In AILD the frequency of 
CD127
pos
 within CD4
pos
CD25
pos
 cells inversely correlated with that of FOXP3
pos
 cells (C). Data 
from 5 healthy subjects and 10 AILD. Error bars represent SEM.  
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Akin to FOXP3, the frequency of CTLA-4
pos
 cells was higher in CD127
neg
 Tregs 
than in cTregs both in AILD (75.01±3.68% vs 51.6±5.69%, p=0.005) and HS 
(87.04±2.84% vs 74.88±2.89%, p=0.01), and lower in CD127
neg
 Tregs and cTregs 
isolated from AILD patients than in those obtained from HS (CD127
neg
 Tregs: p=0.03; 
cTregs: p=0.006). In both groups of subjects CD127
pos
 T cells expressed the lowest 
levels of FOXP3 (AILD: 26.10±2.51% vs HS: 32.90±8.54%, p=NS) and CTLA-4 
(AILD: 38.34±7.59%; HS: 48.46±3.23%, p=NS; Figure 4.5.). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5. Frequency of CTLA-4
pos
 cells within regulatory T cell populations. FACS 
analysis of PBMCs from AILD patients (A) and healthy subjects (B) revealed that CD127
neg
 
Tregs contained a higher frequency of CTLA-4
pos
 cells than cTregs and CD127
pos
 cells. The 
plots summarise data from 10 AILD patients 5 healthy subjects and. Error bars represent SEM.   
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The frequency of cells positive for CD45RO, a marker defining memory T cells, 
was also assessed. In AILD all subsets analysed contained a lower frequency of 
CD45RO
pos
 cells (CD127
neg
 Tregs: 68.88±4.29%; cTregs: 53.74±3.49%; CD127
pos
 T 
cells: 78.73±63.69%) than in HS (CD127
neg
 Tregs: 89.52±2.07%, p=0.001; cTregs: 
75.68±5.38%, p=0.01; CD127
pos
 T cells: 92.52±3.44%, p=0.02). Compared to cTregs, 
CD127
neg
 Tregs displayed higher frequency of CD45RO
pos
 cells both in AILD (p=0.01) 
and HS (p=0.05, Figure 4.6.). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6. Frequency of CD45RO
pos
 cells in regulatory T cell populations. FACS analysis 
revealed that CD127
neg
 Tregs display a higher frequency of CD45RO
pos
 cells compared to 
cTregs in AILD patients and healthy subjects. The plots summarise data from 5 healthy subjects 
10 AILD patients. Error bars represent SEM. 
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3.2. Transcription factor profile  
The frequency of cells positive for T-bet, GATA-3 and RORC -  lineage-specific 
transcription factors for Th1, Th2, and Th17 cells respectively - was assessed in 
CD127
neg
 Tregs, cTregs and CD127
pos
 cells from 10 AILD patients and 5 HS.  
Compared to cTregs, CD127
neg
 Tregs contained fewer Tbet
pos
 and RORC
pos
 cells 
in AILD (Tbet: 8.75±1.15% vs 3.78±0.97%, p=0.004; RORC: 18.01±2.03% vs 
6.83±0.58%, p<0.0001), and to a lesser extent in HS (Tbet: 4.54±1.18% vs 2.08±0.32%, 
p=0.08; RORC: 10.76±1.51% vs 4.78±0.89%, p=0.009). cTregs contained an increased 
frequency of Tbet
pos
 and RORC
pos
 cells in AIH compared to HS (Tbet: p=0.03; RORC: 
p=0.01), whereas such difference was not as evident when CD127
neg
 Tregs from the two 
groups were analysed (Tbet: p=0.13; RORC: p=0.09). CD127
pos
 T cells displayed the 
highest frequency of Tbet
pos
 cells, the proportion of these being more elevated in AILD 
(16.89±2.59%) than in HS (6.64±1.87%, p=0.005; Figure 4.7.). Although CD127
pos
 T 
cells were highly enriched for RORC, no statistically significant difference in the 
percentage of these cells was noted between health (33.86±5.23%) and disease 
(41.7±7.28%, p=NS).  
No significant difference in the percentage of GATA-3
pos
 cells was noted 
between CD127
pos
 cells from AILD and health.  
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Figure 4.7. Transcription factor profile of cTregs, CD127
neg
 Tregs and CD127
pos
 T cells. 
Frequency of T-bet
pos
 (A), GATA-3
pos
 (B), and RORC
pos
 (C) cells within cTregs, CD127
neg
 
Tregs and CD127
pos
 T cells in 10 AILD patients (left plots) and 5 healthy subjects (right plots). 
Error bars represent SEM. 
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3.3. Frequency of cytokine producing cells within regulatory T cell populations 
The frequency of cytokine producing cells within Tregs was assessed in 10 
patients and 5 HS. Compared to cTregs, CD127
neg
 Tregs from AILD and HS contained 
more IL-10
pos
 (AILD: 7.07±1.12% vs 9.77±0.78%, p=0.06; HS: 12.64±1.61% vs 
18.66±2.02%, p=0.05), and similar numbers of TGF-pos cells (AILD: 9.21±0.74% vs 
10.45±1.86%, p=NS; HS: 12.48±1.43% vs 15.32±1.41%, p=NS). In AILD, cTregs and 
CD127
neg
 Tregs contained fewer IL-10
pos
 (cTregs: p=0.03; CD127
neg
 Tregs: p=0.008), 
and TGF-pos cells (cTregs: p=0.09; CD127neg Tregs: p=0.06) than in HS (Figure 4.8.) 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8. Frequency of anti-inflammatory cytokine-producing cells within different T 
cell subsets. Frequency of IL-10
pos
 (A) and  TGF-pos (B) cells within cTregs, CD127neg Tregs 
and CD127
pos
 T cells in 10 AILD patients (left plots) and 5 healthy subjects (right plots). Error 
bars represent SEM. 
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The assessment of pro-inflammatory cytokine profile showed that CD127
neg
 
Tregs from both groups contained a lower frequency of IFN-pos (2.82±0.50% in AILD; 
1.64±0.24% in HS) and IL-17
pos
 cells (3.83±0.63% in AILD; 1.80±0.79% in HS) than 
cTregs (IFN-: 7.45±0.94%, p<0.001 in AILD, 3.48±0.71%, p=0.04 in HS; IL-17: 
10.05±1.41%, p<0.001 in AILD, 5.42±1.82%, p=0.10 for HS). Compared to HS, AILD 
patients had higher frequencies of IFN-pos and IL-17pos cells within cTregs (IFN-: 
p=0.005; IL-17: p=0.05) while this difference was less evident when CD127
neg
 Tregs 
were considered (IFN-: p=0.06; IL-17: p=0.07). The CD127pos T cell fraction showed 
the highest frequency of IFN- (AILD: 13.38±2.55%; HS: 8.70±1.98%, p=0.17) and IL-
17-producing cells (AILD: 17.11±2.76%; HS: 6.46±1.34, p=0.005) when compared 
with cTregs and CD127
neg
 Tregs. Lastly, no differences were observed in terms of 
frequency of IL-2 producing cells amongst cTregs, CD127
neg
 Tregs and CD127
pos
 T 
cells in both groups of subjects (Figure 4.9.). 
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Figure 4.9. Frequency of pro-inflammatory cytokine producing cells within different T cell 
subsets. Frequency of IFN-pos (A), IL-17pos (B), and IL-2pos (C) cells within cTregs, CD127neg 
Tregs and CD127
pos
 T cells in 10 AILD patients (left plots) and 5 healthy subjects (right plots). 
Error bars represent SEM. 
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3.4. Suppressive function 
The suppressive function of cTregs and CD127
neg
 Tregs, assessed as their ability 
to inhibit the proliferation of autologous CD4
pos
CD25
neg
 T cells used as responders, was 
studied in 8 AILD patients and 6 HS. 
Addition of cTregs reduced the mean CD4
pos
CD25
neg
 T cell count per minute 
(cpm) by 26% in AILD patients (from 18,992±2,298 to 14,113±1,835 cpm, p=0.12) and 
by 56% in HS (from 32,253±2,463 to 14,170±911 cpm, p=0.0006; Figure 4.10).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10. Suppressive function of cTregs, CD127
neg
 Tregs and CD127
pos
 T cells. The 
plots show the proliferation (expressed as counts per minute [cpm]) of CD25
neg
 responder cells 
cultured alone (filled bars) or in combination with cTregs (square patterned bars), CD127
neg
 
Tregs (horizontal striped bars) or CD127
pos
 T cells (vertical striped bars). Error bars represent 
SEM. Eight AILD patients (upper panel) and six healthy subjects (bottom panel) were studied. 
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The percentage of inhibition was significantly lower in AILD compared to HS 
(p=0.002). Addition of CD127
neg
 Tregs reduced responder cell proliferation by 42% in 
AILD (p=0.01) and by 67% in HS (p=0.0002). In both AILD and HS CD127
neg
 Tregs 
inhibited responder cell proliferation more effectively than cTregs (AILD: 1.6 fold 
increase in the ability to suppress, p=0.002; HS: 1.2 fold increase, p=0.12, Figure 4.11.). 
Both in AILD and HS, addition of CD127
pos
 T cells failed to result in inhibition of 
responder cell proliferation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11. Suppressive activity of cTregs and CD127
neg 
Tregs. Panel A shows the 
suppressive function (expressed as percentage [%] of inhibition of CD25
neg
 responder cell 
proliferation) of cTregs (left) and CD127
neg
 Tregs (right).  Comparison of suppressive activity 
between cTregs and CD127
neg
 Tregs is shown in Panel B. Data representative of 8 AILD 
patients and 6 healthy subjects. 
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3.5. Neutralisation assays 
To explore whether the suppressive function of regulatory T cells is influenced 
by cytokine secretion, neutralising antibodies to IL-10, TGF-, IFN and IL-17 were 
added to Tregs twelve hours prior to co-culture with responder cells obtained from 4 
AILD patients and 4 HS. 
Following treatment with anti-IL-10 neutralising mAb, cTreg and CD127
neg
 
Treg ability to suppress did not change in AILD but decreased from 56% to 36% 
(p=0.02) and from 67% to 43% (p=0.01) respectively in HS. Treatment of cTregs and 
CD127
neg
 Tregs with anti-TGF- neutralising antibody left unchanged their ability to 
suppress responder cell proliferation in both AILD and HS.  
Anti-IFN- neutralising antibody treatment did not change the ability of cTregs 
to suppress in HS, but tended to decrease it in patients with AILD (p=0.06) and left 
unchanged CD127
neg
 Treg suppressive function in both groups. No change was 
observed in cTreg and CD127
neg
 Treg ability to suppress following exposure to anti-IL-
17 neutralising antibodies in both patients and HS. Treatment with anti-IFN- and anti-
IL-17 neutralising antibodies increased CD127
pos 
T cell suppression in AILD (anti-IFN-
: from –3% to 19%, p=0.02; anti-IL-17: from –3% to 9%, p=0.04) and in HS (anti-
IFN-: from –2% to 18%, p=0.05; anti-IL-17: from –2% to 13%, p=0.04; Figure 4.12). 
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Figure 4.12. Effect of cytokine neutralisation on the ability of cTregs and CD127
neg
 T regs 
to suppress responder cell proliferation. Ability of cTregs (Panel A) and CD127
neg
 Tregs 
(Panel B) to suppress was tested in 8 AILD patients (left plots) and 6 healthy subjects (right 
plots) in the absence (filled bars) or presence of anti-IL-10 (squared bars), anti-TGF- 
(horizontal striped bars), anti-IFN- (vertical striped bars) or anti-IL-17 (diagonal striped bars) 
neutralising antibodies. After 5-day co-culture, responder cell proliferation was assessed by 
3
H-
thymidine incorporation. Bars represent mean percentage (%) inhibition of responder cell 
proliferation by untreated or neutralising-antibody-treated responder cells. Error bars indicate 
SEM. 
 
4. Discussion 
This part of the study has extended recent work on regulatory T cells in AILD 
focusing on CD127
neg
 Tregs, a cell subset that, due to the lack of the activation 
molecule CD127, displays higher suppressor ability than cTregs (Seddiki et al. 2006, 
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Liu et al. 2006, Mazzucchelli and Durum 2007). In line with this, the results presented 
in this chapter provide evidence that CD4
pos
CD25
pos
 cells in AILD are highly enriched 
for CD127, whose expression allows the discrimination of a population of activated 
non-suppressive T cells within conventional regulatory cells. 
While corroborating previous observations documenting a reduced frequency of 
circulating cTregs in AILD patients (Longhi et al. 2004, Ferri et al. 2010), this study 
shows that CD127
neg
 Tregs are also numerically reduced in this condition. Given the 
pro-inflammatory phenotype of CD127 expressing cells, this finding implies that in 
AILD the impaired ability of cTregs to suppress is, at least in part, associated with high 
CD127 expression. Proof that CD127
neg
 Tregs exert a suppressive control was 
supported by the observation of a strong negative correlation between the frequency of 
CD127
neg
 Tregs and levels of transaminases and IgG and titres of autoantibodies, which 
are markers of disease activity. 
That low levels of CD127 allow the identification of Tregs with highest ability 
to suppress was clearly shown in the current chapter by a series of experiments where 
cTregs and CD127
neg
 cell subsets were tested for their ability to suppress the 
proliferation of CD4
pos
CD25
neg
 responder cells. The CD127
neg
 fraction was the most 
capable of inhibiting responder T cell proliferation; suppressive capacity of CD127
neg
 
Tregs was however more evident in health than in AILD. Nevertheless, while in HS 
exclusion of CD127 only increased the suppressive activity of Tregs by 20%, in AILD it 
resulted in 60% increase when compared to cTregs, thus approximating its suppressive 
ability to that observed in HS and possibly reflecting the differential CD127 expression 
between the two groups of subjects.  
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Phenotypic analysis has shown that CD127
neg
 Tregs isolated from both patients 
and HS display a more suppressive phenotype compared to cTregs, characterised by 
enhanced expression of FOXP3, CTLA-4 and IL-10. Interestingly, the difference in the 
level of FOXP3 and CTLA-4 expression between CD127
neg
 Tregs and cTregs was more 
evident in AILD patients, once again approximating their levels to those observed in 
health. As previously reported (Liu et al. 2006, Codarri et al. 2007), we observed an 
inverse correlation between CD127 and FOXP3 expression, indicating that in AILD 
CD127
neg
 cells, at variance with cTregs, contain high number of FOXP3-expressing 
cells. By showing that FOXP3 binds to the CD127 promoter region, Liu et al. proposed 
that CD127 down-regulation on Tregs may be consequent to direct repression of CD127 
expression by FOXP3 (Liu et al. 2006).  
Analysis of lymphocytes expressing CD45RO showed that CD127
neg
 cells 
express higher frequencies of this memory cell marker compared to cTregs. This echoes 
a previous study reporting that CD4
pos
CD25
pos
CD127
neg
CD45RO
pos
 cells are associated 
with a higher ability to suppress (Seddiki et al. 2006). Compared to AILD, HS had 
higher expression of CD45RO, suggesting that lower CD45RO expression could 
account for the lower ability of CD127
neg
 cells to suppress in patients with AILD. 
However, since the expression of these marker increases steadily with age (Booth et al. 
2010), it is possible that the discrepancy in CD45RO expression just reflects the age 
disparity between patients and HS. 
The frequency of IL-10-producing cells was consistently higher in Treg 
populations isolated from HS compared to AILD patients. In addition, neutralising 
experiments showing reduced Treg suppression following treatment with anti-IL-10 
antibodies in HS but not in AILD indicate that the ability to secrete this immune-
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regulatory cytokine is impaired in AILD, while in health it has a positive impact in the 
ability of Tregs to suppress.  
Further phenotypic and functional analysis performed in this study showed that 
compared to cTregs, CD127
neg
 Tregs contained fewer cells expressing T-bet, IFN-, 
RORC and IL-17 – signature transcription factors and cytokines of Th1 and Th17 cells 
respectively – this difference being more evident in AILD than in HS. In sharp contrast, 
analysis of CD127
pos
 T cell subset showed the highest percentage of cells positive for 
these Th1 and Th17 markers both in health and disease compared to other CD25
pos
 
populations. In agreement with recent studies (Codarri et al. 2007, Michel et al. 2008), 
CD127
pos
 cells did not suppress but instead tended to increase T cell proliferation. 
Interestingly, treatment of these cells with anti-IFN- and anti-IL-17 neutralising 
antibodies partially restored their ability to suppress. Codarri et al. implicated 
CD4
pos
CD25
pos
CD127
pos
 T cells in human allograft rejection, showing that this 
population contains allospecific CD4 T cells, secrete effector cytokines, and is 
significantly more expanded in patients with chronic humoral rejection (Codarri et al. 
2007).   Collectively, these results indicate that the CD4
pos
CD25
pos
CD127
pos
 T cell 
population does not contain cells with regulatory function, and its expansion in patients 
with AILD suggests that they may be involved in the process of liver damage.     
In conclusion, the results presented in this chapter show that CD127
low
 Tregs 
bear the phenotypic and functional signature of bona fide Tregs, thus defining CD127 as 
a good marker of regulatory T cells in human peripheral blood. Although reduced in 
patients with AILD, CD127
neg
 Tregs are capable of exerting a superior suppressive 
activity when compared to cTregs, approximating the functional ability of those 
observed in health. On the other hand, the counterpart CD127
pos
 T cell population, 
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which is expanded in AILD, may proliferate and produce pro-inflammatory cytokines 
more vigorously, and therefore inflict hepatocyte damage. These findings show that 
negative selection to remove the activated CD127
pos
 T cell population contaminating the 
pool of Tregs may be a useful tool for the selection and expansion of Tregs for both 
research and therapeutic applications. 
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1. Background 
The last chapter has confirmed and expanded the evidence that in AILD the 
extent of self-reactive CD4 T cell effector immune responses, and therefore the 
magnitude of liver injury, is associated with a numerical impairment of regulatory T 
cells. The results presented also show that CD127
neg
 cells, though characterised by a 
more suppressive phenotype and function than cTregs, are in AILD impaired in their 
ability to control the proliferation of effector cells.  
Although a plethora of molecular and cellular mechanisms have been described 
to explain the function of Tregs, their precise mode of suppression is still matter of 
debate. It is likely that a combination of several mechanisms, mediated either by direct 
cell contact or by the production of inhibitory cytokines, operate together depending on 
the milieu and the type of immune response. In the context of AILD, and akin to cell 
number, whether the impaired immune-regulation is mainly due to a primary Treg 
defect, or to a low responsiveness of CD4 effector cells to Treg control, is unclear.  
Recent work performed in mice has shown that galectin-9 (GAL-9), a -
galactosidase-binding animal lectin belonging to the galectin family, inhibits Th1 
effector immune responses after binding to the T-cell-imunoglobulin-and-mucin-
domain-3 (TIM-3), its receptor on CD4 effector cells (Zhu et al. 2005). The immune-
modulatory properties of GAL-9 have been clearly demonstrated in the context of: a) 
experimental autoimmune encephalomyelitis, where injection of GAL-9 into mice 
previously immunised with MOG peptide led to a loss of MOG-specific IFN- 
producing effector cells (Zhu et al. 2005); b) collagen induced arthritis, where GAL-9 
administration resulted in disease amelioration by inducing synoviocytes apoptosis and 
Treg function and by suppressing the generation of Th17 cells (Seki et al. 2008).  
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In the human setting, Mengshol et al. reported that culture of PBMCs in the 
presence of GAL-9 results in the expansion of CD4
pos
CD25
pos
FOXP3
pos
CD127
neg
 
Tregs, and is accompanied by contraction of CD4
pos
 effector T cells and apoptosis of 
HCV-specific CTLs in both HCV infected patients and healthy subjects (Mengshol et 
al. 2010). 
Within the non-activated immune system, GAL-9 is predominantly expressed on 
naïve CD4
pos
 effector T cells and Tregs. Upon activation, GAL-9 is down-regulated on 
the effector T cell compartment, but importantly is maintained on Tregs (Sabatos et al. 
2003, Sanchez-Fueyo et al. 2003). On this basis I have hypothesed that GAL-9 may be a 
mechanism of suppression employed by Tregs and that their functional impairment in 
AILD may be the result of defective GAL-9 expression. 
Specific objectives of the current chapter are: 1) to determine the frequency of 
circulating and liver infiltrating GAL-9
pos
 Tregs; 2) to provide a transcription factor and 
cytokine profiles of GAL-9
pos
 and GAL-9
neg
 T cell populations and 3) to explore to 
what extent GAL-9 impacts Treg ability to suppress by repressing its translation using 
small-interfering-RNA. 
 
2. Subjects 
The experiments included in this chapter were performed on PBMCs obtained 
from 58 AILD patients. Paraffin-embedded liver sections, available from 10 of those 
patients were also studied.  
Thirty three (57%) patients were female. The median age at the time of study 
was 13.9 years, range 8.8-21.1 years (Table 5.1.). At the time of diagnosis, all 58 
patients were positive for ANA and/or anti-SMA autoantibodies. A liver biopsy 
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Parameter
AILD
(n=58)
[A] patients
(n=20)
[R] patients
(n=38)
p*
Age in years 13.9 (8.8-21.1) 13.6 (9.3-19.5) 14.8 (8.8-21.1) NS†
Female, n of patients (%) 33 (57%) 14 (70%) 19 (50%) NS†
AST (nv<50 IU/L) 39 (16-1061) 88 (51-1061) 28 (16-49) <0.0001‡
GGT  (nv<50 IU/L) 39 (4-503) 85 (17-503) 25 (4-196) <0.0001‡
Total bilirubin (nv<20 mmol/l) 9 (3-705) 11 (3-705) 7 (4-32) 0.008‡
AP (nv<350 IU/L) 211 (49-834) 225 (73-834) 197 (49-388) NS‡
AP/AST ratio 4.46 (0.17-16.38) 2.45 (0.17-4.65) 6.32 (2.12-16.38) <0.0001‡
INR (nv<1.2) 1.05 (0.89-2.06) 1.07 (0.90-2.06) 1.04 (0.89-1.31) 0.08‡
Albumin (nv>35 g/L) 45 (32-50) 44 (32-50) 46 (40-50) NS‡
IgG (nv 6.5-17 g/L) 17.01 (5.70-43.96) 17.34 (6.83-43.96) 12.65(5.70-27.14) 0.007‡
ANA, n of positive patients (%) 21 (36%) 11 (55%) 10 (26%) 0.04†
SMA, n of positive patients (%) 18 (31%) 9 (45%) 9 (24%) 0.14†
pANNA, n of positive patients (%) 29 (50%) 10 (50%) 19 (50%) NS†
AISC, n of positive patients (%) 29 (50%) 11 (55%) 18 (47%) NS†
IBD, n of positive patients (%) 22 (38%) 9 (45%) 13 (34%) NS†
performed at the time or close to diagnosis showed histological features of interface 
hepatitis in all patients. Viral, metabolic, and genetic causes of liver disease were 
excluded by appropriate investigations.  
 
Table 5.1. Demographic, clinical and laboratory features of AILD patients at the time of 
the study. 
 
 
 
 
 
 
 
 
 
 
 
Data presented as median (range) unless noted otherwise. 
AILD, autoimmune liver disease; AST, aspartate aminotransferase; GGT, gamma-glutamyl 
transpeptidase; AP, alkaline phosphatase; INR, international normalised ratio; IgG, 
immunoglobulin G; ANA, anti-nuclear antibodies;  SMA, anti-smooth muscle antibodies; 
pANNA, peripheral anti-nuclear neutrophil antibodies;  AISC, autoimmune sclerosing 
cholangitis; IBD, inflammatory bowel disease; nv, normal value; NS non significant   
*
p value when comparing clinical parameters between [A] and [R] patients 
† 
Fisher´s exact test 
‡ 
Mann-Whitney test
  
 
Twenty-nine patients had bile duct changes characteristic of sclerosing 
cholangitis on retrograde cholangiography and were diagnosed as having AISC 
(Gregorio et al. 2001; Table 5.2.) 
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Parameter
AIH-1 patients
(n=29)
AISC patients
(n=29)
p*
Age in years 13.6 (8.8-21.1) 13.9 (9.1-17.6) NS†
Female, n of patients (%) 21 (72%) 12 (41%) 0.06†
AST (nv<50 IU/L) 36 (16-1061) 38 (17-534) NS‡
GGT (nv<50 IU/L) 35 (9-215) 38 (4-503) 0.10‡
Total bilirubin (nv<20 mmol/l) 8 (4-705) 9 (3-47) NS‡
AP (nv<350 IU/L) 177 (49-340) 201 (68-834) 0.03‡
AP/AST ratio 4.13 (0.17-13.04) 4.44 (1.26-16.38) 0.15‡
INR (nv<1.2) 1.06 (0.89-2.06) 1.05 (0.89-1.78) NS‡
Albumin (nv>35 g/L) 45 (38-50) 45 (32-50) NS‡
IgG (nv 6.5-17 g/L) 13.50 (5.70-43.96) 14.63 (7.99-27.14) NS‡
ANA, n of positive patients (%) 11 (38%) 10 (34%) NS†
SMA, n of positive patients (%) 10 (34%) 8 (28%) NS†
pANNA, n of positive patients (%) 10 (34%) 19 (66%) 0.02†
Active disease, n of patients(%) 10 (34%) 10 (34%) NS†
IBD, n of patients (%) 5 (17%) 17 (59%) 0.001†
Table 5.2. Clinical and laboratory data comparing AIH and AISC patients. 
 
 
 
 
 
 
 
 
 
 
 
 
Data presented as median (range) unless noted otherwise. 
AIH-1, autoimmune hepatitis type 1; AISC, autoimmune sclerosing cholangitis; AST, aspartate 
aminotransferase; GGT, gamma-glutamyl transpeptidase; AP, alkaline phosphatase; INR, 
international normalised ratio; IgG, immunoglobulin G; ANA, anti-nuclear antibodies;  SMA, 
anti-smooth muscle antibodies; pANNA, peripheral anti-nuclear neutrophil antibodies; IBD, 
inflammatory bowel disease; nv, normal value; NS non significant 
*
p value when comparing clinical parameters between AIH-1 and AISC patients 
† 
Fisher´s exact test 
‡ 
Mann-Whitney test 
 
Thirty-eight patients were in drug-induced remission ([R] patients), while 20 
were studied during active disease ([A] patients). From 6 of 20 [A] patients, blood was 
obtained at diagnosis before the treatment was started; the remaining 14 [A] patients 
were studied during relapse.  In one [R] patient blood was collected one year after 
successful treatment withdraw. All other patients were on immunosuppressive 
treatment, consisting of prednisolone either alone or in combination with azathioprine 
and/or MMF. In those diagnosed with AISC, UDCA was added to the treatment 
regimen.
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Epidemiological, clinical and laboratory data for each patient are shown in 
Appendix I.  
At the time of study, 22 AILD patients, including 5 with AIH-1 and 17 with 
AISC, had concomitant inflammatory bowel disease (IBD). Three of the 5 AIH-1 
patients had ulcerative colitis (UC) while 2 had Crohn´s disease (CD); all the 17 AISC 
patients had UC.  
Twenty-four HS, recruited from King’s College Hospital staff members, served 
as normal controls; 16 were females and the median age was 29 years (range 22.6 to 
23.7 years). The disparity between patients and HS age derives from ethical constraints 
in obtaining blood from healthy children. To test whether age disparity accounted for 
differences, patients were divided into 2 subgroups, (≤14 and >14 years old). 
 
3. Results 
3.1. Enumeration of circulating GAL-9
pos
 cells  
The frequency of GAL-9
pos
 cells was analysed in 34 AILD patients and 20 HS. 
The percentage of GAL-9
pos
 cells within CD4
pos
CD25
pos
 cells (cTregs) was lower in 
patients (32.57±2.86%) than in HS (53.85.4±3.13%, p<0.0001), this difference being 
evident also when the CD25
low
 (22.43±2.09% vs 38.42±2.87%, p<0.0001), CD25
med
 
(29.69±2.49% vs 55.02±2.10%, p<0.0001) and CD25
high
 (37.68±2.88% vs 
70.51±2.61%, p<0.0001) fractions were analysed separately (Figure 5.1.).  
Analysis of CD4
pos
CD25
pos
CD127
neg
 cells showed that this subset contained 
higher percentage of GAL-9
pos
 cells (AILD: 44.43±2.61%; HS: 74.18±2.13%) 
compared to cTregs (AILD: p=0.005; HS: p<0.001). This percentage was however 
lower in AILD than in HS (p<0.001; Figure 5.2.).  
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The percentage of GAL-9
pos
 cells within cTregs inversely correlated with the 
titre of IgG (r= –0.49, p=0.003) and, to a lesser extent, with that of ANA (r= –0.31, 
p=0.07; Figure 5.3.). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. Percentage of GAL-9
pos
 lymphocytes within Treg subsets. Percentage of GAL-
9
pos
 lymphocytes within unfractionated CD4
pos
CD25
pos
 cells (Panel A) and within the 
CD4
pos
CD25
low
, CD4
pos
CD25
medium 
and CD4
pos
CD25
high
 subsets (Panel B) in AILD patients 
(green bars, n=34) and healthy subjects (blue bars, n=20). GAL-9
pos
 cells were lower in AILD 
than in health both when undivided CD25
pos
 cells and when individual CD25 low, medium and 
high cell fractions were analysed. Error bars represent SEM. 
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Figure 5.2. Frequency of GAL-9
pos
 cells within CD127
neg
 Tregs and cTregs. FACS analysis 
of PBMCs from healthy subjects (A) and AILD patients (B) revealed a higher GAL-9 
expression within CD127
neg
 Tregs compared to cTregs. The plots summarise data from 34 
AILD patients and 20 healthy subjects. Error bars depict SEM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3. Correlation between the frequency of GAL-9
pos
 cells and indices of disease 
activity. In AILD patients the frequency of GAL-9
pos
 cells within cTregs negatively correlated 
with IgG levels (Panel A), and to a lesser extent ANA titres (Panel B). 
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The frequency of GAL-9
pos
 cells was lower in [A] patients (31.8±3.71%) 
compared to [R] patients (36.78±3.68%, p=0.03). Within [A] patients no differences 
were observed between those studied at diagnosis and those studied during an episode 
of relapse. Within AILD patients, no differences in terms of GAL-9
pos
 cells within 
cTregs were observed between the two age groups (≤14 years: 30.80±4.52%; >14 years: 
34.94±3.90%, p=NS), between AIH and AISC (32.45±3.18% vs 32.69±5.69%, p=NS), 
and between those with or without concomitant IBD (37.75±7.26 vs 30.42±2.71%, 
p=NS, Figure 5.4.). 
 
 
 
 
 
 
 
 
Figure 5.4. Frequency of GAL-9
pos
 cells within cTregs. The frequency of GAL-9
pos
 cells 
within cTregs was higher in patients with active disease compared to those studied during drug-
induced remission (Panel A).  No differences in the frequency of GAL-9
pos
 lymphocytes were 
observed between age groups (Panel B), between AIH and AISC (Panel C), and between those 
with and without concomitant IBD (Panel D). The plots summarise data from 20 healthy 
subjects and 34 AILD patients. Error bars represent SEM. 
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3.2. Phenotype of GAL-9
pos
 T cells 
Transcription factor and cytokine profile of CD4
pos
CD25
pos
GAL-9
pos (“GAL-9pos 
Tregs”) and CD4posCD25posGAL-9neg (“GAL-9neg Tregs”) populations was performed in 
15 AILD patients and 15 HS. 
Both in AILD and HS the frequency of FOXP3
pos
 cells was higher within GAL-
9
pos
 (HS: 42.85±3.03%; AILD: 14.41±2.01%) than GAL-9
neg
 Tregs (HS: 16.45±1.48%, 
p<0.001; AILD: 2.62±0.51, p<0.001). In AILD the GAL-9
pos
 and the GAL-9
neg
 Treg 
subsets contained fewer FOXP3
pos
 cells than in HS (p<0.001 for both).  
The frequency of RORC
pos
 cells was lower in the GAL-9
pos
 (HS: 0.92±0.38%; 
AILD: 1.08±0.60%) than in the GAL-9
neg 
Treg cell fraction (HS: 4.42±0.85%, p=0.02; 
AILD: 8.62±0.80%, p=0.005). GAL-9
neg
 Tregs contained higher frequencies of 
RORC
pos
 cells in AILD than in HS (p=0.04), while such a difference was not observed 
in the GAL-9
pos
 compartment.  
GAL-9
pos
 and GAL-9
neg
 Treg populations had similar proportions of Tbet
pos
 and 
GATA-3
pos
 lymphocytes, with no difference observed between health and disease 
(Figure 5.5.). 
Analysis of the cytokine profile (Table 5.3.) showed that the frequency of IL-
10
pos
 cells was higher in the GAL-9
pos
 than in the GAL-9
neg
 cell fraction (HS: p<0.001; 
AILD: p=0.001). The GAL-9
pos
 fraction contained less IL-10
pos
 cells in AILD than in 
HS (p<0.001) whereas such a difference between the two groups was not evident when 
the GAL-9
neg
 subset was analysed. The percentage of TGF--producing cells was lower 
in the GAL-9
pos
 cells isolated from AILD patients than in those from HS (p=0.04). 
While in HS TGF-pos cells tended to be more frequent within GAL-9pos than within 
GAL-9
neg
 fraction (p=0.07), such a trend was not observed in patients.  
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% of cells GAL-9pos Tregs GAL-9neg Tregs
AILD HS p1 AILD HS p2 p† p‡
IL-10 5.15 0.61 9.11 0.54 <0.001 2.35 0.16 3.29 0.39 NS 0.001 <0.001
TGF- 6.35 0.66 8.03 0.44 0.04 5.29 0.53 5.51 1.15 NS NS 0.07
IFN- 4.39 0.57 2.11 0.35 0.002 5.74 0.78 2.17 0.42 <0.001 NS NS
IL-17 4.08 0.62 1.75 0.22 0.002 7.95 1.17 2.29 0.67 <0.001 0.01 NS
IL-2 8.80 0.70 10.92 1.21 NS 8.34 0.83 9.38 1.55 NS NS NS
Regarding pro-inflammatory cytokines, the percentage of IFN-pos lymphocytes 
was higher in the GAL-9
pos
 cells isolated from AILD patients than in those obtained 
from HS (p=0.002). The same tendency between subjects was observed regarding IFN- 
production by GAL-9
neg
 population (p<0.001).  However, when GAL-9
pos
 and GAL-9
neg
 
populations were compared they showed similar numbers of IFN-pos cells both in 
AILD and HS. The frequency of IL-17
pos
 cells was higher in AILD than in HS both 
when GAL-9
pos
 (p=0.002) and GAL-9
neg
 (p<0.001) populations were analysed. While in 
health the percentage of IL-17
pos
 cells did not differ between GAL-9
pos
 and GAL-9
neg
 
subsets, in AILD it was significantly higher in the latter compared to the former 
(p=0.01).  
No differences were observed in the frequency of IL-2-producing cells between 
GAL-9
pos
 and GAL-9
neg 
cells in both groups of subjects. 
 
Table 5.3. Transcription factor and of cytokine profile of  CD4
pos
CD25
pos
GAL-9
pos 
and 
GAL-9
neg 
cells. 
 
HS, healthy subjects; AILD, autoimmune liver disease; NS, non significant 
Data are represented as mean±SEM 
p values comparing the percentage of IL-10
pos
, TGF-pos, IFN-pos, IL-17pos, and IL-2pos cells: 
p
1
: within the GAL-9
pos
 subset between AILD and healthy subjects 
p
2
: within the GAL-9
neg
 subset between healthy AILD and healthy subjects 
p
†
: between the GAL-9
pos
 and the GAL-9
neg
 subset in AILD  
p
‡
: between the GAL-9
pos
 and the GAL-9
neg
 subset in healthy subjects 
Data referring to 20 healthy subjects and 34 AILD patients and 20 healthy subjects 
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Figure 5.5. Transcription factor profile of GAL-9
pos
 and GAL-9
neg
 Treg subsets. Frequency 
of FOXP3
pos
 (A), RORC
pos
 (B), Tbet
pos
 (C), and GATA-3
pos
 (D) cells within 
CD4
pos
CD25
pos
GAL-9
pos
 (filled bars) and GAL-9
neg
 (squared pattern bars) cell subsets in 15 
patients (left plots) and healthy subjects (right plots). Error bars represent SEM. 
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3.3. Galectin-9 gene knockdown 
The effect of GAL-9 gene silencing on the ability of cTregs and CD127
neg
 Tregs 
to suppress was investigated in 20 AILD patients and 8 HS. The suppressor function of 
untreated and siRNA-treated Tregs was tested using autologous CD25
neg
 cells as 
responders. Treatment of Tregs with GAL-9-RNAi led to a decrease in the expression 
of GAL-9 gene by 86% in AILD and by 88% in HS.  
Inhibition of cell proliferation observed with untreated cTregs was reduced by 
44% in AILD (from 25% with untreated to 14% with siRNA-treated Tregs , p<0.001) 
and by 67% in HS (from 49% to 16%, p<0.001) . Treatment with GAL-9-RNAi, 
reduced the suppressor function of CD127
neg
 Treg suppressor by 54% (from 46±3.14% 
to 21%, p<0.001) in AILD and 67% (from 60% to 21±1.76%, p<0.001) in HS (Figure 
5.6.) 
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Figure 5.6. Suppressive function of untreated and GAL-9 siRNA-treated regulatory T 
cells. The plots show the proliferation (expressed as counts per minute [cpm]) of CD25
neg
 
responder cells cultured alone (filled bars) or in combination with untreated (square patterned 
bars) or siRNA-treated (horizontal striped bars) cTregs, CD127
neg
 Tregs and CD127
pos
 T cells 
in AILD (Panel A) and healthy subjects (Panel B). Error bars represent SEM. Data 
representative of 20 AILD patients and 8 healthy subjects. 
 
In 2 HS, the effect of GAL-9 gene knockdown on Treg suppression was also 
evaluated after FACS-sorting Tregs according to their CD25 expression. CD25
high
 Treg 
suppressor function was markedly reduced by GAL-9 siRNA treatment: inhibition of 
CD25
neg
 cell proliferation was 57% following addition of untreated and 14% after 
addition of GAL-9 siRNA-treated CD25
high
 Tregs. No difference in the ability of 
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CD25
low
 Tregs to suppress was noted before and after GAL-9 siRNA treatment (25% vs 
27%, Figure 5.7.). 
 
 
 
 
 
Figure 5.7. Effect of GAL-9 siRNA on CD25
high
 and CD25
low
 cells. The graph shows the 
proliferation (expressed as counts per minute [cpm]) of CD25
neg
 responder cells cultured alone 
or in combination with untreated (square patterned bars) or siRNA-treated (horizontal striped 
bars) CD4
pos
CD25
high
 and CD4
pos
CD25
low
 cell subsets. Error bars represent SEM. Data 
representative of 2 healthy subjects.  
 
3.4. Neutralisation assay 
To explore whether Treg control over responder cell proliferation is influenced 
by secretion of inhibitory cytokines, anti-IL-10 or anti-TGF- neutralising antibodies 
were added to Tregs prior co-culturing them with CD25
neg
 as well as purified TIM-3
pos
 
and TIM-3
neg
 target cells obtained from 4 AILD patients and 4 HS.  
Following treatment with anti-IL-10 mAb, Treg inhibition of CD25
neg
 cell 
proliferation did not change in AILD but was decreased from 51% to 34% (p=0.07) in 
HS. Anti-IL-10 neutralising antibody treatment resulted in no change in the ability of 
Tregs to suppress TIM-3
neg
 cells, but decreased Treg inhibition over TIM-3
pos
 cell 
proliferation from 42% to 36% (p=0.06) in AILD and from 56% to 48% (p=0.04) in HS. 
Treatment with anti-TGF- did not change Treg inhibition of CD25neg, TIM-3neg and 
TIM-3
pos
 cell proliferation both in AILD patients and HS (Figure 5.8.). 
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Figure 5.8. Effect of cytokine neutralisation on the ability of Tregs to inhibit proliferation 
of CD25
neg
, TIM-3
neg 
and TIM-3
pos
 responder cells. CD25
neg
 (Panel A), TIM-3
neg
 (Panel B), 
and TIM-3
pos
 cells (Panel C) purified from 4 AILD patients (n=4, left plots) healthy subjects 
(n=4, right plots) were cultured with Tregs either untreated or treated with anti-IL-10 (squared 
bars) or anti-TGF- (horizontal striped bars) neutralising antibodies. After 5-day co-culture, 
responder cell proliferation was assessed by 
3
H-thymidine incorporation. Bars represent mean + 
SEM percentage (%) inhibition of responder cell. Error bars represent SEM. 
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A B
C D
3.5. Immunohistochemistry 
The frequency of liver infiltrating GAL-9
pos
 lymphocytes was sought by 
immunohistochemistry in 13 liver biopsies available from 10 AILD patients. All 
patients were studied during a period of histologically active disease, and 3 of them 
were also investigated during inactive disease. The numbers of CD4
pos
FOXP3
pos
GAL-
9
pos
 lymphocytes were counted at three high-power fields (x400) in each case 
GAL-9
pos
 cells were detected in the portal tracts of 10 of 13 liver biopsy samples 
(Figure 5.9.).  
 
 
Figure 5.9. Liver infiltrating FOXP3
pos
 and GAL-9
pos
 lymphocytes. The number of CD4
pos
 
lymphocytes was counted at three high-power fields (x400, A). Lymphocytes positive for 
FOXP3 and CD4 were counted at the same places (B). Similarly GAL-9
pos
 and CD4
pos
 
lymphocytes were also counted at the same sample sections (C). Presence of lymphocytes 
positive for both GAL-9 and FOXP3 was confirmed by double immunostaining (D).   
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The percentage of CD4
pos
 cells positive for GAL-9 was 4.70±2.15%, and that of 
FOXP3
pos
 cells was 13.89±3.62%. The frequency of GAL-9
pos
 lymphocytes within 
CD4
pos
 cells correlated with that of FOXP3
pos
 cells (r=0.81, p=0.0008; Figure 5.10.) 
FOXP3/GAL-9 double staining showed that GAL-9 and FOXP3 are co-expressed in the 
lymphocytes infiltrating the portal areas. However, many FOXP3
pos
 cells lack GAL-9 
expression, thus mirroring the results obtained from the peripheral blood.  In addition to 
lymphocytes, GAL-9 strongly stained Kupffer and endothelial cells; some spindle cells 
in the portal tracts were also positive for GAL-9. 
 
Figure 5.10. Correlation between the frequency of GAL-9
pos
 and FOXP3
pos
 liver 
infiltrating lymphocytes. The frequency of GAL-9
pos
 cell correlates with that of FOXP3
pos
 
lymphocytes in patients with AILD.   
 
4. Discussion 
Although Tregs have the ability to inhibit the activation, proliferation and 
effector function of different immune cells, its exact mechanism of action and what 
causes its defect in autoimmunity is not yet known. This chapter explores the expression 
of GAL-9, a molecule known to inhibit Th1 immune responses, as a potential 
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mechanism of Treg-mediated suppression as well as its putative role in the defective 
immune-regulation in AILD. 
The results presented in this chapter provide evidence that defective GAL-9 
expression is one of the mechanisms responsible for Treg impairment in AILD.  The 
role of GAL-9 in the ability of Tregs to exert their function has been highlighted by 
gene knockdown experiments where treatment of Tregs with a set of GAL-9-specific 
stealth RNAi led to a less effective control of responder cells´ proliferation, particularly 
in the case of treated-CD25
high
 Tregs. The observed inverse correlation between the 
frequency of GAL-9
pos
 cells and the levels of IgG and titres of SMA, both serological 
markers of disease, suggests that GAL-9
pos
 Tregs exert control over disease activity. 
These results echo a murine study where in the context of autoimmune 
encephalomyelitis GAL-9 was shown to have a direct effect on disease severity, as mice 
immunised with a MOG immunodominant peptide and injected in vivo with GAL-9 had 
a less severe disease course and a lower mortality rate than mice that were not injected 
(Zhu et al. 2005). 
Phenotypic analysis has shown that GAL-9
pos
 Tregs have a more suppressive 
phenotype compared to their negative counterparts, being characterised by higher 
FOXP3 expression and more IL-10 production. Indeed, the vast majority of IL-10
pos
 
cells in both health and disease were found within GAL-9
pos
 Treg subset. Neutralisation 
experiments showing reduced Treg suppression following treatment with anti-IL-10 
neutralising antibodies indicate that GAL-9
pos
 Tregs partly act through IL-10 
production/secretion. Taken together, these findings suggest that GAL-9
pos
 Tregs, in 
addition to regulating effectors via induction of their apoptosis by binding to TIM-3 
(Kashio et al. 2003, Zhu et al. 2005), can deliver suppression via IL-10 secretion. 
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Relatively recently, it has been shown that Treg and Th17 cells originate from 
the same progenitor, having a reciprocal induction during differentiation (Bettelli et al. 
2006). While the concomitant presence of TGF- and IL-6 leads to the differentiation of 
naïve CD4
pos
 cells into Th17 cells, the presence of TGF- alone leads to differentiation 
into Tregs, but prevents that into Th17 cells (Chen et al. 2003, Veldhoen et al. 2006). 
Seki et al. showed in the context of CIA that administration of exogenous GAL-9, by 
decreasing IL-6 production, leads to complete suppression of IL-17 expression at both 
gene and protein levels, even upon stimulation with high levels of TGF- and IL-6 
(Seki et al. 2008). In line with this, the results presented in this chapter suggest that the 
loss of GAL-9 expression within CD4
pos
CD25
pos
 T cells in AILD is mirrored by a 
reciprocal increase in RORC and IL-17 expression by the now GAL-9
neg
CD4
pos
CD25
pos
 
cells. Whether these GAL-9
neg
 cells correspond to the population of pathogenic effector 
“ex-FOXP3” cells, recently reported in a murine model of autoimmune diabetes as 
promoters of inflammation through the production of IL-17 (Zhou et al. 2009), is 
unknown. Nonetheless, GAL-9 seems then to play a key role in preventing Th17 
differentiation both in mice and in humans. Thus, in view of the potential application of 
Tregs as an immunotherapeutic tool for the treatment/cure of AILD, the role of GAL-9 
as a marker for the identification of stable, non-contaminated Tregs should be 
investigated. For that purpose, future studies should also focus on the phenotypic and 
functional stability of human GAL-9
pos
 Tregs over time and upon pro-inflammatory 
challenges. 
Akin to the results in the circulation, in this study GAL-9
pos
 lymphocytes were 
detected in most liver biopsy samples from AILD patients, but they represented a very 
small component of the florid portal tract inflammatory infiltrate, hence mirroring the 
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picture observed in  the peripheral blood. Although no healthy or pathological controls 
were studied, a recent report has demonstrated a high percentage of GAL-9
pos
 cells in 
the periportal area of patients with chronic HCV infection, and to a lesser extent in 
normal tissue obtained from donors evaluated for living-related liver transplantation or 
patients undergoing resection for metastatic adenocarcinoma (Mengshol et al. 2010).  
Interestingly, in the present study the frequency of liver-infiltrating GAL-9
pos
 
cells negatively correlated with that FOXP3
pos
 lymphocytes, suggesting that GAL-9, 
besides being pivotal to Tregs function, may also be involved in their induction. In line 
with this, studies performed in different murine models of autoimmunity (Seki et al. 
2008, Sehrawat et al. 2009, Lv et al. 2011) consistently showed that treatment with 
GAL-9 resulted in up-regulation of FOXP3 mRNA expression and in expansion of 
TGF- induced Tregs, leading to improvements in disease severity. Similar results have 
also been reported in the human setting, where culture of PBMCs in the presence of 
GAL-9 resulted in the expansion of CD4
pos
CD25
pos
FOXP3
pos
CD127
neg
 Tregs both in 
HCV infected patients and healthy subjects (Mengshol et al. 2010). On the other hand, 
GAL-9 deficient mice had significantly decreased numbers of Tregs (Seki et al. 2008). 
Collectively, these data indicate that GAL-9 regulates, at least in part, the 
differentiation, maintenance and expansion of FOXP3
pos
 Tregs. Of interest, 
immunohistochemical studies presented in this chapter show that cells other than Tregs, 
particularly Kupffer and to a lesser extent endothelial cells, express GAL-9. Due to the 
absence of a control group, we do not know whether the frequencies of these GAL-9
pos
 
cells are reduced or not in the livers of AILD patients. However, the study by Mengshol 
et al. showed that patients with chronic HCV, concomitantly to an enhanced Treg 
function, had a higher intensity of GAL-9 staining within Kupffer cells compared to 
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controls (Mengshol et al. 2010). In view of this, the contribution of GAL-9 either 
expressed by other immune cell types or given exogenously should be addressed in the 
context of AILD. If the link between macrophage-derived GAL-9 and a selective 
expansion of Tregs in the liver environment proves to be correct, GAL-9 may in the 
future be successful in restoring tolerance to liver self-antigens by enhancing the 
function and numbers of Tregs.       
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CHAPTER VI 
Contribution of TIM-3 to the determination of effector T cell fate in 
autoimmune liver disease 
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1. Background 
Whether the impaired immune-regulation in AILD is the result of a numerical 
and functional Treg defect, as highlighted in chapters IV and V, or is also due to low 
responsiveness of CD4 effector cells to Treg control, is unknown. Indeed, whereas 
many of the molecular and cellular mechanisms that regulate the function of regulatory 
T cells, at least in health, are understood, the molecules that determine the fate of 
effector T cell populations remain to be elucidated. 
The immunoglobulin superfamily member TIM-3 was first identified as a 
specific cell marker of mouse Th1 CD4 cells (Monney et al. 2002)  and was shown to 
be selectively expressed on the surface of fully differentiated Th1 but not Th2 cells 
(Rodriguez-Manzanet et al. 2009).  
A number of studies conducted in animals have provided evidence of the role of 
TIM-3 in the modulation of Th1 immune responses For example, in the context of 
experimental allergic encephalomyelitis, in vivo administration of TIM-3 monoclonal 
antibody worsens the disease leading to severe brain inflammation (Monney et al. 
2002).  Moreover, blockade of TIM-3 on Th1 cells through the administration of the 
same anti-TIM-3 antibody accelerated diabetes development in NOD mice and 
prevented transplantation tolerance in a model of islet allograft (Sanchez-Fueyo et al. 
2003, Sabatos et al. 2003). Further studies demonstrated that TIM-3, upon interaction 
with its ligand GAL-9, promotes termination of Th1 cell responses (Zhu et al. 2005).  
Down-regulation of TIM-3 has been reported in T cell clones established from 
the cerebrospinal fluid of patients with multiple sclerosis and found to be associated 
with high levels of IFN- secretion (Koguchi et al. 2006, Li Yang et al. 2008).  
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Collectively, all these studies indicate that TIM-3 plays a role in modulating Th1 
immune responses and that its expression has a role in limiting effector cell 
pathogenicity and therefore in promoting tolerance. The recent observation that effector 
Th17 cells express low levels of TIM-3 (Nakae et al. 2007b) raises the possibility that 
TIM-3 plays a role in the regulation of this subset. In view of this, I hypothesise that 
impaired expression of TIM-3 renders CD4 effector cells less amenable to Treg control 
in AILD. 
Specific objectives of the current chapter are 1) to provide a phenotypic 
characterisation of effector CD4 T cells in AILD; 2) to determine the frequency of 
circulating and liver infiltrating TIM-3
pos
 effector cells; 3) to assess the transcription 
factor and cytokine profiles of TIM-3
pos
 and TIM-3
neg
 T cell subsets and 4) to test the 
susceptibility of TIM-3
pos 
and TIM-3
neg
 effector T cells to Treg control. 
 
2. Subjects 
For this part of the study fifty four patients with ANA and/or SMA positive 
AILD were investigated. Thirty one (57%) patients were female. The median age at the 
time of study was 14.3 years (range 8.2-21.1). Thirty seven patients were studied during 
drug-induced remission ([R] patients) while 17 patients had active disease ([A] patients) 
at the time of investigation. Five [A] patients was studied at diagnosis before treatment 
was started; the remaining 12 [A] patients were studied during an episode of relapse. 
A liver biopsy performed at the time or close to diagnosis showed histological 
features of interface hepatitis in all patients. Viral, metabolic, and genetic causes of liver 
disease were excluded by appropriate investigations. In the group of [A] patients, ANA 
were present in 8 patients and SMA were present in 7 (Table 6.1); concomitant presence 
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Parameter
AILD
(n=54)
[A] patients
(n=17)
[R] patients
(n=37)
p*
Age in years 14.3 (8.2-21.1) 14.4 (9.3-19.5) 14.2 (8.2-21.1) NS†
Female, n of patients (%) 31 (57%) 12 (70%) 19 (51%) NS†
AST (nv<50 IU/L) 36 (16-1061) 91 (61-1061) 30 (16-49) <0.0001‡
GGT  (nv<50 IU/L) 35 (4-503) 55 (17-503) 20 (4-169) <0.0001‡
Total bilirubin (nv<20 mmol/l) 9 (4-705) 13 (7-705) 7 (4-32) 0.0007‡
AP (nv<350 IU/L) 198 (49-834) 222 (88-834) 186 (49-411) NS‡
AP/AST ratio 4.38 (0.17-16.38) 2.20 (0.17-6.55) 6.03 (2.12-16.38) <0.0001‡
INR (nv<1.2) 1.07 (0.89-2.06) 1.10 (0.92-2.06) 1.05 (0.89-1.27) 0.03‡
Albumin (nv>35 g/L) 46 (32-50) 44 (32-50) 46 (40-50) 0.09‡
IgG (nv 6.5-17 g/L) 13.03 (5.70-43.96) 17.10 (6.83-43.96) 12.38(5.70-27.14) 0.002‡
ANA, n of positive patients (%) 19 (35%) 9 (53%) 10 (27%) 0.08†
SMA, n of positive patients (%) 16 (30%) 8 (47%) 8 (22%) 0.11†
pANNA, n of positive patients (%) 21 (39%) 7 (41%) 14 (38%) NS†
AISC, n of positive patients (%) 21 (39%) 8 (47%) 13 (35%) NS†
IBD, n of positive patients (%) 16 (30%) 6 (35%) 10 (27%) NS†
of ANA and SMA occurred in 4 individuals. At the time of diagnosis, all 37 [R] patients 
tested positive for ANA and/or SMA whereas at the time of study 18 remained either 
ANAs and/or SMAs positive (one patient tested positive for both) and 19 were 
autoantibody negative. All patients were negative for anti-LKM-1 and anti-LC-1. 
Relevant demographic, clinical and laboratory data are summarised in Table 6.1. 
 
Table 6.1. Demographic, clinical and laboratory features of AILD patients at the time of 
the study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data presented as median (range) unless noted otherwise. 
AILD, autoimmune liver disease; AST, aspartate aminotransferase; GGT, gamma-glutamyl 
transpeptidase; AP, alkaline phosphatase; INR, international normalised ratio; IgG, 
immunoglobulin G; ANA, anti-nuclear antibodies;  SMA, anti-smooth muscle antibodies; 
pANNA, peripheral anti-nuclear neutrophil antibodies;  AISC, autoimmune sclerosing 
cholangitis; IBD, inflammatory bowel disease; nv, normal value; NS non significant   
*
p value when comparing clinical parameters between [A] and [R] patients 
† 
Fisher´s exact test 
‡ 
Mann-Whitney test
  
 
Twenty one patients had bile duct changes characteristic of sclerosing 
cholangitis on retrograde cholangiography and were diagnosed as having AISC 
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Parameter
AIH-1 patients
(n=33)
AISC patients
(n=21)
p*
Age in years 13.9 (8.2-21.1) 13.9 (9.1-17.6) NS†
Female, n of patients (%) 21 (64%) 10 (48%) NS†
AST (nv<50 IU/L) 35 (16-1061) 40 (17-534) NS‡
GGT (nv<50 IU/L) 31 (8-215) 52 (4-503) 0.04‡
Total bilirubin (nv<20 mmol/l) 8 (4-705) 9 43-47) NS‡
AP (nv<350 IU/L) 178 (49-344) 232 (68-834) 0.05‡
AP/AST ratio 4.29 (0.17-15.64) 5.09 (1.56-16.38) NS‡
INR (nv<1.2) 1.07 (0.92-2.06) 1.05 (0.89-1.78) NS‡
Albumin (nv>35 g/L) 46 (38-50) 45 (32-50) NS‡
IgG (nv 6.5-17 g/L) 13.50 (5.70-43.96) 12.44 (8.01-27.14) NS‡
ANA, n of positive patients (%) 12 (36%) 7 (33%) NS†
SMA, n of positive patients (%) 11 (33%) 5 (24%) NS†
pANNA, n of positive patients (%) 11 (33%) 10 (48%) NS†
Iactive disease, n of patients (%) 12 (36%) 7 (33%) 0.004†
IBD, n of patients (%) 4 (12%) 12 (57%) NS†
(Gregorio et al. 2001). Biochemical and immunological differences between AIH-1 and 
AISC patients investigated in this chapter are depicted in Table 6.2. 
 
Table 6.2. Clinical and laboratory data comparing AIH and AISC patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data presented as median (range) unless noted otherwise. 
AIH-1, autoimmune hepatitis type 1; AISC, autoimmune sclerosing cholangitis; AST, aspartate 
aminotransferase; GGT, gamma-glutamyl transpeptidase; AP, alkaline phosphatase; INR, 
international normalised ratio; IgG, immunoglobulin G; ANA, anti-nuclear antibodies;  SMA, 
anti-smooth muscle antibodies; pANNA, peripheral anti-nuclear neutrophil antibodies; IBD, 
inflammatory bowel disease; nv, normal value; NS non significant 
*
p value when comparing clinical parameters between AIH-1 and AISC patients 
† 
Fisher´s exact test 
‡ 
Mann-Whitney test 
 
 
Patients were treated with prednisolone (2.5-5 mg daily at remission and 1-2 
mg/kg/day at relapse) either alone or in combination with azathioprine (1-2 mg/kg/day) 
and/or MMF (up to 40 mg/kg/day). In those patients diagnosed with AISC, UDCA at a 
dose of 15-30 mg/kg/day was added to the immunosuppressive regimen. 
Epidemiological, clinical and laboratory data for each patient are shown in Appendix I.   
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At the time of study, 4 patients with AIH-1 and 12 with AISC had concomitant 
IBD: one AIH-1 patient had CD, while the remaining AIH-1 and all the AISC patients 
had UC. 
Controls were fifteen HS (median age: 29.0 years, range 22.6-39.0 years, 75% 
female), recruited from hospital staff, as for ethical reasons blood could not be obtained 
from healthy children. To test whether age disparity may account for differences, 
patients were divided into 2 subgroups (≤14 and >14 years old). 
 
3. Results 
3.1. Characterisation of CD4 effector cells in AILD 
The frequency and the phenotype of circulating CD4
pos
 T cells was analysed in 
18 AILD patients (9 AIH-1 and 9 AISC) and 10 HS. Gating of PBMCs according to 
their forward (FSC) and side (SSC) scatter characteristics and antibody fluorescence 
patterns (Figure 6.1.), revealed a population of lymphocytes expressing CD3
 
and CD4 
in AILD and HS patients, the proportion of these cells being similar in the two groups 
(49.16±3.80% vs 56.62±2.39%; p=NS). When patients were subdivided into AIH-1 and 
AISC frequency of CD4 T cells was found to be higher in the former (62.50±5.51%) 
than in the latter (42.48±1.37%, p=0.001), and lower in AISC than in HS (p=0.002). No 
differences were observed between AIH-1 patients and HS (Figure 6.2.).  
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Figure 6.1. Gating strategy used to analyse effector T cells. PBMCs were gated according to 
their forward (FSC) and side (SSC) scatter characteristics (A); lymphocytes were subsequently 
gated according to their CD3 and CD4 expression (B); a population of cells positive for CD3 
and CD4 was then identified and subdivided according to the expression CD25 (C) into CD25
neg
 
and CD25
pos
 populations.  
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Figure 6.2. Frequency of CD4
pos
 T cells.  Plots in Panel A show the frequency of 
CD3
pos
CD4
pos
 cells in one representative AIH patient, in one representative AISC patient and in 
one representative healthy subject. The graph in Panel B summarises data from 9 AIH patients, 
9 AISC patients and 10 healthy subjects. Error bars represent SEM. 
 
CD4
pos 
cells were subsequently gated according to their CD25 expression and 
subdivided into CD25
neg 
and CD25
pos 
T cell subsets (Figure 6.1.). AILD patients had a 
higher frequency of CD25
neg
 cells than HS (93.52±0.61% vs 89.42±1.72%: p=0.01; 
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Figure 6.3.). There was no difference in the percentage of CD25
neg
 cells between AIH-1 
and AISC.  
 
 
 
 
 
 
 
 
 
 
Figure 6.3. Percentage of CD4
pos
CD25
neg
 and CD4
pos
CD25
pos
 T lymphocytes. Percentage of 
CD4
pos
CD25
neg
 (bottom) and CD4
pos
CD25
pos
 (top) cells in one representative AILD patient (A) 
in one representative healthy subject (B). Dot plots of CD4(x axis) versus CD25. 
 
Analysis of the CD4
pos
CD25
neg
 cell transcription factor showed that Tbet
pos
 and 
RORC
pos
 cells were higher in AILD (Tbet: 10.29±0.88%; RORC: 10.15±1.44%) than 
HS (Tbet: 6.52±0.91%, p=0.01; RORC: 2.58±0.54%, p=0.007). The frequency of 
Tbet
pos
 cells did not differ between AIH-1 (10.92±1.35%) and AISC patients 
(9.66±1.16%, p=NS) being in both cases higher than in HS (AIH-1: p=0.01; AISC: 
p=0.05); in contrast the frequency of RORC
pos
 cells was higher in AISC (12.90±2.46%) 
than in AIH-1 (7.40±0.93%, p=0.05), being in both cases higher than in HS (AISC: 
p=0.005; AIH-1: p=0.02). The frequency of GATA-3
pos
 cells did not differ among 
different groups. 
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Figure 6.4. Transcription factor profile of CD4
pos
CD25
neg
 T cells in autoimmune liver 
disease. Frequency of Tbet
pos
 (A), GATA-3
pos
 (B), and RORC
pos
 (C) cells within CD4
pos
CD25
neg
 
cells in 9 AIH patients (red bars), 9 AISC patients (green bars), and 10 healthy subjects (blue 
bars). Error bars represent SEM. 
 
 
Analysis of the CD4
pos
CD25
neg
 cytokine profile revealed that CD25
neg
 cells from 
AILD patients displayed higher frequencies of IFN-pos (5.23±0.83%) and IL-17pos 
(5.04±0.79%) cells when compared to HS (IFN-: 2.70±0.36%, p=0.03; IL-17: 
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2.06±0.27%, p=0.01). Similar to what observed for the transcription factors, while the 
frequency of IFN-pos cells did not vary between AIH-1 and AISC, that of IL-17pos cells 
was lower in the former (3.52±0.81%) than in the latter (6.56±0.87%, p=0.05). No 
differences in the frequency of CD25
neg
 cells positive for IL-10 and TGF- were noted 
among the different groups.  
 
 
 
 
 
 
 
 
Figure 6.5. Frequency of cytokine producing cells within CD4
pos
CD25
neg
 effector T cells in 
autoimmune liver disease. Frequency of IFN-pos (A), IL-17pos (B), and IL-10pos (C), and TGF-
pos (D) cells within CD4posCD25neg T cells in 9 AIH patients (red bars), 9 AISC patients (green 
bars) and 10 healthy subjects (blue bars). Error bars represent SEM. 
 
In AILD patients, the frequency of CD25
pos
Tbet
pos
 cells positively correlated 
with AST levels. When AISC patients were analysed separately, there was a positive 
correlation between the frequency of CD25
neg
IL-17
pos
 cells and the levels of AP, and 
GGT.    
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Figure 6.6. Correlation between the frequency of CD25
neg
Tbet
pos
 cells and AST levels in 
AILD patients. In AILD patients the percentage of CD25
neg
Tbet
pos
 cells positively correlates 
with levels of AST..  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7. Correlation between the frequency of IL-17
pos
 cells and biochemical indices of 
cholestasis in AISC patients. In AISC patients the frequency of IL-17
pos
 cells within 
CD4
pos
CD25
neg
 T cells positively correlated with AP (Panel A), and GGT levels (Panel B). 
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3.2. Frequency of circulating TIM-3
pos
 lymphocytes 
The percentage of circulating TIM-3
pos
 lymphocytes was determined in 47 AILD 
patients and in 15 healthy subjects. In AILD patients, the mean percentage of TIM-3
pos
 
cells within CD4
pos
 lymphocytes (3.66±0.30%) was lower than in HS (6.93±0.66%, 
p=0.0001), this difference being also significant when [R] (4.39±0.36%, p=0.0007) and 
[A] patients (1.92±0.26%, p<0.00001) were analysed separately. TIM-3
pos
CD4
pos
 cells 
were significantly less numerous in [A] than in [R] patients (p=0.0001; Figure 6.8.). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.8. Percentage of TIM-3
pos
 lymphocytes within CD4
pos
 T cells. Percentage of TIM-
3
pos
 lymphocytes within CD4
pos
 cells in 17 [A] patients, 30 [R] patients and 15 healthy subjects 
Error bars represent SEM 
 
After CD4
pos
 cells were gated according to their CD25 expression, frequency of 
TIM-3
pos
 cells within the CD4
pos
CD25
pos
 and the CD4
pos
CD25
neg
 subsets was 
determined (Figure 6.9.). While the frequency of TIM-3
pos
 lymphocytes within the 
CD4
pos
CD25
pos
 subset was negligible in both AILD (0.39±0.05%) and HS (0.45±0.11%, 
p=NS), that of TIM-3
pos
 cells within the CD4
pos
CD25
neg
 subset was lower in patients 
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(4.02±0.31%) than in HS (7.95±0.82%, p<0.00001) whether patients were studied 
during active disease (2.66±0.35%, p<0.00001) or during remission (4.60±0.38%, 
p=0.0001). TIM-3
pos
 cells were lower in [A] than in [R] patients (p=0.003). Within 
AILD patients, no differences were observed between the two age groups, between AIH 
and AISC, or between those with or without concomitant UC. 
 
 
 
 
 
Figure 6.9. Frequency of TIM-3
pos
 cells within CD4
pos
CD25
pos
 and CD4
pos
CD25
neg
 cell 
subsets. PBMCs were gated according to CD4 and CD25 expression (A); TIM-3 expression, 
represented as mean fluorescence intensity on histogram plots, was evaluated within CD25
pos 
(B 
& C), and CD25
neg
 (D & E) populations. Plots are from one representative AILD patients (B & 
C), and one representative healthy subject (A, D & F). Values represent the frequency of cells 
within each CD25 population. 
 
To determine the frequency of TIM-3
pos
 cells within CD4 Th subsets 
intracellular staining for Tbet, GATA-3 or RORC  was performed in 15 AILD patients 
and in 15 HS. The percentage of TIM-3
pos
 cells within the Tbet
pos
 and the RORC
pos
 
effector subsets was lower in AILD (Tbet: 5.13±0.69%; RORC: 4.07±0.64%) than in 
health (Tbet: 13.59±1.72%, p<0.0001; RORC: 8.23±1.13%, p=0.02) while that of 
GATA-3
pos
 cells was negligible in both groups (0.65±0.29% vs 0.72±0.15%, p=NS).   
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In AILD patients, the frequency of TIM-3
pos 
effector cells was negatively correlated 
with AST levels (r= –0.34, p=0.02), and with the frequency of CD25negTbetpos cells (r= 
–0.81, p<0.0001).  
 
3.3. Characterisation of TIM-3
pos
 and TIM-3
neg
 effector cells 
The phenotypic profile of TIM-3
pos
 and TIM-3
neg
 cells was assessed in 10 AILD 
patients and 10 HS using mAbs to CD45RA and CCR7 to assign T cells into naïve, 
central memory (CM), and effector memory (EM) subsets  (Sallusto et al. 1999, 
Sallusto and Lanzavecchia 2000).  Co-expression of CD45RA and CCR7 defines naïve 
T cells, presence of CCR7 and absence of CD45RA indicates central memory (CM) 
cells, while absence of both markers defines effector memory (EM) cells (Figure 6.10.).  
 The frequency of naïve cells did not differ between TIM-3
pos
 and TIM-3
neg
 cell 
subsets whether they were obtained from AILD patients (12.77±2.11% vs 14.84±4.48%, 
p=NS) or HS (15.80±6.35% vs 16.88±6.66%, p=NS).  
Compared to the TIM-3
neg
 fraction, TIM-3
pos
 cells showed a higher proportion 
of CM cells both in AILD (49.14±2.04% vs 32.98±4.88%, p=0.01) and in health 
(55.40±6.33% vs 32.31±6.06, p=0.03). Conversely, the proportion of EM cells was 
lower within TIM-3
pos
 cells compared to their negative counterparts (AILD: 
10.43±1.43% vs 34.49±7.05%, p=0.007; HS: 17.22±3.16% vs 28.42±3.62%, p=0.05), 
and lower in the TIM-3
pos
 cells isolated from patients than in those obtained from HS 
(p=0.05). 
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Figure 6.10. TIM-3 expression according to CD4 T cell maturation status. Naïve, central 
memory (CM), and effector memory (EM) CD4 T cell subsets can be defined by the pattern of 
expression of CD45RA and CCR7 as shown in A. A higher proportion of the TIM-3pos 
demonstrated a central memory (CM) phenotype, while fewer demonstrated an effector memory 
phenotype than their TIM-3neg counterparts in both AILD patients (B, n=10) and healthy 
subjects (C, n=10).  
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% of cells TIM-3pos Tregs TIM-3neg Tregs
AILD HS p1 AILD HS p2 p† p‡
T-bet 91.2±0.8 93.1±0.5 NS 10.1±0.9 6.1±0.9 0.005 <0.001 <0.001
GATA-3 0.71±0.23 0.78±0.24 NS 2±0.5 2.8±0.4 0.08 0.02 0.01
RORC 7.2±0.9 2.9±0.5 0.03 5.9±0.4 3.5±0.5 0.02 NS NS
FOXP3 2.84±0.85 2.74±0.49 NS 0.5±0.2 1.6±0.8 NS 0.06 NS
IFN- 11.2±0.8 4.2±0.6 <0.001 6.09±0.7 2.4±0.3 0.001 <0.001 <0.001
IL-17 7.9±1.2 4.3±0.8 0.04 3.1±0.7 1.5±0.2 0.07 0.02 0.02
IL-10 7.1±1 9.9±1.2 NS 5.1±0.7 6.7±1 NS 0.11 0.09
TGF- 6.8±0.4 9.8±1.9 NS 3.9±1.2 4.7±0.4 NS 0.03 0.03
Analysis of the TIM-3
pos
 and TIM-3
neg
 transcription factor profile showed that 
the majority of TIM-3
pos
 cells expressed Tbet both in AILD  and in health and that the 
percentage of Tbet
pos
 cells within the TIM-3
neg
 subset was higher in AILD than in HS 
(p=0.005). While the frequency of GATA-3
pos
 cells within the TIM-3
pos
 subset was 
similar in the two groups, when the TIM-3
neg
 subset was considered GATA-3
pos
 cells 
tended to be lower in AILD than in HS (p=0.08).The frequency of RORC-expressing 
cells did not differ between the TIM-3
pos
 and the TIM-3
neg
 subpopulation, but was 
higher in patients than in normal controls both within the positive (p=0.03) and the 
negative (p=0.02) fraction. The percentage of FOXP3
pos
 cells within TIM-3
pos
 subset 
was similar in AILD patients and in HS in patients, however, TIM-3
pos
 cells tended to 
contain more FOXP3
pos
 cells than their negative counterparts (p=0.06; Table 6.3.). 
 
Table 6.3. Transcription factor and of cytokine profile of  CD4
pos
CD25
neg
TIM-3
pos 
and 
TIM-3
neg 
cells. 
HS, healthy subjects; AILD, autoimmune liver disease; NS, non significant 
Data are represented as mean±SEM 
p values comparing the percentage of Tbet
pos
, GATA-3
pos
, RORC
pos
, FOXP3
pos
, IFN-pos, IL-
17
pos
, IL-10
pos
, and TGF-pos cells: 
p
1
: within the TIM-3
pos
 subset between AILD and healthy subjects 
p
2
: within the TIM-3
neg
 subset between healthy AILD and healthy subjects 
p
†
: between the TIM-3
pos
 and the TIM-3
neg
 subset in AILD  
p
‡
: between the TIM-3
pos
 and the TIM-3
neg
 subset in healthy subjects 
Data referring to 34 AILD patients and 20 healthy subjects 
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Analysis of the cytokine profile indicated that the frequency of IFN- and IL-17-
producing cells was higher in the TIM-3
pos
 than in the TIM-3
neg 
cell fraction both in 
AILD patients (IFN-: p=0.004; IL-17: p=0.006) and in HS (IFN-: p=0.01; IL-17: 
p=0.006). In both effector subsets, AILD patients contained higher frequencies of IFN-
pos (TIM-3pos: p<0.0001; TIM-3neg: p<0.0001) and IL-17pos cells (TIM-3pos: p=0.02; 
TIM-3
neg
: p=0.02) than HS (Table 6.3.). In both groups no differences were noted in the 
frequency of TGF- and IL-10-producing cells between the two effector cell subsets. 
 
3.4. Effect of stimulation with anti-CD3/anti-CD28 T cell expander and IL-2 on 
TIM-3 expression  
Immunomagnetically isolated CD4
pos
 and CD4
pos
CD25
neg
 cells from 4 HS and 4 
AILD patients were stimulated with anti-CD3/anti-CD28 T cell expander and IL-2. The 
expression of TIM-3 on effector cells was then tested by flow cytometry after 12 hours 
and 5 days culture.  
The frequency of TIM-3
pos
 cells within CD4
pos
 lymphocytes did not change after 
12 hours culture both in AILD patients (% of TIM-3
pos
 cells: 2.23±0.47 vs 2.93±0.38, 
p=NS; MFI: 390±25 vs 347±21, p=NS) and in HS (% TIM-3
pos
 cells: 6.70±0.49% at 
baseline vs 7.25±0.39% after 12 hours, p=NS; TIM-3 MFI: 639±25 vs 671±73, p=NS). 
After 5 days culture, there was an increase in the frequency of TIM-3
pos
CD4
pos
 cells in 
HS (% of TIM-3
pos
 cells: 12.65±1.30%, p=0.01; MFI: 881±37, p=0.002), but not in 
AILD patients (%TIM-3
pos
 cells: 2.98±0.75%, p=NS; MFI: 344±50, p=NS; Figure 
6.11.). Akin to what observed for CD4
pos
 cells, while in HS frequency of TIM-3
pos
 
lymphocytes and TIM-3 MFI in CD25
neg
 cells were higher after 5 days compared to 12 
hours culture and baseline, such an increase was not observed in AILD patients. The 
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frequency of TIM-3
pos
 cells and TIM-3 MFI were higher in HS than in AILD at all time 
points (baseline: % TIM-3pos cells: p=0.0006; MFI: p=0.0004; 12 hours: % TIM-3pos cells: 
p=0.0002; MFI: p=0.0006; 5 day culture:  % of TIM-3
pos
 cells: p=0.0007; MFI: p=0.0001).   
 
 
 
 
 
 
 
 
Figure 6.11. Effect of stimulation with anti-CD3/anti-CD28 T cell expander and 
IL-2 on TIM-3 expression CD4pos cells were purified from PBMCs using immunomagnetic 
beads, and cultured in the presence of CD3/CD28 T cell expander and rIL-2. TIM-3 expression 
was assessed at baseline, after 12 hours and after 5 days in culture.  
 
3.5. Proliferation of CD4
pos
CD25
neg
, TIM-3
pos
 and TIM-3
neg
 cells and 
responsiveness to Treg control  
Purified CD25
neg
, TIM-3
pos
 and TIM-3
neg
 cell populations obtained from 18 
AILD patients and 9 HS were cultured with CD3/CD28 T cell expander and rIL-2 in the 
absence and presence of regulatory T cells. Cell proliferation was assessed after 5 days 
culture. 
The proliferation of unfractionated CD25
neg
 cells (AILD: 6,160±714 cpm; HS: 
37,745±5,015 cpm) was lower than in TIM-3
neg
 cells (AILD: 9,659±1,041 cpm, p=0.02; 
HS: 115,488±8348 cpm, p=0.001) and higher than in TIM-3
pos
 cells (AILD: 
4,604±1,177 cpm; p=0.004; HS: 29,382±2,323 cpm, p=0.03; Figure 6.12.). 
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Figure 6.12. Proliferation of CD4
pos
CD25
neg
, TIM-3
neg
 and TIM-3
pos
 responder cells. 
CD4
pos
CD25
neg
 cells were purified from PBMCs by two-step negative selection using 
immunomagnetic beads. TIM-3
neg
 and TIM-3
pos
 cell fractions were obtained following 
incubation of CD25
neg
 cells with PE-labeled TIM-3 mAbs and with anti-PE microbeads. 
Unfractionated CD25
neg
 cells (filled bars) and TIM-3
neg
 (squared bars) and TIM-3
pos 
(horizontal 
stripped bars) fractions from 18 AILD patients (A) and 9 healthy subjects (B) were cultured for 
5 days in the presence of CD3/CD28 T cell expander and rIL-2. Results are expressed as mean 
+ SEM cpm. 
 
After addition of cTregs, the mean CD25
neg
 cell proliferation decreased by 26% 
in AILD patients (p=NS) by 53% in HS (p=0.007), being the percentage inhibition 
lower in the former than in the latter (p=0.0006). Addition of cTregs reduced cell 
proliferation by 23% (p=NS) in AILD by 25% (p=NS) in HS when TIM-3
neg 
cells were 
used as responders, the percentage inhibition of TIM-3
neg
 proliferation being similar in 
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the two groups (p=NS). While in HS the percentage inhibition of TIM-3
neg
 cells was 
significantly lower than that of CD25
neg
 responders (56% vs 25%, p=0.0003), such a 
difference was not observed in AILD patients (26% vs 23%, p=NS). When TIM-3
pos
 
cells were used as responders, cTregs addition resulted in a decrease in cell proliferation 
by 47% (p=0.03) in AILD and by 62% in HS (p=0.001), the percentage inhibition being 
lower in patients than in HS (p=0.04). In AILD inhibition of TIM-3
pos
 cell proliferation 
was higher than that of CD25
neg
 responders (47% vs 26%, p<0.0001), whereas in HS 
there was no statistically significant difference in terms of cell proliferation inhibition 
between the two types of responders (62% vs 53%, p=NS).  
Addition of CD127
neg
 Tregs reduced cell proliferation by 46% in AILD 
(p<0.001) and by 60% in HS (p<0.001) when CD25
neg
 were the targets; by 11% in 
AILD (p=NS) and by 13% in HS (p=NS) when the targets were TIM-3
neg
 cells; and by 
56% in AILD (p=0.006) and by 69% in HS (p<0.001) when TIM-3
pos
 cells were used as 
responders. Compared to cTregs, addition of CD127
neg
 Tregs led to a higher 
suppression rate when CD25
neg
 (AILD: p=0.0001; HS: p=0.11) and TIM-3
pos
 (AILD: 
p=0.02; HS: p=0.05) cells were used as responders, while leaving unchanged the 
percentage inhibition over TIM-3
neg
 cell proliferation (AILD: p=NS; HS: p=NS). 
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Figure 6.13. Suppression of CD4
pos
CD25
neg
, TIM-3
neg
 and TIM-3
pos
 responder cell 
proliferation by Tregs. Tregs purified from 18 AILD patients (left plots) and 9 healthy subjects 
(right plots) were added to CD4
pos
CD25
neg
 (A), TIM-3
neg
 (B) or TIM-3
pos 
(C) responder cells. 
After 5-day co-culture, responder cell proliferation was assessed by 
3
H-thymidine incorporation. 
Bars represent mean + SEM proliferation of before and after T-reg addition.  
 
To determine whether the expression of GAL-9 by Tregs affects effector cell 
responsiveness to immune-regulation, TIM-3
pos
 cells were cultured in the presence of 
untreated and GAL-9 siRNA-treated Tregs. After addition of GAL-9-siRNA-treated 
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cTregs, inhibition of TIM-3
pos
 cell proliferation was reduced by 70% in AILD (from 
46% to 13%, p<0.0001) and 74% in HS (from 62% to 16%, p<0.0001). After treatment 
with GAL-9-siRNA, CD127
neg
 Treg suppressor function was reduced by 75% (from 
56% to 14%, p<0.0001) in AILD patients and 71% (from 69% to 20%, p<0.001) in HS. 
 
3.6. Neutralisation assay  
Since the percentage of IFN- and, to a lesser extent, IL-17-producing cells was 
higher in TIM-3
pos
 than in TIM-3
neg
 cells, the effect of IFN- and IL-17 neutralisation 
on the ability of CD25
neg
, TIM-3
neg
 and TIM-3
pos
 cells to be regulated by Tregs was 
investigated in 9 HS and 18 AILD patients. 
Addition of anti-IFN- neutralising antibodies did not change CD25neg and TIM-
3
neg
 cell responsiveness to Treg control in both AILD patients (CD25
neg
: 33% of 
inhibition without vs 30% in the presence of anti-IFN- mAbs, p=NS; TIM-3neg: 23% vs 
25%, p=NS) and HS (CD25
neg
: 53% vs 54%, p=NS; TIM-3
neg
: 25% vs 31%, p=NS). In 
contrast, treatment with anti-IFN- abrogated TIM-3pos responsiveness to Treg control 
(AILD: 46% vs –2%, p<0.0001; HS: 62% vs 10%, p<0.0001).  
Treatment with anti-IL-17 neutralising antibodies did not change the 
responsiveness of CD25
neg
, TIM-3
neg
 and TIM-3
pos 
responder cells to Treg control in 
both patients (CD25
neg
: 26% vs 30%, p=NS; TIM-3
neg
: 23% vs 28%, p=NS; TIM-3
pos
: 
47 vs 46%, p=NS) and HS (CD25
neg
: 53% vs 54%, p=NS; TIM-3
neg
: 25% vs 29%, 
p=NS; TIM-3
pos
: 62% vs 59%, p=NS).  
Addition of anti-IFN- and anti-IL-17 neutralising antibodies together reduced 
responsiveness of TIM-3
pos
 cells (AILD: 47% vs 3%, p<0.0001; HS: 62% to 13%, 
p<0.0001), while leaving unchanged that of CD25
neg
 (AILD: 26% vs 34%, p=NS; HS: 
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Figure 6.14. Inhibition of CD4
pos
CD25
neg
, TIM-3
neg
 and TIM-3
pos
 responder cell 
proliferation by T-regs in the presence of anti-IFN- and anti-IL-17 mAbs. Tregs from 18 
AILD patients (left plots) and 9 HS(right plots) were added to CD4
pos
CD25
neg
 (A), TIM-3
neg
 (B) 
or TIM-3
pos 
(C) responder cells, either untreated (filled bars) or treated with anti-IFN- (squared 
bars), anti-IL-17 (horizontal striped bars) or both (vertical striped bars) mAbs. After 5-day co-
culture, responder cell proliferation was assessed by 
3
H-thymidine incorporation.  
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Since the responsiveness of TIM-3
pos
 cells to Treg control was abrogated only in 
the presence of anti-IFN- neutralising antibodies, the effect of cytokine neutralisation 
on the frequency of TIM-3
pos
 lymphocytes was then tested after 12 hour and 5 days 
culture in 4 AILD patients and in 4 HS.  
Treatment with anti-IFN- neutralising antibodies, compared to untreated 
effector cells, did not change the percentage of TIM-3
pos
 lymphocytes within CD4
pos
 
isolated cells after 12 hours (AILD: 2.93±0.38% vs 2.73±0.71%, p=NS; HS: 
7.25±0.39% without vs 5.83±1.16% with anti-IFN- mAbs, p=NS) and 5 days (AILD: 
2.98±0.75% vs 2.88±0.61%, p=NS; HS: 12.65±1.30% vs 9.58±0.90%, p=NS) culture. 
When CD25
neg
 purified cell fraction was analysed, no difference in the frequency of 
TIM-3
pos
 cells between untreated and treated CD25
neg
 cells were noted in AILD patients 
at any time point (12 hours: 2.63±0.53% vs 2.55±0.55%, p=NS; 5 days: 2.80±0.49% vs 
3.03±0.29%, p=NS), whereas in HS anti-IFN- neutralising antibodies tended to 
decrease it (12 hours: 8.55±0.41% vs 6.25±1.21%, p=0.12; 5 hours: 15.55±1.64% vs 
12.20±0.61%, p=0.10). However, when CD25
neg
 cells were co-cultured with Tregs no 
difference in terms of TIM-3 expression was observed between untreated and IFN- 
treated effector cells in HS (7.40±1.18% vs 7.23±1.73%, p=NS), as well as in AILD 
patients (2.30±0.60% vs 2.75±0.78%, p=NS).  
 
3.7. Immunohistochemistry 
The frequency of liver infiltrating TIM-3
pos
 and CD4
pos
 lymphocytes was 
determined by immunohistochemistry in 13 liver biopsies obtained from 10 AILD 
patients (5 AIH-1 and 5 AISC). All patients were studied while on histologically active 
disease; from 3 of these patients biopsies were also obtained during inactive disease. 
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A B
The number of positive lymphocytes was counted at three high-power fields (x400) in 
each case. TIM-3
pos
 and CD4
pos
 lymphocytes were enumerated in the same areas within 
a biopsy specimen. 
TIM-3
pos
 lymphocytes were detected in the portal tracts of all patients with 
histologically active disease, though representing a very small proportion of the portal 
tract inflammatory infiltrate (Figure 6.15.). While the numbers of TIM-3
pos
 cells did not 
differ between AIH-1 and AISC patients, the frequency of CD4
pos
 cells tended to be 
higher in the former (195.2±19.8) than in the latter (106.8±41.0, p=0.09).   
 
Figure 6.15. Liver infiltrating CD4
pos
 and TIM-3
pos
 lymphocytes. The number of CD4
pos
 
lymphocytes was counted at three high-power fields (x400, A). Lymphocytes positive for TIM-
33 and CD4 were counted at the same biopsy sample (B).  
 
4. Discussion 
This chapter has provided evidence that defective immune-regulation in AILD 
results not only from numerical and functional impairment of Tregs (see chapters IV 
and V) but also from low responsiveness of effector CD4 T cells to Treg control. The 
data presented clearly indicate that in AILD down-regulation of TIM-3 on the surface of 
responder CD4 T cells leads to lower control of their effector function by Tregs. That 
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TIM-3 renders effectors responsive to Treg control has been shown by a series of 
experiments where the TIM-3
neg
 and the TIM-3
pos
 cell fractions were tested for their 
ability to be regulated by Tregs. Effective control of cell proliferation was observed 
when TIM-3
pos
 cells were used as responders, confirming that the presence of TIM-3 on 
effectors confers responsivity to Treg control. Furthermore, TIM-3
neg
 cells were not 
only resistant to cTregs but also to the more suppressive bona fide CD127
neg
 Tregs, thus 
demonstrating that the down-modulation of TIM-3 in AILD renders effector cells 
refractory to the control exerted by Tregs.  That low levels of TIM-3 expression are 
associated with poor Treg control and therefore with more inflammation was further 
confirmed by the strong negative correlation between the percentage of TIM-3
pos
 
effector lymphocytes and the levels of transaminases. Evidence supporting a relative 
resistance of effector cells to regulatory control had been previously shown in different 
animal models of autoimmunity, in which target organ inflammation progresses despite 
the presence of appropriate numbers of functional Tregs (Monk et al. 2005, Korn et al. 
2007b, D'Alise et al. 2008).  
Further phenotypic and functional analyses performed in the current study 
indicate that regulation of TIM-3
pos
 cells by Tregs depends on IFN- production, as 
blockade of IFN- resulted in a lower susceptibility of TIM-3pos cells to Tregs. These 
data suggest that a pro-inflammatory signature is necessary for the effectors in order to 
be ‘seen’ and consequently regulated by Tregs via the TIM-3/GAL-9 pathway.  
In AILD down-regulation of TIM-3 on the surface of effector cells is mirrored 
by a decreased percentage of GAL-9 expressing regulatory cells, as shown in Chapter 
V. Whether down-regulation of TIM-3 on effectors is the result of low GAL-9
pos 
Treg 
number or of a defective Th1 cell maturation/differentiation process, is unclear. The 
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results presented in this chapter support the second hypothesis. First, analysis of the 
maturation phenotype showed that TIM-3 expression is associated with markers of 
memory differentiation. Second, treatment of cells with IL-2 and T cell expander – a T 
cell activation protocol that mimics TCR and CD80/CD86-mediated co-stimulation 
(Bonyhadi et al. 2005) – induced an increase in the expression of TIM-3 in HS, whereas 
AILD patients failed to up-regulate it following 5 days in culture. Third, patients 
displayed a low percentage of TIM-3 on Tbet
pos
 cells compared to HS. These data 
suggests that in AILD Th1 cells arrest at a Tbet positive status, acquiring effector 
properties typical of Th1 cells without further differentiating into the Tbet/TIM-3 
double positive status, which would confer them susceptibility to Treg control. In line 
with this, Anderson et al. have recently documented that Tbet
-/- 
mice show defective 
TIM-3 expression on CD4 T cells and that Tbet over-expression results in constitutive 
TIM-3 expression; moreover, by showing that Tbet binds directly to the Tim-3 
promoter, the authors suggest that Tim-3 is a direct transcriptional target of Tbet 
(Anderson et al. 2010). As supported by the data presented in this chapter, it is therefore 
plausible that in AILD Tbet
pos
/TIM-3
neg
 cells prevail over the Tbet
pos
/TIM-3
pos 
cells, 
accounting for the high number of poorly controllable effectors that contribute to the 
unfolding of the liver damage.   
It has recently been reported that TIM-3 is expressed also on other types of 
effectors; for example, its expression by Th17 cells has been documented in mice and in 
humans (Chen et al. 2006, Hastings et al. 2009). Interestingly, RORC
pos
 cells in AILD 
not only displayed lower levels of TIM-3 compared to the same subset in health, as they 
expressed even lower levels compared to Tbet
pos
 cells.  Since low levels of TIM-3 are 
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associated with poor Treg control, it is plausible that Th17 cell pathogenicity is at least 
in part attributable to a lower susceptibility to the TIM-3/gal9 mediated suppression.  
GAL-9 gene knock-down experiments showed that although treatment of Tregs 
with GAL-9 siRNA led to a significant reduction in the suppression of TIM-3
pos
 cell 
proliferation, it did not abrogate it completely. The evidence that after addition of 
siRNA-treated Tregs, some 20% and 15% inhibition of TIM-3
pos
 cell proliferation was 
still observed, indicates that TIM-3 mediated immune-regulation may operate in a 
GAL-9-dependent and -independent fashion. That TIM-3 may have more than one 
ligand was first suggested by crystallography studies demonstrating that, in addition to 
the -galactosidase bound characteristic of the TIM-3/GAL-9 interaction (Zhu et al. 
2005), non-glycosylated TIM-3-Ig was able to bind to ligands other than GAL-9 in 
various cell types (E. Cao et al. 2007).  Although the nature of these additional ligands 
is still largely unknown, two different groups have recently reported that both in 
humans and mice TIM-3 is a receptor of phosphatidylserine (PtdSer), and that TIM-3
pos
 
cells can bind apoptotic cells expressing PtdSer (Nakayama et al. 2009, DeKruyff et al. 
2010). Whether this or other TIM-3 ligands are expressed by Tregs and/or have an 
impact in their ability to suppress is unknown. 
The present chapter has also provided a phenotypic analysis of CD4
pos
 effector 
cells and by showing an increased frequency of Tbet
pos
, RORC
pos
, IFN-pos and IL-17pos 
cells in AILD, implicates an involvement for both Th1 and Th17 cell subsets in the 
autoimmune liver damage. Interestingly while Th1 effectors are increased in both AIH 
and AISC, Th17 cells predominate in the latter. The correlation between frequency of 
‘type 1’ immune responses and AST in both groups of patients suggests that IFN- 
orchestrates hepatocyte damage, whereas the correlation between ‘type 17’ immune 
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responses and biochemical indices of cholestasis observed in AISC only indicates that 
IL-17 is more likely to be involved in the bile duct damage characteristic of this 
condition. While the association between IFN- and tissue damage in AIH had been 
known for many years, the relationship between IL-17 and bile duct destruction was 
less evident. A putative pathogenic role for Th17 cells has been recently documented in 
primary biliary cirrhosis (PBC), another autoimmune liver disorder in which bile ducts 
are affected. According to Harada et al., IL-17
pos
 cells accumulate around the damaged 
interlobular bile ducts within areas of chronic non-suppurative destructive cholangitis 
(Harada et al. 2009). Collectively, it seems that the Th1/Th17 division of labor may 
correspond in terms of liver pathology to a similar hepatocyte vs bile duct damage 
dichotomy.  
Although AISC patients displayed more prominent Th17 immune responses than 
AIH-1 patients, no differences in terms of TIM-3 expression were observed. However, 
both flow cytometric and immunohistochemical studies have revealed that CD4
pos
 cells 
are reduced in AISC, indicating that this condition may be also associated with more 
vigorous CD8 immune-response. Thus, future studies should focus on CD8 cells and on 
the role of TIM-3 in their responsiveness to Treg control in AISC.  
In summary, the results presented in this chapter show that impaired immune-
regulation in AILD also derives from poorly controllable effectors that are likely to 
have undergone a defective differentiation process. Importantly phenotypic analysis of 
CD4 effector cells has highlighted that while Th1 cells are elevated in both AIH and 
AISC, Th17 cells predominate in the latter and correlate with biochemical indices of 
cholestasis, suggesting that the biliary damage characteristic of AISC is driven by an 
immunologically distinct response. 
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Experimental work performed before this project commenced had shown that 
liver damage in AILD is orchestrated by CD4
pos
 T cells that recognise autoantigenic 
liver epitopes (Ma et al. 2006). Compelling evidence deriving from both animal models 
and human disease had indicated that in AIH the extent of self-reactive CD4 T cell 
effector immune responses is associated with an impairment of CD4
pos
CD25
pos
 
regulatory T cells (Tregs; Longhi et al. 2004, Longhi et al. 2005, Ferri et al. 2010, Kido 
et al. 2008), a cell subset that plays a central role in maintaining peripheral tolerance 
and controlling organ-specific autoimmunity (Sakaguchi 2000). Defects in Treg number 
and/or function had also been described in several other autoimmune diseases, including 
T1D, RA, SLE, and MS. Strategies to augment Treg activity are therefore being 
considered for treatment of these diseases. 
Since Tregs are defective in AIH, they are unable to control the proliferation and 
the effector cytokine production of responder CD4 T cells, stimulated in vitro with 
polyclonal or antigen-specific stimuli (Longhi et al. 2011). However, before this Thesis 
had started the mechanisms responsible for this Treg impairment were largely unknown. 
This thesis has thus explored possible mechanisms governing the loss of immune 
tolerance and leading to the development of liver damage in patients with autoimmune 
liver disease. In particular this study aimed to understand whether the impaired 
immune-regulation is mainly due to a primary Treg defect, or to low responsiveness of 
effector cells to Treg control. 
The most logical first objective was however to evaluate whether an inadequate 
number of functional Tregs accounts for the impaired immune-regulation observed in 
AILD patients (Chapter IV). Most previous studies had characterised Tregs on the basis 
of CD25 positivity, which defines a population frequently contaminated by effector T 
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cells. In this thesis, I have investigated the frequency of Tregs in patients with AILD by 
analysing the properties of Treg subsets taking into consideration the recent 
observations that activated effector cells within the CD4
pos
CD25
pos
 T cell population are 
characterised by the expression of CD127 (Seddiki et al. 2006, Liu et al. 2006). In this 
regard, the results presented in Chapter IV showed that CD4
pos
CD25
pos
 T cells deprived 
of CD127 expression (CD127
neg
 Tregs) bear the phenotypic and functional signature of 
bona fide Tregs, being characterised by a higher suppressive activity than conventional 
Tregs. The frequency of CD127
neg
 T cells is, however, reduced in patients with AILD 
compared to healthy subjects. Akin to cell number, functional analyses revealed that 
these cells are in patients less capable to suppress the proliferation of responder cells 
than in healthy subjects. Concomitantly, the counterpart CD4
pos
CD25
pos
CD127
pos
 T cell 
subset did not suppress but rather proliferated and was characterised by the production 
of pro-inflammatory cytokines, indicating that physical removal of CD127 expressing 
cells may be a useful approach to facilitate the purification of highly functional Tregs. 
The role of the CD4
pos
CD25
pos
CD127
pos
 T cell subset should be the subject of future 
investigations, since it might play a role in the inflammatory process observed in AILD. 
After confirming and extending the previous observations of impaired Treg-
mediated suppression in the context of AILD, this Thesis proceeded to analyse 
mechanistic causes that may account for that defect by studying the role of the TIM-
3/GAL-9 pathway. GAL-9, a member of the galectin family expressed by Tregs, had 
been shown to inhibit Th1 effector immune responses after binding to TIM-3 (Sanchez-
Fueyo et al. 2003, Zhu et al. 2005), demonstrating a role of this pathway in the 
inhibition of effector cells during normal immune responses and in the induction of 
peripheral tolerance.  
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This thesis clearly shows that in AILD an intrinsic Treg defect (Chapter V) is 
accompanied by low susceptibility of responder cells to the control exerted by Tregs 
(Chapter VI), indicating that there is a defect both at the regulatory and effector cell 
levels. 
The results presented in Chapter V confirm previous observations of a reduced 
suppressor function of Tregs in AILD and provide evidence that low expression of 
GAL-9 is one of the mechanisms responsible for Treg impairment, as highlighted by 
gene knockdown experiments where Tregs treated with a set of GAL-9-specific siRNAs 
were less effective at controlling the proliferation of responder cells. To further validate 
this observation and to definitively establish GAL-9 as one physiological mechanism of 
action employed by Tregs, future studies will explore whether in the context of AILD 
Treg suppression can be restored by transfecting these cells with human GAL-9 cDNA. 
In addition, several studies have shown that in vivo and in vitro culture of Tregs in the 
presence of a soluble form of GAL-9 results in the boosting of their function (Zhu et al. 
2005, Seki et al. 2008), by promoting their differentiation, maintenance and expansion. 
Immunohistochemical studies performed in this Thesis demonstrated that GAL-9 is also 
expressed by other liver cell populations, particularly by Kupffer and to a lesser extent 
by endothelial cells. Similarly, in the context of HCV infection macrophage-derived 
GAL-9 was associated with the expansion of Tregs that characterises this chronic 
condition (Mengshol et al. 2010). In view of this, the role of GAL-9, either expressed by 
Kupffer cells or given exogenously, should be investigated in the context of liver 
autoimmunity as a potential treatment aimed at restoring Treg number and function, and 
thus leading to the reconstitution of tolerance to liver self-antigens.  
Effectors and regulators in autoimmune liver disease 
 
 
[314] 
 
In AILD the decreased percentage of GAL-9
pos
 Tregs is mirrored by a down-
modulation of TIM-3 on the surface of CD4
pos
CD25
neg
 cells, as well as Th1 and Th17 
subsets, rendering these cells less susceptible to the immune-regulatory control exerted 
by Tregs (Chapter VI). Functional analyses performed in this study showed that 
effective control of cell proliferation was achieved when TIM-3
pos
 cells were used as 
responders, indicating that the presence of this molecule on the surface of effector cells 
confers responsivity to Treg control. In contrast, Tregs were unable to control the 
proliferation of TIM-3
neg
 responder cells, clearly demonstrating that the down-
regulation of TIM-3 in patients with AILD renders effector cells resistant to the action 
of Tregs. The information obtained in the present study is crucial for devising 
regulatory T cell based immunotherapy for the treatment of AILD: since TIM-3 
expression is reduced when the disease is active, adoptive transfer of autologous Tregs 
may be more efficacious once inflammation is dampened by immunosuppression to 
render effectors more amenable to Treg inhibition. 
Although no differences in terms of TIM-3 expression were noted between 
patients with AIH-1 and those with AISC overlap syndrome, phenotypic analysis of 
effector T cell populations showed that circulating and liver-infiltrating CD4
pos
 cells are 
reduced in AISC compared to AIH-1, indicating that AISC may be associated with a 
more vigorous CD8 immune-response. Thus, future studies will focus on CD8 cells and 
on the role of TIM-3 in their responsiveness to Treg control in AISC.  
Further comparisons between the two conditions revealed that Th1 effector cells 
are associated with hepatocyte damage in both AIH-1 and AISC, whereas Th17 immune 
responses predominate in the latter where they correlate with biochemical indices of 
cholestasis, indicating that IL-17 is involved in the bile duct damage characteristic of 
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this condition. Since a substantial difference between these two pathologies is the 
frequent association of AISC with IBD (Gregorio et al. 2001), an observation also 
corroborated in this thesis, it can be speculated that lymphocytes of intestinal origin are 
present in patients with a diagnosis of AISC rather than those suffering from AIH. 
Interestingly, it has recently been suggested that IBD may also be linked with a 
vigorous Th17 immune response. Moreover, murine studies have shown that intestinal 
Th17 cells are characterised by the expression of 47 (Wang et al. 2010), an integrin 
that mediates adherence to tissues by binding to specific ligands such as vascular cell 
adhesion molecule (VCAM)-1 and mucosal vascular addressin cell adhesion molecule 
(MadCAM)-1 (Briskin et al. 1997, Hillan et al. 1999, Grant et al. 2001). It has been 
postulated that gut mucosa T cells primed during the active phases of IBD possess the 
ability to bind both hepatic and mucosal endothelium through the interaction between 
47 and its ligands (Adams and Eksteen 2006).  Some of these cells may persist as 
long-lived memory T cells after resolution of IBD, therefore providing an explanation 
for the independent courses of bowel and liver disease. Thus, future studies will 
investigate whether lymphocytes of gut origin, namely those expressing 47, are 
present in the liver inflammatory infiltrate of patients with AISC and whether they are 
also present in AIH. Since a humanised mAb that specifically recognises the 47 
heterodimer is now available and has been shown to be effective for the induction of 
clinical and endoscopic remission in patients with active UC (Feagan et al. 2005), it is 
reasonable to hypothesise that such 47 antagonist, useful as anti-inflammatory agents 
in bowel disease, may in the future be successful in treating liver diseases such as AISC 
or adult PSC. 
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In conclusion, the results present in this thesis show that the immune-regulatory 
defects in AILD span multiple levels. Reduced numbers of CD127
neg
 Tregs (Chapter 
IV), an intrinsic Treg inability to suppress (Chapter V), and also low susceptibility of 
effector cells to Treg control all contribute to the loss of immunological tolerance to 
liver autoantigens (Figure 7.1.). Additionally, this thesis shows that distinct patterns of 
autoimmune liver injury are likely mediated by different effector immune responses: 
Th1 immunity mediating hepatocyte injury, and Th17 cells responsible for the bile duct 
damage characteristic of the overlap syndrome.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1. Effectors and regulators imbalance  in autoimmune liver disease. In health, 
appropriate balance between Tregs and effector cell prevents autoimmunity (top panel). In 
autoimmune liver disease, this balance is destroyed. The immune-regulatory defect spans 
different levels: reduced numbers of Tregs, impaired intrinsic suppression, as well as resistance 
of effector cells to control of Tregs all contribute to the loss self tolerance with consequent 
ensuing of liver damage (bottom panel).  
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Parameter
AILD
(n=77)
[A] patients
(n=23)
[R] patients
(n=54)
p*
Age in years 14.0 (5.6-26.7) 13.6 (5.6-19.5) 14.4 (8.2-26.7) NS†
Female, n of patients (%) 41 (53%) 15 (65%) 26 (48%) NS†
AST (nv<50 IU/L) 36 (16-1061) 91(51-1061) 30 (16-49) <0.0001‡
GGT  (nv<50 IU/L) 38 (4-503) 78 (17-503) 25 (4-196) <0.0001‡
Total bilirubin (nv<20 mmol/l) 8 (3-705) 10 (3-705) 7 (4-32) 0.003‡
AP (nv<350 IU/L) 136 (39-834) 228 (39-834) 190 (49-111) 0.09‡
AP/AST ratio 4.48 (0.17-16.38) 2.38 (0.17-6.54) 6.21 (1.58-16.38) <0.001‡
INR (nv<1.2) 1.05 (0.86-20.6) 1.07 (0.90-2.06) 1.04 (0.86-1.31) 0.12‡
Albumin (nv>35 g/L) 45 (32-50) 44 (32-50) 46 (40-50) 0.03‡
IgA (nv 0.8-4.8 g/L) 1.75 (<0.03-4.21) 1.84 (0.67-4.21) 1.65 (<0.03-3.96) NS‡
IgG (nv 6.5-17 g/L) 13.16 (5.70-43.96) 17.57 (6.83-43.96) 12.42 (5.70-27.14) 0.002‡
IgM (nv 0.5-2 g/L) 1.39 (0.54-3.92) 1.35 (0.85-3.92) 1.40 (0.54-3.73) NS‡
ANA, n of positive patients (%) 32 (42%) 13 (57%) 19 (33%) 0.13†
SMA, n of positive patients (%) 21 (27%) 10 (43%) 11 (20%) 0.05†
pANNA, n of positive patients (%) 38 (49%) 12 (52%) 26 (48%) NS†
AISC, n of positive patients (%) 38 (49%) 12 (52%) 26 (48%) NS†
IBD, n of positive patients (%) 30 (39%) 10 (43%) 20 (37%) NS†
Table A. Clinical and laboratory features of all AILD patients included in this thesis 
Data presented as median (range) unless noted otherwise. 
AILD, autoimmune liver disease; AST, aspartate aminotransferase; GGT, gamma-glutamyl 
transpeptidase; AP, alkaline phosphatase; INR, international normalised ratio; IgG, 
immunoglobulin G; ANA, anti-nuclear antibodies;  SMA, anti-smooth muscle antibodies; 
pANNA, peripheral anti-nuclear neutrophil antibodies;  AISC, autoimmune sclerosing 
cholangitis; UC, ulcerative colitis; nv, normal value; NS non significant 
*
p value when comparing clinical parameters between [A] and [R] patients 
† 
Fisher´s exact test 
‡ 
Mann-Whitney test 
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Parameter
AIH-1 patients
(n=39)
AISC patients
(n=38)
p*
Age in years 13.7 (5.6-21.1) 14.8 (8.2-26.7) NS†
Female, n of patients (%) 24 (62%) 17 (45%) NS†
AST (nv<50 IU/L) 34 (16-1061) 41 (17-534) NS‡
GGT (nv<50 IU/L) 33 (8-492) 50 (4-503) 0.04‡
Total bilirubin (nv<20 mmol/l) 4 (8-705) 9 (3-47) NS‡
AP (nv<350 IU/L) 178 (49-669) 228 (68-834) 0.07‡
AP/AST ratio 4.37 (0.17-15.64) 5.12 (1.26-16.38) NS‡
INR (nv<1.2) 1.07 (0.89-2.06) 1.05 (0.86-1.78) NS‡
Albumin (nv>35 g/L) 45 (38-50) 45 (32-50) NS‡
IgA (nv 0.8-4.8 g/L) 1.67 (<0.03-3.89) 1.83 (<0.03-4.21) NS‡
IgG (nv 6.5-17 g/L) 13.16 (5.70-43.96) 14.21 (7.99-27.14) NS‡
IgM (nv 0.5-2 g/L) 1.12 (0.54-3.15) 1.56 (0.83-3.92) NS‡
ANA, n of positive patients (%) 16 (41%) 16 (42%) NS†
SMA, n of positive patients (%) 12 (31%) 9 (24%) NS†
pANNA, n of positive patients (%) 14 (36%) 24 (63%) 0.03†
Active disease, n of patients (%) 11 (28%) 12 (32%) NS†
IBD, n of patients (%) 7 (18%) 23 (61%) <0.0001†
Table B. .Clinical and laboratory data comparing all AIH and AISC patients included in 
this thesis 
Data presented as median (range) unless noted otherwise. 
AIH-1, autoimmune hepatitis type 1; AISC, autoimmune sclerosing cholangitis; AST, aspartate 
aminotransferase; GGT, gamma-glutamyl transpeptidase; AP, alkaline phosphatase; INR, 
international normalised ratio; IgG, immunoglobulin G; ANA, anti-nuclear antibodies;  SMA, 
anti-smooth muscle antibodies; pANNA, peripheral anti-nuclear neutrophil antibodies; UC, 
ulcerative colitis; nv, normal value; NS non significant 
*
p value when comparing clinical parameters between AIH-1 and AISC patients 
† 
Fisher´s exact test 
‡ 
Mann-Whitney test 
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De acordo com o Artigo 8º do Decreto-Lei nº 388/70, fazem parte integrante desta 
dissertação os seguintes trabalhos publicados ou em publicação: 
 
1. Liberal R, Longhi MS, Mieli-Vergani G, Vergani D (2011) “Pathogenesis of 
autoimmune hepatitis” Best Pract Res Clin Gastroenterol 25(6):653-64 
2. Liberal R, Longhi MS, Grant CR, Mieli-Vergani G, Vergani D (2012) 
"Autoimmune hepatitis after liver transplantation" Clin Gastroenterol Hepatol 
10(4):346-53  
3. Liberal R, Grant CR, Holder B, Ma Y, Mieli-Vergani G, Vergani D, Longhi 
MS (2012) “The impaired immune regulation of autoimmune hepatitis is linked 
to a defective Galectin-9/Tim-3 pathway.” Hepatology Feb 28. doi: 
10.1002/hep.25682. [Epub ahead of print]  
4. Longhi MS, Liberal R, Holder B, Robson SC, Ma Y, Mieli-Vergani G, Vergani 
D (2012) “Inhibition of Interleukin-17 Promotes Differentiation of CD25- Cells 
into Stable T Regulatory Cells in Patients with Autoimmune Hepatitis”. 
Gastroenterology 142(7): 1526-1535.e6. 
5. Liberal R, Vergani D. “Effect of ethnicity on the clinical presentation and 
outcome of autoimmune hepatitis”. Expert Rev Gastroenterol and Hepatol 6(3): 
267-9 
 
Em cumprimento do disposto no referido Decreto-Lei, declaro que participei 
activamente na recolha e estudo do material incluído em todos os trabalhos.  
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